

Cochrane Database of Systematic Reviews

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, Kutlubaev MA, Dennis M, Soleimani B, Barugh A, Hackett ML, Hankey GJ, Mead GE

Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, Kutlubaev MA, Dennis M, Soleimani B, Barugh A, Hackett ML, Hankey GJ, Mead GE. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. *Cochrane Database of Systematic Reviews* 2019, Issue 11. Art. No.: CD009286. DOI: 10.1002/14651858.CD009286.pub3.

www.cochranelibrary.com



TABLE OF CONTENTS

HEADER	. 1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	4
BACKGROUND	6
OBJECTIVES	6
METHODS	6
RESULTS	10
Figure 1.	11
Figure 2.	15
Figure 3.	17
DISCUSSION	. 19
AUTHORS' CONCLUSIONS	21
ACKNOWLEDGEMENTS	21
REFERENCES	22
CHARACTERISTICS OF STUDIES	29
DATA AND ANALYSES	. 143
Analysis 1.1. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 1 Disability (primary analysis)	145
Analysis 1.2. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 2 Independent on modified Rankin score (mRS 0 to 2) (primary analysis).	
Analysis 1.3. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 3 Neurological deficit score.	146
Analysis 1.4. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 4 Depression (continuous data)	146
Analysis 1.5. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 5 Depression (dichotomous data)	. 147
Analysis 1.6. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 6 Death.	147
Analysis 1.7. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 7 Seizures.	147
Analysis 1.8. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 8 Gastrointestinal side effects	148
Analysis 1.9. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 9 Bleeding.	
Analysis 1.10. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 10 Leaving the trial before the end of scheduled follow-up.	
Analysis 1.11. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 11 Motor deficits.	149
Analysis 1.12. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 12 Disability (sensitivity analyses all studies regardless of RoB).	
Analysis 1.13. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 13 Independent on modified Rankin score (mRS 0 to 2) (sensitivity analysis).	
APPENDICES	
WHAT'S NEW	
HISTORY	
CONTRIBUTIONS OF AUTHORS	. 157
DECLARATIONS OF INTEREST	157
SOURCES OF SUPPORT	158
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	158
INDEX TERMS	158



[Intervention Review]

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery

Lynn A Legg¹, Russel Tilney², Cheng-Fang Hsieh³, Simiao Wu⁴, Erik Lundström⁵, Ann-Sofie Rudberg^{6,7}, Mansur A Kutlubaev⁸, Martin Dennis⁹, Babak Soleimani^{10,11}, Amanda Barugh¹², Maree L Hackett¹³, Graeme J Hankey¹⁴, Gillian E Mead⁹

¹NHS Greater Glasgow and Clyde Health Board, Paisley, UK. ²Department of Medicine, Mater Dei Hospital, Msida, Malta. ³Division of Geriatrics and Gerontology, Department of Internal Medicine and Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. ⁴Department of Neurology, West China Hospital, Sichuan University, Chengdu, China. ⁵Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden. ⁶Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden. ⁷Department of Neurology, Danderyd Hospital, Danderyd, Sweden. ⁸Department of Neurology, Neurosurgery and Medical Genetics, Bashkir State Medical University, Ufa, Russian Federation. ⁹Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. ¹⁰Department of Stroke Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK. ¹¹Department of General Medicine, Borders General Hospital, Melrose, UK. ¹²Department of Geriatric Medicine, University of Edinburgh, Edinburgh, Edinburgh, UK. ¹³Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. ¹⁴Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia

Contact address: Gillian E Mead, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. gillian.e.mead@ed.ac.uk, gmead@staffmail.ed.ac.uk.

Editorial group: Cochrane Stroke Group.

Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 11, 2019.

Citation: Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, Kutlubaev MA, Dennis M, Soleimani B, Barugh A, Hackett ML, Hankey GJ, Mead GE. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. *Cochrane Database of Systematic Reviews* 2019, Issue 11. Art. No.: CD009286. DOI: 10.1002/14651858.CD009286.pub3.

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Stroke is a major cause of adult disability. Selective serotonin reuptake inhibitors (SSRIs) have been used for many years to manage depression and other mood disorders after stroke. The 2012 Cochrane Review of SSRIs for stroke recovery demonstrated positive effects on recovery, even in people who were not depressed at randomisation. A large trial of fluoxetine for stroke recovery (fluoxetine versus placebo under supervision) has recently been published, and it is now appropriate to update the evidence.

Objectives

To determine if SSRIs are more effective than placebo or usual care at improving outcomes in people less than 12 months post-stroke, and to determine whether treatment with SSRIs is associated with adverse effects.

Search methods

For this update, we searched the Cochrane Stroke Group Trials Register (last searched 16 July 2018), the Cochrane Controlled Trials Register (CENTRAL, Issue 7 of 12, July 2018), MEDLINE (1946 to July 2018), Embase (1974 to July 2018), CINAHL (1982 July 2018), PsycINFO (1985 to July 2018), AMED (1985 to July 2018), and PsycBITE March 2012 to July 2018). We also searched grey literature and clinical trials registers.

Selection criteria

We included randomised controlled trials (RCTs) that recruited ischaemic or haemorrhagic stroke survivors at any time within the first year. The intervention was any SSRI, given at any dose, for any period, and for any indication. We excluded drugs with mixed pharmacological effects. The comparator was usual care or placebo. To be included, trials had to collect data on at least one of our primary (disability score or independence) or secondary outcomes (impairments, depression, anxiety, quality of life, fatigue, healthcare cost, death, adverse events and leaving the trial early).



Data collection and analysis

We extracted data on demographics, type of stroke, time since stroke, our primary and secondary outcomes, and sources of bias. Two review authors independently extracted data from each trial. We used standardised mean differences (SMDs) to estimate treatment effects for continuous variables, and risk ratios (RRs) for dichotomous effects, with their 95% confidence intervals (CIs). We assessed risks of bias and applied GRADE criteria.

Main results

We identified a total of 63 eligible trials recruiting 9168 participants, most of which provided data only at end of treatment and not at followup. There was a wide age range. About half the trials required participants to have depression to enter the trial. The duration, drug, and dose varied between trials. Only three of the included trials were at low risk of bias across the key 'Risk of bias' domains. A meta-analysis of these three trials found little or no effect of SSRI on either disability score: SMD -0.01 (95% CI -0.09 to 0.06; P = 0.75; 2 studies, 2829 participants; moderate-quality evidence) or independence: RR 1.00 (95% CI 0.91 to 1.09; P = 0.99; 3 studies, 3249 participants; moderatequality evidence). We downgraded both these outcomes for imprecision.

SSRIs reduced the average depression score (SMD 0.11 lower, 0.19 lower to 0.04 lower; 2 trials, 2861 participants; moderate-quality evidence), but there was a higher observed number of gastrointestinal side effects among participants treated with SSRIs compared to placebo (RR 2.19, 95% CI 1.00 to 4.76; P = 0.05; 2 studies, 148 participants; moderate-quality evidence), with no evidence of heterogeneity ($I^2 = 0\%$). For seizures there was no evidence of a substantial difference. When we included all trials in a sensitivity analysis, irrespective of risk of bias, SSRIs appeared to reduce disability scores but not dependence. One large trial (FOCUS) dominated the results.

We identified several ongoing trials, including two large trials that together will recruit more than 3000 participants.

Authors' conclusions

We found no reliable evidence that SSRIs should be used routinely to promote recovery after stroke. Meta-analysis of the trials at low risk of bias indicate that SSRIs do not improve recovery from stroke. We identified potential improvements in disability only in the analyses which included trials at high risk of bias. A further meta-analysis of large ongoing trials will be required to determine the generalisability of these findings.

PLAIN LANGUAGE SUMMARY

Selective serotonin reuptake inhibitors for stroke recovery

Review question

What are the effects of selective serotonin uptake inhibitor (SSRI) drugs on recovery from stroke?

Background

Stroke is a major cause of disability. Stroke-related disability can include difficulty with daily tasks such as toileting, washing, and walking. Sometimes disability is so severe that a person becomes dependent on others for performing basic activities (this is known as 'dependence'). Our previous Cochrane Review published in 2012 suggested that SSRI drugs (a class of drug usually used to treat mood problems, which work by changing the level of chemicals in the brain), might improve recovery after stroke, thereby reducing disability and increasing the chance of being independent after a stroke, However, when we looked at only the high-quality trials, the effect was less convincing.

A large trial recruiting more than 3000 participants has now been completed and so it is necessary to update this review. In our main analyses we decided to include only high-quality trials, that is those which used rigorous methods to avoid biases (such as the person assessing outcome being aware of whether the stroke survivor received the active drug or placebo). In this review, we refer to them as 'low risk of bias' trials.

If disability and dependency can be improved by a simple drug, this could have a major impact on quality of life for many stroke survivors.

We also wanted to find out whether SSRIs had other benefits, for example improving the severity of any arm or leg weakness, mood, anxiety, quality of life, and also whether SSRIs were associated with side effects such as bleeding or seizures.

Study characteristics

In total we found 63 trials recruiting 9168 stroke survivors within one year of their stroke. There was a wide age range. About half the trials required participants to have depression to enter the trial. The duration, drug, and dose varied between trials. However, only three of these trials were at low risk of bias; the participants in these trials did not have to be depressed to enter the trial, and they were all recruited soon after the stroke.

Key results

When we combined data from these three studies at low risk of bias, which recruited 3249 participants, SSRIs did not affect disability score or dependency. SSRIs reduced the risk of future depression but increased the risk of problems with the digestive system. There was no evidence of a substantial difference in seizures. When we combined data from all the studies, irrespective of risks of bias, there appeared to



be a beneficial effect on recovery, but this was almost certainly because the studies at high risk of bias tended to give the positive results. The evidence is current until July 2018.

Quality of the evidence

We are confident that the results are reliable when we included just the studies at low risk of bias. When we included all studies regardless of risk of bias we found that SSRIs reduced disability. When they become available, we will include the results from two large ongoing trials in a future update.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. SSRI versus control at end of treatment, by SSRI for stroke recovery

SSRI versus control at end of treatment, by SSRI, for stroke recovery*

Patient or population: people with stroke recovery Settings: hospital

Intervention: SSRI versus control at end of treatment, by SSRI

* Summary of Findings table based on studies with low risk of bias.

Outcomes Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Partici- pants	Quality of the evidence	Comments	
	Assumed risk	Corresponding risk	(3370 CI)	(studies)	(GRADE)	
	Control	SSRI versus control at end of treat- ment, by SSRI				
Disability (pri- mary analysis)		The mean disability (primary analysis) in the intervention groups was 0.01 stan- dard deviations lower (0.09 lower to 0.06 higher)		2829 (2 studies)	⊕⊕⊕⊝ moderate ^a	Outcomes: Stroke Impact Scale (SIS) score at 6 months (FOCUS Trial Collaboration 2018); Barthel Index (BI) score on day 90 (Marquez Romero 2013)
Independent on modified	Study populatio	n	RR 1.00 (0.91 to 1.09)	3249 (3 studies)	⊕⊕⊕⊝ moderate ^{b,c}	-
Rankin score (mRS 0 to 2)	367 per 1000	367 per 1000	(0.51 (0 1.05)	(5 36665)	moderate»,«	
(primary analy- sis)		(334 to 400)				
Neurological deficit score		The mean neurological deficit score in the intervention groups was 0.3 stan-		142	⊕⊕⊕⊙	Outcomes: Fugl-Meyer As- sessment (FMA) score on day
		dard deviations lower (0.63 lower to 0.04 higher)		(2 studies)	moderate ^d	90 (Marquez Romero 2013); National Institutes of Health Stroke Scale (NIHSS) score on day 90 (Chollet 2011)
Depression (continuous da- ta)		The mean depression (continuous data) in the intervention groups was 0.11 standard deviations lower (0.19 to 0.04 lower)		2861 (2 studies)	⊕⊕⊕⊙ moderate ^e	Outcomes Mental Health Inven- tory 5 (MHI-5) score at 6 months (FOCUS Trial Collaboration 2018); Montgomery-Åsberg De-

Cochrane Library

						pression Rating Scale (MADRS) score on day 90 (Chollet 2011)
	Death	Study population	RR 0.99 (0.79 to 1.25)	3254 (3 studies)	⊕⊕⊕⊕ high	-
•		80 per 1000 80 per 1000 (64 to 101)	(0.15 (0 1.25)	(5 studies)		
	Number of seizures	Study population	RR 1.47 (0.99 to 2.18)	3275 (3 studies)	⊕⊕⊕⊝ moderate ^f	-
		24 per 1000 36 per 1000 (24 to 53)	(0.00 to 2.120)	(0 500005)	moderate	
	Gastrointestinal side effects	Study population	RR 2.19 (1.00 to 4.76)	148 (2 studies)	⊕⊕⊕⊝ moderate ^g	-
	Side cheels	107 per 1000 234 per 1000 (107 to 508)	(1.00 to 4.10)	(2 300003)	moderates	

*The basis for the **assumed risk** (e.g. the mean control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; SMD: standardised mean difference

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

^aDisability is outcome is reported as a standardised mean difference. The sample size is large (> 400) and the 95% CI overlaps no effect and therefore we have downgraded for imprecision.(GRADE 2013).

^bHeterogeneity may be due to clinical variation - Chollet 2011 and Marquez Romero 2013 give 20 mg fluoxetine for 90 days and FOCUS Trial Collaboration 2018 gives 20 mg for 180 days; methodological differences (when the outcomes are measured) - Chollet 2011 and Marquez Romero 2013 measure at 90 days and FOCUS Trial Collaboration 2018 measures at 180 days; or population differences - Chollet 2011 recruited participants only with ischaemic stroke with motor deficits, Marquez Romero 2013 recruited only participants with haemorrhagic stroke and FOCUS Trial Collaboration 2018 recruited all pathological subtypes. The trials were performed in different countries where other factors such as the amount of therapy might influence outcome. These are plausible explanations for the observed heterogeneity and we have therefore we have not downgraded the evidence (Schünemann 2017).

^cThe optimal information size criterion (FOCUS Trial Collaboration 2018) has been met and the 95% CI overlaps no effect; we have therefore downgraded for imprecision (GRADE 2013).

^dNeurological deficit outcomes reported as a SMD. Sample size is < 400 and we have therefore downgraded for imprecision (GRADE 2013).

eStudies used different measures of depression. This variability in study design may have contributed to variability in intervention effects.

^fThe sample size is large (> 2000) but the 95% CI overlaps no effect; we have therefore downgraded for imprecision (GRADE 2013).

gStudies are small with too few events and wide CIs; we have therefore downgraded for imprecision (Schünemann 2017).

chrane



BACKGROUND

Description of the condition

Worldwide, stroke is the second leading cause of death, the third leading cause of disability (Johnson 2016), and results in 6.5 million years being lived with disability (GBD 2015). Although major advances in the early reperfusion of ischaemic stroke have been achieved in recent years (e.g. by intravenous thrombolysis, thrombectomy, and prevention of early recurrent stroke), effective, safe and widely accessible and affordable treatments that facilitate early and sustained recovery after stroke are urgently needed to further reduce the burdens of disability and dependency after stroke.

Description of the intervention

Selective serotonin reuptake inhibitors (SSRIs) are drugs that have been available for many years. They are widely used to treat mood disorders, including those that occur after stroke, such as depression and emotional lability (i.e. emotional behaviour that the patient reports as being outside normal control and that occurs in situations that previously would not have provoked such behaviour) (Allida 2019). Small trials suggest that fluoxetine, one of the SSRIs, might have a favourable effect on motor recovery after stroke (Chollet 2011; Yi 2010). Our 2012 Cochrane Review of SSRI for stroke recovery confirmed the positive effects seen in the small trials. Combining all SSRIs into a single review and meta-analysis is justified because the mechanism of action for the different drugs are very similar.

How the intervention might work

In animal studies, multiple potentially beneficial effects of SSRIs have been demonstrated in both normal and diseased brains. First, SSRIs have a neurotrophic effect. Neurotrophins are a family of proteins that are involved in embryogenesis (formulation of an embryo) and organogenesis (development of organs). They control neural plasticity (ability to change, or easily changed or shaped) in adults, regulate synaptic activity and neurotransmitter synthesis, and are essential for the regeneration of nerves (Lang 2004). The development of new nerve cells in adults is generally restricted to specific areas of the brain, namely the subependymal cells of the ventricular system and the subgranular zone of the dentate gyrus in the hippocampus (Ming 2005). SSRIs increase neurogenesis and expression of neurotrophic or growth factors in the adult hippocampus (Schmidt 2007), and this is likely to account for the behavioural benefits of antidepressants in animals (Santarelli 2003). Importantly, several studies have shown that migration of new neurones to damaged areas of brain may occur (Wiltrout 2007), and that neurogenesis can also occur within areas of damaged brain, for example in people with Alzheimer's disease and in animal models of Alzheimer's disease (Taupin 2006). Second, fluoxetine may have a neuroprotective effect (i.e. protect nerve cells when the brain is damaged, e.g. by a stroke). In animals, there may be several mechanisms for neuroprotective effects of SSRIs, such as reducing inflammation (e.g. repression of microglia activation) (Lim 2009), and by enhancement of specific protein expression (hypoxia inducible factor-1 alpha, heme oxygenase-1) (Shin 2009). Third, SSRIs can indirectly affect an important hormonal system in the body, the adrenergic system, through up-regulation (i.e. increase a cellular component of a cell, such as ribonucleic acid (RNA) or

protein, in response to an external variable) of beta1 receptors (Pälvimäki 1994).

In healthy humans, functional magnetic resonance imaging (fMRI) studies have demonstrated that fluoxetine can modulate cerebral motor activity (Loubinoux 1999). In eight chronic stroke participants in Zittel 2008, a single dose of citalopram 40 mg led to improvements in dexterity.

SSRIs may also improve recovery after stroke simply through their effect on preventing or treating depression and anxiety, and through improving sleep and alertness.

Why it is important to do this review

Our 2012 Cochrane Review of SSRIs for stroke recovery showed that SSRIs appeared to reduce dependence, disability, neurological impairment, anxiety, and depression after stroke, even in participants without depression. However, there was heterogeneity between trials and methodological limitations in many of the trials. When we included only those trials at low risk of bias, effect sizes were much smaller. The review generated the hypothesis that SSRIs might promote recovery after stroke, and the review authors recommended that well-designed trials were needed to determine whether SSRIs given routinely to people early after stroke improved their recovery.

SSRIs interact with platelet function and clotting, and therefore may have adverse effects in people with stroke, particularly those with haemorrhagic stroke, and these adverse effects might outweigh any potential benefits.

Three large collaborative trials were designed based on the results of the 2012 Cochrane Review (Mead 2012), to test the hypothesis that fluoxetine given early after stroke would improve recovery, or in other words, lead to less dependency and less disability at followup. The largest, the FOCUS Trial Collaboration 2018, recruited over 3000 participants and has now reported, but is not included in any systematic review or meta-analysis.

Cochrane Reviews should be updated regularly, ideally every two years. In practice, this is not always possible but they should certainly be updated when substantial new evidence becomes available. Our review team knew that the results of FOCUS, a major trial, would be available in December 2018 and so we planned this current update to include FOCUS (FOCUS Trial Collaboration 2018). If a simple, inexpensive drug such as one of the SSRIs improves stroke recovery, this would have major implications for patients, carers, health services, social care services, and the economy.

OBJECTIVES

To determine if SSRIs are more effective than placebo or usual care at improving outcomes in people less than 12 months post-stroke, and to determine whether treatment with SSRIs is associated with adverse effects.

METHODS

Criteria for considering studies for this review

Types of studies

We included all randomised controlled trials (RCTs) in people with a clinical diagnosis of stroke (Hatano 1976), where an SSRI had

been given within the first year of stroke onset, i.e.: 1) trials that stipulated that participants had to be recruited within 12 months of stroke onset, or 2) trials where the mean (or median) time since stroke was less than 12 months. Trials had to have measured at least one of our outcomes of interest in order to be included in the metaanalysis. For those trials which did not report data in a form that we could use, we attempted to get the raw data from the authors, and if this was not possible, we retained the studies in the list of included studies.

We included trials:

- with more than two arms (e.g. SSRI versus another active treatment versus placebo). We included data from the SSRI arm and the placebo arm (or usual-care arm if a placebo was not used), and discarded data from the other active treatment arms;
- in all languages.

We excluded trials:

- using a quasi-experimental design (i.e. where investigators describe a non-random component in the sequence generation process, such as date of admission);
- using a cross-over design;
- in which two or more active interventions were compared against each other rather than against a placebo or a standard care group;
- combined an SSRI with another active intervention and compared it to the active treatment alone.

There was no restriction on the eligibility of RCTs on the basis of sample size or duration of follow-up.

Types of participants

We included trials that had recruited survivors of a stroke, defined as a sudden-onset focal neurological disturbance, assumed to be vascular in origin, and lasting more than 24 hours (Hatano 1976). Trials had to recruit participants within 12 months of stroke onset, or the mean time since stroke had to be less than 12 months. We intended to include trials in subarachnoid haemorrhage and perform a subgroup analysis but we did not find any such trials. We intended to exclude trials of mixed populations (e.g. stroke and head injury) unless separate results for those with stroke were available, but we found no such trials.

Types of interventions

We included any drug classified as a SSRI (e.g. fluvoxamine, fluoxetine, sertraline, citalopram and paroxetine). We included any dose or mode of delivery, given for any duration and for any reason (e.g. to aid neurological recovery, to treat depression or anxiety or emotionalism, or to prevent depression or anxiety or other mood disorders). We did not include drugs that have mixed effects that include SSRI actions.

The comparator arm could include usual care or a placebo. We excluded studies in which fluoxetine was compared with another active intervention (e.g. another type of drug or herb or acupuncture). In this update, we also excluded trials that combined an SSRI with another active treatment and compared with the active treatment alone, because of the potential for interaction between the SSRI and other active treatment.

Types of outcome measures

Primary outcomes

We had two primary outcomes:

- independence at end of treatment. In stroke trials this is typically measured using the modified Rankin Scale (mRS), with a score of 0 to 2 conventionally considered to represent independence;
- disability score at the end of treatment. Measures included, but were not limited to, Barthel index (BI) or Functional Independence Measure (FIM).

Although disability scores and independence (or not) are arguably measuring the same concept, disability scores provide a more detailed description of functional outcome than simply using a dichotomous outcome such as independence or not. In other words, we were interested in performance in personal activities of daily living (ADL)/disability (measured using disability scores) and independence in performance in personal ADL/disability measured using dichotomous outcome (independent or not).

Note that 'end of treatment' depends on the duration of treatment, and so the outcome might be measured at different time points in different trials. But we justified this approach provided that trials measured the outcome at the same time point in each group.

Secondary outcomes

- Impairments (which can include neurological deficit scores, motor deficit scores)
- Depression
- Anxiety
- Quality of life
- Fatigue
- Healthcare cost
- Death
- Adverse events including gastrointestinal (GI) side effects, bleeding, seizures, and any other side effect
- Leaving the trial early (for any reason, including death)

We anticipated that most trials would assess these at the end of treatment and possibly at one or more time points. We did not stipulate a minimum follow-up time. We did not stipulate in advance precisely how multiple time points would be handled (if they had been found); we will consider this for the next update.

Search methods for identification of studies

See the methods for the Cochrane Stroke Group Specialised register. We searched for trials in all languages and arranged for the translation of trials where necessary.

Electronic searches

We developed the MEDLINE search strategy with the help of the Cochrane Stroke Group Information Specialist and adapted it for the other databases.

We searched the following electronic bibliographic databases:

- Cochrane Stroke Group Trials Register (16 July 2018);
- Cochrane Central Register of Controlled Trials (CENTRAL) Issue 7 of 12, (July 2018) (Appendix 1);



- MEDLINE (from 1948 to 16 July 2018) (Appendix 2);
- Embase Ovid (from 1980 to 16 July 2018) (Appendix 3);
- CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature (1982 to July 2018) (Appendix 4);
- AMED Ovid (Allied and Complementary Medicine) (from 1985 to 16 July 2018) (Appendix 5);
- PsycINFO Ovid (from 1967 to 16 July 2018) (Appendix 6);
- PsycBITE Pyschological Database for Brain Impairment Treatment Efficacy (www.psycbite.com/) (16 July 2018).

In addition, we searched the following ongoing trials registers (Appendix 7):

- Stroke Trials Registry (www.strokecenter.org/trials) (26 June 2018);
- US National Intitutes of Health ongoing Trials Register ClinicalTrials.gov (www.ClinicalTrials.gov) (16 July 2018);
- ISRCTN Registry (www.isrctn.com) (26 June 2018);
- EU Clinical Trials Register (www.clinicaltrialsregister.eu) (26 June 2018);
- World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/) (last searched 16 July 2018).

Evidence for this update included search results from the previous version of this review (Mead 2012), combined with results from the above searches. In Mead 2012 there were no date limits and searches were applied from inception of databases.

Searching other resources

In an effort to identify further published, unpublished and ongoing trials, we:

- searched reference lists of included trials and relevant reviews when full texts were retrieved for detailed scrutiny;
- contacted researchers in the field.

Data collection and analysis

Selection of studies

Joshua Cheyne (Cochrane Stroke Group Information Specialist), ran the searches of CENTRAL, MEDLINE, Embase, CINAHL, AMED, and PsycINFO, and downloaded the resulting references into Reference Manager. These were imported into Covidence, which automatically removed some, but not all, of the duplicates.

Any two review authors (from GM, EL, LL, MK, BS, SW, RT, A-SR, or C-FH) independently scrutinised the resulting titles and abstracts and excluded obviously irrelevant reports and duplicates. We obtained full texts of potentially eligible studies. Any two review authors (from GM, EL, LL, MK, BS, SW, RT, A-SR, C-FH) independently applied inclusion and exclusion criteria; if there was lack of consensus, a third review author (usually GM unless she had already scrutinised the paper) also applied inclusion and exclusion criteria.

For this update we include a study flow diagram that includes the number of unique references identified by the searches, the number of records excluded after preliminary screening of titles and abstracts, the number of records retrieved in full text, and the number fulfilling our inclusion criteria (see Figure 1).

Data extraction and management

For the new eligible trials we had identified, we created the necessary data fields in Covidence for each individual trial. Any two review authors (from GM, EL, LL, MK, MH, BS, SW, RT, LL, A-SR, C-FH) independently extracted data from each new trial.

We extracted the following data:

- the report: author, year and source of publication;
- the study: sample characteristics, social demography;
- the participants: stroke sequence (first-ever versus recurrent), social situation, time since stroke onset, prior history of psychiatric illness, current neurological status, stroke severity, whether people with aphasia were recruited, the proportion with depression at baseline (if recorded by trialists). We did not extract information on location or size of lesion as this was unlikely to have been recorded by the trialists, and brain imaging often does not show a visible infarct in people with minor strokes;
- the research design and features: adherence, non-response and length of follow-up;
- the intervention: type, duration, dose, timing and mode of delivery;
- the effect size: sample size, nature of outcome, estimate and standard deviation (SD) (or standard error (SE));
- Source of funding.

Assessment of risk of bias in included studies

We assessed risks of bias using the Cochrane 'Risk of bias' tool (Higgins 2017). We assessed the methods used in each study to control for the following potential sources of bias: sequence generation (selection bias); allocation concealment (selection bias); blinding of participants, personnel and outcome assessors (performance and detection bias); incomplete outcome data (attrition bias); selective outcome reporting (reporting bias); and other potential threats to validity.

For incomplete outcome data, we categorised as 'low risk' if missing data were imputed using appropriate methods or if missing outcome data overall were less than 5%.

We extracted data on source of funding, and listed this under 'Other sources of bias'. If the source of funding was not given, or if there were links with the pharmaceutical industry and no explicit statement that the funder had no input into the design or analysis of the study, we classified this as 'unclear risk'. We also recorded any other potential threats to validity.

We also extracted data on how adverse effects were reported, and listed these in the descriptions of the studies.

If a trial author was also one of the review authors, then a review author who was not involved in the trial extracted data and assessed quality.

Measures of treatment effect

For dichotomous data, we reported risk ratios (RRs). For ordinal scales, where there was a well-recognised cut-point in the scale (e.g. mRS) we analysed the data as a dichotomous outcome (dependent or independent).

For ordinal scales with no recognised cut-point, we analysed the data as continuous data. The data required for metaanalyses of continuous data in Review Manager 5 are means and standard deviations (SDs) (Review Manager 2014). When extracting continuous data from the study reports, we checked whether trials reported the SD or the standard error (SE). We had planned to use the SE or 95% confidence interval (CI) to compute the SD when SDs were missing, but this was not needed as all the trials reported SDs.

For ordinal scales and continuous data, we calculated standardised mean differences (SMDs), because different scales were used for the same outcomes (e.g. BI and FIM for disability score, the Beck Depression Inventory (BDI) or the Hamilton Rating Scale for Depression (HAMD) for depression). It should be noted that the SMD does not correct for differences in the direction of the scale. As some scales increase with disease severity and others decrease, we multiplied the mean value from one set of trials by –1. For example, in the National Institute of Health Stroke Scale a low score indicates a less severe stroke, whilst a low score in the Scandinavian Stroke Scale (SSS) indicates a more severe stroke.

If there was more than one outcome measure in the same domain (e.g. two different depression scales), we made a post hoc decision to select the one with the most complete data. We did not specify all 'acceptable' outcome measures in this review, but we will need to do this for future updates.

Unit of analysis issues

The number of observations in the analysis should match the number of 'units' that were randomised. We considered outcomes measured at the end of treatment and at the end of follow-up in separate analyses. For side effects, we considered the number of participants developing a particularly side effect rather than the total number of side effects in each group.

Dealing with missing data

For this update, we contacted authors of new trials to obtain any data that we needed for our meta-analysis that had not been included in a published full-text article or an abstract.

Assessment of heterogeneity

We assessed whether there was evidence of inconsistency in our results by considering possible clinical, methodological, and statistical heterogeneity. We assessed clinical and methodological heterogeneity by comparing similarities in our included studies between study designs, participants, interventions, and outcomes.

We quantified the effect of heterogeneity using the I^2 statistic. We assessed statistical heterogeneity by visually examining forest plots. We used the following cut-offs from the *Cochrane Handbook for Systematic Reviews of Interventions* as a rough guide to interpretation (Section 9.5.2; Deeks 2017):

- 0% to 40% is not considered important;
- 30% to 60% suggests moderate heterogeneity;
- 50% to 90% suggests substantial heterogeneity;
- 75% to 100% is considerable heterogeneity

Assessment of reporting biases

We searched clinical trials registers to identify published protocols for each of our included studies. We checked for selective reporting of results by comparing the published protocol with the published full-text article and by scrutinising the aims and methods of the trials and comparing these with outcomes reported. We found several papers by the same authors, and contacted the authors to check whether the publications were duplicates or to check if the included study populations were unique. If it was not possible to determine whether different publications reported overlapping groups of participants, we included just one of the papers and listed the others as awaiting assessment.

If we had identified a sufficient number of included studies at low risk of bias (i.e. more than 10 studies (Sterne 2017)), we would have generated a funnel plot to assess risk of publication bias in the review; an asymmetrical funnel plot might have suggested publication of only positive results (Egger 1997).

We deployed a comprehensive search strategy in an effort to avoid reporting biases in our review methodology. See Search methods for identification of studies.

We tried to avoid language bias by including all trials, irrespective of language: we sought translation where needed.

Data synthesis

We completed meta-analysis of outcomes for which we had comparable effect measures from more than one study, and when measures of heterogeneity indicated that pooling of results was appropriate. We used the statistical calculator provided in Review Manager 5 to perform meta-analysis (Review Manager 2014).

We used a fixed-effect model (Mantel 1959), rather than a randomeffects model because of the dominance of the FOCUS trial (FOCUS Trial Collaboration 2018); random effects would have given too much weight to the smaller trials. The dominance of the FOCUS trial makes a fixed-effect model a more reliable indicator of the effect than the average across the smaller trials. We assessed the robustness of the results to choice of model using a sensitivity analysis.

In the 2012 review, we performed multiple meta-analyses of all outcomes, and included all trials irrespective of risk of bias. We then explored the influence of each aspect of bias on estimates of effects in a series of sensitivity analyses. This approach generated the hypothesis that SSRIs might improve stroke recovery, but also suggested that the apparently beneficial effects might simply have been due to bias, with trials at higher risk of bias tending to give positive results. This approach generated multiple forest plots.

For this update, we decided to limit our primary analysis to studies at low risk of bias (Higgins 2017), as we wanted to reliably find out whether SSRIs are more effective than placebo or usual care at improving disability or independence in people less than 12 months post-stroke.

We reached decisions on overall risk of bias by study by consideration of six 'Risk of bias' domains: sequence generation, allocation concealment, blinding of participants and trial personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting. We required a study to have a judgement of low risk of bias in all six domains in order to categorise it as having an overall low risk of bias. We did, however, include the studies with an unclear or high risk of bias judgements

in these six domains in a sensitivity analysis of our co-primary outcomes of disability and independence.

Subgroup analysis and investigation of heterogeneity

If there had been at least two studies at low risk of bias, we would have explored variability in the participants, interventions, and outcomes among studies using the following subgroups.

- Type of SSRI.
- Trials with depression at baseline as an inclusion criterion and those where depression was not an inclusion criterion.
- Time since stroke at recruitment. We categorised these as less than three months (0 90 days), three to six months (91 to 108 days), six to nine months (181 to 271 days) or nine to 12 months (272 to 365 days).

If we found high statistical heterogeneity we still performed the subgroup analysis, but considered the reason for this heterogeneity.

Sensitivity analysis

We explored the potential effects of decisions made as part of the review process as follows.

- We then included all studies regardless of 'Risk of bias' judgement for our primary outcomes of disability score and independence.
- We conducted meta-analysis using the alternate meta-analytical effects model (fixed-effect or random-effects).
- We conducted a meta-analysis using the alternate 'last available follow-up' time point.

We compared effect estimates from the above results with effect estimates from the main analysis. We reported differences that altered the interpretation of effects.

GRADE and 'Summary of findings'

We created a 'Summary of findings' table using the following outcomes: disability; dependent according to the mRS; neurological deficit score; depression (continuous data); death; seizures; and gastrointestinal side effects (Summary of findings for the main comparison). We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence as it relates to the studies that contribute data to the meta-analyses for the prespecified outcomes (Atkins 2004). We used methods and recommendations described in Chapter 11 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Schünemann 2017), using GRADEproGDT software (GRADEproGDT 2015). We justified all decisions to downgrade the quality of studies using footnotes, and made comments to aid the reader's understanding of the review where necessary.

RESULTS

Description of studies

For substantive descriptions of studies see: Characteristics of included studies, Characteristics of excluded studies, Characteristics of studies awaiting classification, and Characteristics of ongoing studies.


Results of the search

For this update, we screened 2988 references from database searches and accessed the available full-text reports for 499 studies.


The previous version of this review (Mead 2012) identified 56 eligible completed studies recruiting 4109 participants, five ongoing studies (Anonymous 2005; Hankey 2011; Carda 2009; Kim 2011; FOCUS Trial Collaboration 2018), and two studies that were awaiting classification (Sitzer 2002; Whyte 2005).

The flow of search results for the previous version of the review are reported in Mead 2012. We report details of the search for this update in a PRISMA flow chart (Figure 1).

Figure 1. Flow diagram showing the searches for this update. FOCUS Poland identified through personal communication







The previous version of this review identified 56 eligible completed studies recruiting 4109 participants (Acler 2009; Almeida 2006; Andersen 1994; Brown 1998; Burns 1999; Chen 2001; Chen 2002; Chen 2005a; Chen 2005b; Cheng 2003; Chollet 2011; Dam 1996; Feng 2004; Fruehwald 2003; GlaxoSmithKline 1998; Guo 2009; He 2004; He 2005; Hu 2002; Huang 2002; Jia 2005; Kong 2007; Lai 2006; Li 2004a; Li 2004b; Li 2005; Li 2006; Li 2008; Liu 2006; Meara 1998; Miao 2004; Murray 2005; Pariente 2001; Rasmussen 2003; Restifo 2001; Robinson 2000a; Robinson 2000b; Robinson 2008; Song 2006; Wang 2003; Wen 2006; Wiart 2000; Xie 2005; Xu 2001; Xu 2006; Yang 2002; Yang 2011; Ye 2004; Zhou 2008; Finkenzeller 2009; Ji 2000; Li 2002; Liang 2003; Liu 2004; Xu 2007; Zhou 2003).

Of these we excluded seven (439 participants) from this update (Finkenzeller 2009; Ji 2000; Li 2002; Liang 2003; Liu 2004; Xu 2007; Zhou 2003), as they did not fulfil our more stringent inclusion criteria. See Excluded studies.

Two previously ongoing studies are now complete (FOCUS Trial Collaboration 2018; Kim 2011), two studies are still ongoing (Anonymous 2005; Hankey 2011), and one study has been moved to studies awaiting assessment, as we were unable to make contact with the investigators (Carda 2009). One study previously classified as 'Awaiting assessment' was terminated due to difficulties meeting recruitment goals; it did not state the number of participants but has been retained in our narrative review (Whyte 2005).

We identified a further 11 eligible studies from the 2018 search (Andersen 2013; Black-Schaffer 2012; Birchenall 2019; Gao 2016; He 2016; Marquez Romero 2013; Pan 2018; Razazian 2014; Savadi Oskouie 2012; Shah 2016; Zhao 2011). Thus, in addition to FOCUS Trial Collaboration 2018, Kim 2011 and Whyte 2005 there is a total of 14 new studies for this update, recruiting a further 5498 participants.

There are now 63 included studies recruiting a total of 9168 randomised participants. Not all the studies provided data that

Cochrane Database of Systematic Reviews

could be used in the meta-analysis (thus the denominator in the forest plots does not equal 9168). Two trials did not state the number of participants (Meara 1998; Whyte 2005).

Of the 63 included studies:

- 32 trials used fluoxetine (Birchenall 2019; Black-Schaffer 2012; Brown 1998; Chen 2001; Cheng 2003; Chollet 2011; Dam 1996; Feng 2004; FOCUS Trial Collaboration 2018; Fruehwald 2003; He 2004; He 2016; Hu 2002; Huang 2002; Kong 2007; Li 2004a; Li 2004b; Li 2008; Marquez Romero 2013; Pariente 2001; Razazian 2014; Restifo 2001; Robinson 2000a; Robinson 2000b; Shah 2016; Song 2006; Wang 2003; Wen 2006; Wiart 2000; Xu 2001; Zhao 2011; Zhou 2008);
- 8 trials used sertraline (Almeida 2006; Burns 1999; Guo 2009; Meara 1998; Murray 2005; Rasmussen 2003; Whyte 2005; Xie 2005);
- 11 used paroxetine (Chen 2002; Chen 2005b; GlaxoSmithKline 1998; He 2005; Lai 2006; Li 2005; Pan 2018; Xu 2006; Yang 2002; Yang 2011; Ye 2004);
- 8 used citalopram (Acler 2009; Andersen 1994; Andersen 2013; Gao 2016; Li 2006; Liu 2006; Miao 2004; Savadi Oskouie 2012);
- 2 used escitalopram (Kim 2011; Robinson 2008);
- 1 used either sertraline or fluoxetine (Jia 2005)
- 1 used citalopram or fluoxetine (Chen 2005a)

Baseline sociodemographic and clinical characteristics

Six trials do not present baseline demographic and clinical characteristics for each group, but rather the baseline demographic and clinical characteristics for only those completing the trial are presented (He 2016; Kim 2011; Pan 2018; Razazian 2014; Savadi Oskouie 2012; Shah 2016).

The mean age of participants ranged from 51 ± 7 years (Song 2006) to 75.6 years (Wang 2003), with most trials recruiting participants in their 60s (data from 48/63studies).

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review) Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Mean time since stroke

Of the 63 included studies:

- 38 report recruiting participants between 0 and 90 days after stroke onset: (Acler 2009; Almeida 2006; Andersen 1994; Andersen 2013; Birchenall 2019; Chen 2001; Chen 2005b; Cheng 2003; Chollet 2011; Feng 2004; FOCUS Trial Collaboration 2018; Fruehwald 2003; Gao 2016; He 2004; He 2016; Hu 2002; Huang 2002; Kim 2011; Kong 2007; Li 2004a; Li 2004b; Li 2008; Marquez Romero 2013; Pan 2018; Rasmussen 2003; Robinson 2008; Savadi Oskouie 2012; Shah 2016; Song 2006; Wen 2006; Wiart 2000; Xie 2005; Xu 2001; Xu 2006; Yang 2011; Ye 2004; Zhao 2011; Zhou 2008). A further three trials described participants as having an 'acute stroke'; we assume this meant zero to three months, so have included these in the zero-to-threemonth group (He 2005; Lai 2006; Li 2006).Two further studies reported that the mean time since stroke was between five and 16 weeks, so we included these in the zero-to three-month group (Robinson 2000a; Robinson 2000b). One trial, which did not recruit any participants, had an inclusion criterion of less than 15 days before stroke (Black-Schaffer 2012);
- four trials report recruiting participants three to six months (91 to 108 days) after stroke onset: Dam 1996 (described as participants being one to six months); Miao 2004, Murray 2005, and Yang 2002 ('recovery phase of stroke' two to six months);
- two trials report recruiting participants at six to nine months (181 to 271 days) after stroke onset (Guo 2009; Liu 2006);
- no trials reported recruiting participants between nine and 12 months after stroke;
- one trial reported the experimental and control group being median 10.5 months and 5.5 months after stroke, respectively (Burns 1999).
- 12 trials did not report the precise time (Brown 1998; Chen 2002; Chen 2005a; GlaxoSmithKline 1998 (less than 12 months); Jia 2005; Li 2005; Meara 1998; Pariente 2001; Razazian 2014; Restifo 2001; Wang 2003; Whyte 2005).

Depression as an inclusion criterion

Thirty-three studies included participants affected by depression (i.e. depression used as an inclusion criterion): Andersen 1994; Chen 2001; Chen 2002; Chen 2005a; Chen 2005b; Cheng 2003; Feng 2004; Fruehwald 2003; GlaxoSmithKline 1998; Guo 2009; He 2005; Hu 2002; Huang 2002; Jia 2005; Lai 2006; Li 2004a; Li 2004b; Li 2005; Li 2006; Li 2008; Liu 2006; Meara 1998; Miao 2004; Murray 2005; Robinson 2000a; Song 2006; Wang 2003; Wiart 2000; Xie 2005; Xu 2001; Yang 2002; Yang 2011; Ye 2004.

Thirty studies did not use depression as an inclusion criterion: Acler 2009; Almeida 2006; Andersen 2013; Birchenall 2019; Black-Schaffer 2012; Brown 1998; Burns 1999; Chollet 2011; Dam 1996; FOCUS Trial Collaboration 2018; Gao 2016; He 2004; He 2016; Kim 2011; Kong 2007; Marquez Romero 2013; Pan 2018; Pariente 2001; Rasmussen 2003; Razazian 2014; Restifo 2001; Robinson 2000b; Robinson 2008; Savadi Oskouie 2012; Shah 2016; Wen 2006; Whyte 2005; Xu 2006; Zhao 2011; Zhou 2008.

Criteria for diagnosing depression varied between trials.

Excluded studies

In line with the guidance for Cochrane Reviews, which states that the list of excluded studies should be as brief as possible and should not list studies that obviously do not fulfil the inclusion criteria, we have now listed only 20 of these in the Characteristics of excluded studies'. Of these 20 studies, the reasons for exclusion are as follows.

We excluded three studies that we had previously included but were no longer eligible for this review, as there was no random component in the sequence generation process (Li 2002; Liang 2003; Zhou 2003). We excluded four studies that combined an SSRI with another active intervention and compared it to the active treatment alone (Finkenzeller 2009; Ji 2000; Liu 2004; Xu 2007).

We excluded two studies listed as 'Awaiting classification' in the previous version of this review because we could find no published results, and when we sought further information from the authors we received no responses (Graffagnino 2002; Sitzer 2002). Given the insufficient information to assess eligibility and, owing to the length of time since the study abstract was published, we have now excluded these studies.

We excluded four studies because they recruited participants more than one year post-stroke (Berends 2009; Choi Kwon 2008; Gourab 2015; Sun 2015).

Other reasons for exclusion were: cross-over design (Andersen 1993), ineligible outcomes (Robinson 2011), trial never started (Andersen 2012; Anderson 2002), study withdrawn (no funding) (University of Alabama 2013), and unable to find publication after extensive searching (Anonymous 2012; Anonymous 2012b).

See Characteristics of excluded studies for studies excluded during this update. Studies excluded in previous searches are listed in Mead 2012.

Ongoing studies

In addition to one study identified as ongoing in the previous review (Anonymous 2005), we identified 14 new ongoing studies from the clinical trials register searches (Chollet 2016; Cocho 2015; Dike 2019; Farokhi 2017; Fregni 2014; Hankey 2011; Karimialavijeh 2017; Leibovitch 2018; Levitt 2019; Lundström 2014; Pastore-Wapp 2016; Pirzeh 2012; Sadaat 2012; Sahin 2016), and one from personal contact (FOCUS-Poland 2014). See Characteristics of ongoing studies.

Studies awaiting classification

We were unable to assess review eligibility for four studies (Carda 2009; Guo 2015; He 2012; Jurcau 2016). Carda 2009 has been moved from 'Ongoing studies' in the previous review (Mead 2012), to 'Studies awaiting classification' in this update, as we were unable to make contact with the investigators. Jurcau 2016 was published as an abstract and included insufficient detail; the author did not respond to requests for information. From a combination of trial registration details and published information, and after contacting authors, we were uncertain whether three studies (Guo 2015; He 2012; He 2016) included unique study populations and we therefore decided to include the data from one publication (He 2016), and classified the remaining two as 'Awaiting classification' (Guo 2015; He 2012). See Characteristics of studies awaiting classification.



Risk of bias in included studies

All 63 studies were RCTs.

See Figure 2 and Figure 3.



Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.






Figure 2. (Continued)


GlaxoSmithKline 1998	?	?	?	?	•	?	?
Guo 2009	•	?	•	•	•	?	•
He 2004	?	?	•	•	•	?	•
He 2005	?	?	•	?	•	•	•
He 2016	•	?	?	•	•	•	•
Hu 2002	?	?	•	?	•	?	?
Huang 2002	?	?	?	?	÷	?	?
Jia 2005	?	?	•	?	?	?	?
Kim 2011	•	•	•	•	•	•	•
Kong 2007	•	?	•	•	•	?	?
Lai 2006	?	?	?	?	•	•	?
Li 2004a	•	•	•	?	÷	?	?
Li 2004b	?	?		?		?	?
Li 2005	?	?	•	?	•	?	?
Li 2006	?	?	•	?	•	?	?
Li 2008	•	?	•	•	?	?	•
Liu 2006	?	?	•	?	•	?	?
Marquez Romero 2013	•	•	•	•	•	•	•
Meara 1998	?	?	?	?	?	?	?
Miao 2004	?	?	•	•	•	?	?
Murray 2005	•	•	•	•	•	•	?
Pan 2018	•	?	?	•	•	?	•
Pariente 2001	•	•	•	•	•	?	?
Rasmussen 2003	?	?	•	?	•	•	?
Razazian 2014	?	?	•	?	•	•	•
Restifo 2001	?	?	?	?	?	?	?
Robinson 2000a	•	•	•	?	•	•	?
Robinson 2000b	•	•	•	?	•	•	?
Robinson 2008	•	?	•	•	•	•	?
Savadi Oskouie 2012	•	•	?	?		•	
Shah 2016	?	?		2		2	
511an 2010	-	•	-	•	-	•	-



Figure 2. (Continued)



Figure 3. 'Risk of bias' graph: review authors' judgements about each 'risk of bias' item presented as percentages across all included studies.



Allocation

We judged the random sequence generation to be adequately presented (i.e. there was a low risk of bias) in 22 studies. For the remaining 41 studies, the risk of selection bias was unclear. There was no study in which the random sequence generation was inadequate (i.e. there was a high risk of bias). Sixteen studies had adequate (low risk) allocation concealment. In the other 47 studies, the details provided did not allow an assessment of the methods used to prevent investigators and participants from foreseeing the assignment (unclear risk of bias).



Blinding

We judged the blinding of participants and personnel (performance bias) as low risk in 22 studies, as high risk in 24 studies, and as unclear risk in the remaining 17 studies.

We judged the blinding of outcome assessment (detection bias) to be at low risk in 19 studies, at high risk in two studies, and at unclear risk in the remaining 42 studies.

Incomplete outcome data

The risk of incomplete outcome data (attrition bias) was at low risk in 30 studies, at high risk in 22 studies, and at unclear risk in the remaining 11 studies.

Selective reporting

We judged missing data to be at low risk in 16 studies, high risk in seven studies, and as having unclear risk in the other 40 studies.

Other potential sources of bias

We judged 13 studies to be at low risk of bias from other potential sources of bias, at high risk in six studies, and as having unclear risk in the other 44 studies.

Overall risk of bias

The FOCUS Trial Collaboration 2018, Chollet 2011, and Marquez Romero 2013 studies had an overall low risk of bias (i.e. low risk of bias in each of six domains: sequence generation, allocation concealment, blinding of participants and trial personnel, blinding of outcome assessment, incomplete outcome data and selective outcome reporting) (Figure 2).

Effects of interventions

See: Summary of findings for the main comparison SSRI versus control at end of treatment, by SSRI for stroke recovery

Primary outcomes

Disability score at the end of treatment

We combined data for studies with an overall low risk of bias for the outcome of disability score, using a standardised mean difference (SMD) with a fixed-effect model (SMD-0.01, 95% CI-0.09 to 0.06; P = 0.75; 2 studies, 2829 participants; moderate-quality evidence) with no important heterogeneity There was no difference in measures of disability score between SSRI intervention and placebo (Analysis 1.1).

Independent on modified Rankin score (mRS 0 to 2) at the end of treatment

We combined data for studies with an overall low risk of bias for the outcome of independent on mRS 0 to 2 using a risk ratio with a fixed-effect model (RR 1.00, 95% CI 0.91 to 1.09; P = 0.99; 3 studies, 3249 participants; moderate-quality evidence). There was no difference in mRS (independence) between SSRI intervention and placebo (Analysis 1.2), but substantial heterogeneity between studies with an I² of 78%.

Secondary outcomes

Neurological deficit score at the end of treatment

We combined data for studies with an overall low risk of bias for the outcome of neurological deficit score, using the SMD with a fixed-effect model. The analysis found no difference in neurological scores between SSRI and placebo (SMD –0.30, 95% CI –0.63 to 0.04; P = 0.08; 2 studies, 142 participants; moderate-quality evidence), with no important heterogeneity (I² = 0%) (Analysis 1.3).

Depression severity at end of treatment (continuous data)

We combined data for studies with an overall low risk of bias for the outcome of depression using the SMD with a fixed-effect model (SMD -0.11, 95% CI -0.19 to -0.04; P = 0.002; 2 studies, 2861 participants; moderate-quality evidence). Participants who received an SSRI intervention had significantly lower end-of-treatment scores on measures of depression than those participants receiving placebo (Analysis 1.4). However, there was substantial heterogeneity between trials ($I^2 = 69\%$).

Depression at the end of treatment (dichotomous data)

Data were not available for more than one study at low risk of bias for any analysis (Analysis 1.5). This high-quality study demonstrated that fluoxetine reduced the risk of depression at the end of treatment (RR 0.78, 95% CI 0.66 to 0.92; 1 study, 3127 participants).

Anxiety severity at end of treatment (continuous data)

No studies at low risk of bias reported measures of anxiety.

Anxiety severity at end of treatment (dichotomous data)

No studies at low risk of bias reported number of diagnoses of anxiety.

Cognition at end of treatment (continuous data)

No studies at low risk of bias reported cognition at the end of treatment.

Death at end of treatment

We combined data for studies with an overall low risk of bias for the outcome of death, using a risk ratio with a fixed-effect model. The analysis found no difference in the total number of deaths between SSRI and placebo (RR 0.99, 95% CI 0.79 to 1.25; P = 0.95; 3 studies, 3254 participants; high-quality evidence), with no evidence of heterogeneity ($l^2 = 0\%$) (Analysis 1.6).

Side effects: seizures at end of treatment

We combined data for studies with an overall low risk of bias for the outcome of seizures, using a risk ratio with a fixed-effect model. The analysis found no evidence of a substantial difference in the total number of seizures between SSRI and placebo (RR 1.47, 95% CI 0.99 to 2.18; 3 studies, 3275 participants; moderate-quality evidence), with no evidence of heterogeneity (I² = 0%) (Analysis 1.7).

Side effects: gastrointestinal side effects at end of treatment

We combined data for studies with an overall low risk of bias for the outcome of gastrointestinal side effects, using a risk ratio with a fixed-effect model. There was a higher number of gastrointestinal side effects (P = 0.05) among participants treated with SSRIs

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright $\ensuremath{\mathbb S}$ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cochrane Database of Systematic Reviews

compared to placebo (RR 2.19, 95% CI 1.00 to 4.76; 2 studies, 148 participants; moderate-quality evidence), with no evidence of heterogeneity ($I^2 = 0\%$) (Analysis 1.8).

Side effects: bleeding at end of treatment

Data were not available for more than one study at low risk of bias for any analysis (Analysis 1.9). The risk ratio was 0.96, 95% CI 0.56 to 1.66.

Change in depression score between baseline and follow-up

No studies at low risk of bias reported change in depression score between baseline and follow-up.

Change in cognition between baseline and follow-up

No studies at low risk of bias reported change in cognition between baseline and follow-up.

Leaving the study early (before the end of scheduled followup)

We combined data for studies with an overall low risk of bias for the outcome of leaving the study before the end of scheduled follow-up, using a risk ratio with a fixed-effect model. The analysis found no difference between SSRI and placebo, with no evidence of heterogeneity (RR 1.01, 95% CI 0.48 to 2.10; P = 0.98; 3 studies, 3277 participants) with no heterogeneity ($I^2 = 0\%$) (Analysis 1.10).

Motor deficits

We combined data for studies with an overall low risk of bias for the outcome of motor deficit score, using the SMD with a fixedeffect model. The analysis found no difference between SSRI and placebo (SMD 0.02, 95% CI –0.05 to 0.09; P = 0.58; 3 studies, 2936 participants) with considerable evidence of heterogeneity (I² = 88%) (Analysis 1.11).

Note that data from Chollet 2011 are adjusted means, and data from Marquez Romero 2013 are means and SDs estimated from reported medians and interquartile ranges (Wan 2014).

Quality of life

Of the high-quality trials, only FOCUS reported quality of life (FOCUS Trial Collaboration 2018). There was no difference between groups in the Euroquol 5D-5L.

Fatigue

Of the high-quality trials, only FOCUS reported fatigue (FOCUS Trial Collaboration 2018). This was measured using the SF-36 vitality score. There was no difference in fatigue between the groups.

Healthcare costs

No trial reported healthcare costs.

We have included those outcomes in the Summary of findings for the main comparison which we decided were key to decisionmaking.

Subgroup analyses by intervention characteristics and subsets of participant

We did not perform preplanned subgroup analyses by intervention characteristics and subsets of participant (including with or without

depression) as there were insufficient studies at low risk of bias. All the trials at low risk of bias stipulated that the participants did not have to have depression to enter the trial.

Sensitivity analysis

Inclusion of all studies regardless of 'Risk of bias' judgement for our primary outcomes

We included all studies regardless of 'Risk of bias' judgement for the co-primary outcome of disability at the end of treatment using a SMD and a fixed-effect model. Participants who received an SSRI intervention had significantly lower end-of-treatment scores on measures of disability than those participants receiving placebo or standard care/practice (SMD 0.23, 95% CI 0.18 to 0.29; P < 0.001; 26 studies, 5334 participants) with considerable heterogeneity between trials (Chi² = 328.10, df = 25 (P < 0.001); I² = 92%) (Analysis 1.12).

Re-analysis included all studies regardless of 'Risk of bias' judgement for the outcome of independence. Modified Rankin score (mRS 0 to 2) at the end of treatment did not alter the result (RR 0.97, 95% Cl 0.91 to 1.03; P = 0.35, $l^2 = 74\%$; 5 studies, 4002 participants) (Chi² = 15.57, df = 4 (P = 0.004) (Analysis 1.13).

Meta-analysis using the alternate meta-analytical effects model (fixed-effect or random-effects)

We re-analysed the data for our primary outcomes (disability score and independence on modified Rankin score 0 to 2) using the random-effects analysis for the three high-quality trials. For mRs 0 to 2, this altered the effect estimate to 1.83 (95% CI 0.74 to 4.56). Note that the random-effects model gives more weight to smaller trials; this explains the implausibly large effect size. For disability, the same effect size was obtained irrespective of whether fixed or random effects were used.

Meta-analysis using the alternative end of follow-up time point

Two of the studies at low risk of bias (Chollet 2011; Marquez Romero 2013) reported outcome data only at the end of treatment. FOCUS Trial Collaboration 2018 reported outcomes at the end of treatment and also six months after the end of treatment. With just one high-quality trial reporting results at an alternative end point, it was therefore not possible to perform a meta-analysis.

DISCUSSION

Summary of main results

For this update we included 63 studies with 9168 participants.

Of the 63 included studies, 32 trials used fluoxetine, eight trials used sertraline, 11 used paroxetine, eight used citalopram, two used escitalopram, one used either sertraline or fluoxetine, and one used citalopram or fluoxetine.

We assessed only three of the 63 included studies to be at low risk of bias across the key domains. The three trials at low risk of bias compared fluoxetine to placebo. We included these three trials in our meta-analysis.

Comparing fluoxetine to placebo, we found moderate-quality evidence of no beneficial effects of fluoxetine on our two primary outcomes (disability and independence). We found moderate-



quality evidence that fluoxetine reduced the severity of depression evaluated using a continuous outcome. We found moderate-quality evidence that fluoxetine increased gastrointestinal side effects compared to placebo. We found a non-significant excess of seizures in those allocated to fluoxetine. We found no difference for other outcomes.

Overall completeness and applicability of evidence

This review includes studies from different settings (e.g. countries; high-, middle- and low-income settings; healthcare systems), with different criteria for selecting participants (e.g. methods of prerandomisation diagnosis and investigation, inclusion and exclusion criteria), that may reflect differences between the trial protocol and routine clinical practice (e.g. inclusion of participants based on a diagnosis of stroke made using brain imaging: brain imaging is unlikely to be either available or affordable in routine clinical care in many low- and middle-income country settings); and different characteristics of randomised participants (e.g. baseline demographic and clinical characteristics, stroke severity, time since stroke onset, presence or absence of depression, severity of depression). These trial characteristics may in part explain the heterogeneity of results, but we know from our previous review that the most probable cause of heterogeneity is trial quality.

Six published studies did not present the baseline demographic and clinical characteristics for each group, but rather they reported the baseline demographic and clinical characteristics for those completing the trial (i.e. a subset of all those randomised). This makes it very difficult to compare the study groups at baseline.

There is a discordance between the results for disability (one of our co-primary outcomes) between the trials at low risk of bias, which showed no effect, and all trials (a positive effect). This is because trials at high risk of bias tended to be positive.

The results of the meta-analysis of the three trials at low risk of bias are applicable to clinical practice, although the metaanalysis is dominated by the UK FOCUS trial which recruited participants from the National Health Service (FOCUS Trial Collaboration 2018). Nevertheless, FOCUS had broad inclusion criteria, and the demographics of those recruited are similar to UK patients with stroke. Chollet 2011 recruited participants from France and Marquez Romero 2013 recruited participants from Mexico. FOCUS Trial Collaboration 2018 included participants with both haemorrhagic and ischaemic stroke, Chollet 2011 recruited participants with ischaemic stroke, and Marquez Romero 2013 recruited participants with haemorrhagic stroke.

There is a theoretical risk that SSRIs might carry particular risks in people with haemorrhagic stroke, due to their effects on platelet aggregation and bleeding. An individual patient meta-analysis is needed to explore this. This might be possible when the AFFINITY (Hankey 2011), and EFFECTS (Lundström 2014) trials are published.

We were unable to explore the influence of the type of SSRI, as all three high-quality trials used fluoxetine.

The searches were performed in July 2018. Had we had sufficient resources, we would have updated the searches again immediately prior to publication of the review. Instead, we aim to update the review soon after two large key trials are published in 2020. We are not aware of any studies that have been published since July 2018.

Quality of the evidence

For the evaluation of quality of the evidence, we contacted authors of primary studies as yet unpublished for data on outcomes. We did not contact authors of primary studies for supplementary information on features of the study design that were unclear or omitted from published trial reports; rather, we assessed the study based on the information available in the published report. We did contact authors of primary studies for clarification when there were multiple publications indicating separate studies with unique populations.

We used the Cochrane 'Risk of bias' tool to assess study methodology. In this update we decided to restrict meta-analyses to studies at low risk of bias, because in the previous review there was evidence that the apparently beneficial effects of SSRI on recovery might have been simply due to methodological limitations of the included trials. For this update, only three of the 63 included studies met our criteria for overall low risk of bias.

The meta-analysis of the high-quality studies is dominated by FOCUS Trial Collaboration 2018, which provided more than 90% of the data, and so it is not surprising that the results of the metaanalysis are very similar to the results of FOCUS. FOCUS was neutral for its primary outcome (mRS at six months), unlike the other two high-quality but smaller studies, which were both positive.

We performed sensitivity analyses of our two co-primary outcomes (disability and independence) by including all the available outcome data, irrespective of risk of bias. Like our initial (hypothesis-generating) Cochrane Review, we found that SSRIs reduced disability at the end of treatment. However, it is highly likely that this positive effect is due to biases in trial quality. It will therefore be important to update this review again when further data become available, to increase the generalisability of the findings.

We found a high l^2 measure for independence. This might reflect different settings, different stroke types, and different durations of treatment.

Potential biases in the review process

We conducted the review using robust Cochrane methodology, with two review authors independently assessing studies for eligibility, extracting data, and carrying out 'Risk of bias' assessment. Five review authors were also authors of the FOCUS Trial Collaboration 2018 (MD, GM, EL, GH, MH) and so review authors who were independent of the trial extracted the data from FOCUS, and performed quality assessment and the meta-analysis.

We made some changes to the review during this update. We used Covidence for screening and data extraction. We excluded trials which combined an SSRI with another active intervention and compared it to the active treatment alone. We restricted the criteria for considering studies for this review to randomised controlled trials and excluded studies where investigators described a nonrandom component in the sequence-generation process. We incorporated 'Risk of bias' assessments in analyses by restricting the primary analysis to studies at low risk of bias. We performed sensitivity analyses to determine how the conclusions were affected by including studies at unclear and high risk of bias; we found evidence of a beneficial effect of SSRIs on measures of disability with inclusion of studies at unclear and high risk of bias



with considerable heterogeneity. For the outcome 'independence', the results were unchanged. We made these changes to the review in order to increase the robustness of our evidence.

Comparing the effect estimates in the this update with the effect estimates from only the high-quality trials in the original review suggest that our decisions have not introduced bias.

Agreements and disagreements with other studies or reviews

This review has demonstrated that SSRIs do not improve recovery after stroke. This is in contrast with other meta-analyses, including our own 2012 Cochrane Review, which showed a positive effect of SSRIs on recovery.

This difference is almost certainly because previous meta-analyses included trials at higher risk of bias.

AUTHORS' CONCLUSIONS

Implications for practice

Based on our meta-analysis of the trials at low risk of bias, there is currently no indication for the routine prescription of SSRIs to promote stroke recovery. Fluoxetine reduces the risk of depression, but this is probably not a sufficiently strong rationale to give all people with stroke a six-month course of the drug. Nevertheless, the data in this review have provided further information about the risks of SSRIs in stroke, which will enable those clinicians who may wish to give prophylactic SSRI to patients at high risk of depression to weigh up the risks and the benefits.

Implications for research

A meta-analysis is generally more robust if it includes several high-quality trials. We will therefore update this review when two further large trials using fluoxetine have been published. There are also smaller ongoing trials which we will include in a future update. In the meantime, we recommend that further new trials exploring whether fluoxetine improves recovery after stroke are not established.

ACKNOWLEDGEMENTS

For this update, we are grateful to the following people.

Joshua Cheyne, Cochrane Stroke Information Specialist, ran the literature searches.

Maureen Harding obtained articles for full-text review.

Dr Juan Marquez Romero provided unpublished data from the FMRICH trial on 8 September 2018 (Professor Mead was the recipient of this information).

Professor Chollet responded to requests for information about other new trials.

Dr Jan Bembenek and Professor Anna Czlonkowska provided further information about FOCUS-Poland.

Professor Peter Sandercock commented on the analysis of the fluoxetine data.

Dr Pavel Lindberg kindly provided information from Birchenall 2019.

REFERENCES

References to studies included in this review

Acler 2009 {published data only}

Acler M, Avesani A, Fiaschi A, Manganotti P. Serotonergic modulation of brain excitability and motor recovery in patients affected by stroke. A double blind placebo RCT. *International Journal of Stroke* 2008;**3**:336.

* Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. *Journal of Neurology* 2009;**256**(7):1152-8.

Almeida 2006 {published data only}

Almeida OP, Waterreus A, Hankey GJ. Preventing depression after stroke: results from a randomized placebo-controlled trial. *Journal of Clinical Psychiatry* 2006;**67**(7):1104-9.

Andersen 1994 {published data only}

Andersen G, Vestergaard K, Lauritzen L. Effective treatment of post-stroke depression with selective serotonin reuptake inhibitors. *Journal of Neurology* 1994;**241**:S42.

* Andersen G, Vestergaard K, Lauritzen L. Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. *Stroke* 1994;**25**(6):1099-104.

Andersen G, Vestergaard K, Lauritzen L. Post-stroke depression treated with citalopram. *Acta Neurologica Scandinavica* 1994;**89 Suppl 155**:20.

Andersen G, Vestergaard K, Lauritzen L. Post-stroke depression treated with citalopram - a selective serotonin reuptake inhibitor. *Canadian Journal of Neurological Sciences* 1993;**20**:S115.

Andersen G, Vestergaard K, Lauritzen L. Post-stroke depression treated with citalopram a selective serotonin reuptake inhibitor. 7th Scandinavian Meeting on Cerebrovascular Disease. 1993:54.

Andersen G, Vestergaard K, Lauritzen LU. Effective treatment of depression following apoplexy with citalopram. *Ugeskrift for Laeger* 1995;**157**(14):2000-3.

Flicker C, Andersen G, Bayer L. A placebo controlled study of citalopram treatment for post-stroke depression. 11th Annual Meeting of the American Association for Geriatric Psychiatry. 1998.

Andersen 2013 {published data only}

*Kraglund KL, Mortensen JK, Damsbo AG, Modrau B, Simonsen SA, Iversen HK, et al. Neuroregeneration and vascular protection by citalopramin in acute ischemic stroke (TALOS). *Stroke* 2018;**49**(11):2568-76.

Andersen 2013. The efficacy of citalopram treatment in acute stroke (TALOS). www.clinicaltrials.gov/ct2/show/NCT01937182 (first received 9 September 2013).

Kraglund K, Mortensen JK, Grove EL, Johnsen SP, Andersen G. TALOS: a multicenter, randomised, double blind, placebo controlled trial to test the effects of citalopram in patients with acute stroke; Protocol. *International Journal of Stroke* 2015;**10**:985-987.

Birchenall 2019 {published and unpublished data}

Birchenall J, Térémetz M, Roca P, Lamy JC, Oppenheim C, Maier MA, et al. Individual recovery profiles of manual dexterity, and relation to corticospinal lesion load and excitability after stroke - a longitudinal pilot study. *Neurophysiologie Clinique* 2019;**49**(2):149-64.

* Centre Hospitalier St Anne. Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke (EFLUSTIM). clinicaltrials.gov/ct2/show/ NCT02063425 2014.

Black-Schaffer 2012 {published data only}

Black-Schaffer R. Fluoxetine for motor, aphasia, and neglect recovery after ischemic stroke (FLAN). www.clinicaltrials.gov/ ct2/show/NCT01674868 (first received 29 August 2012).

Brown 1998 {published data only}

Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism. *Acta Psychiatrica Scandinavica* 1998;**98**(6):455-8.

Burns 1999 {published data only}

Burns A, Russell E, Stratton-Powell H, Tyrell P, O'Neill P, Baldwin R. Sertraline in stroke-associated lability of mood. *International Journal of Geriatric Psychiatry* 1999;**14**(8):681-5.

Chen 2001 {*published data only*}

Chen WY, Liu FY, Yang AP. Study of effect of integrative Chinese herbs with fluoxetine on rehabilitation of neurological impairment in patients with post-stroke depression. *Journal of Chengdu University of Traditional Chinese Medicine* 2001;**24**(4):20-3.

Chen 2002 {published data only}

Chen W, Wang G-F, Chen X-H, Sheng Y-L, Zhu H. Effects of paroxetine on function recovery in patients with post-stroke depression. *Chinese Journal of Clinical Rehabilitation* 2002;**6**(13):2014-5.

Chen 2005a {published data only}

Chen KN. Changes of neurotransmitter in patients with poststroke depression observed with encephalofluctuography technology. *Chinese Journal of Clinical Rehabilitation* 2005;**9**(16):118-9.

Chen 2005b {*published data only*}

Chen T, Li J, Han M. A study on paroxetine in the treatment for post-stroke depression. *Jiangxi Medicine* 2005;**40**(7):382-4.

Cheng 2003 {published data only}

Cheng F, Shao G, Bao S. Study of effect on neurologic function rehabilitation in patient with post-stroke depression. *Chinese Journal of Clinical Rehabilitation* 2003;**7**(1):108-9.



Chollet 2011 {published data only}

Chollet F, Tardy J, Albucher J-F, Thalamas E, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *Lancet Neurology* 2011;**10**(2):123-30.

Dam 1996 {published data only}

Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. *Stroke* 1996;**27**(7):1211-4.

Feng 2004 {published data only}

Feng B-L, Wang Q-C, Zheng-Yuan LI. Influence of Jieyu Huoxue decoction on rehabilitation of patients with depression after cerebral infarction. *Journal of Chinese Integrated Medicine* 2004;**2**(3):182-4.

FOCUS Trial Collaboration 2018 {published data only}

* FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. *Lancet* 2018;**393**(10168):265-74.

Mead G. Fluoxetine Or Control Under Supervision (FOCUS) trial: to establish the effect(s) of routine administration of Fluoxetine in patients with a recent stroke. www.isrctn.com/ ISRCTN83290762 (first received 23 May 2012).

Mead GE, Dennis MS, Innes K, MacLeod M, Sandercock PA, House A, et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). 21st European Stroke Conference. 2012:Abst OAID 26.

Fruehwald 2003 {published data only}

Fruehwald S, Gatterbauer. Early fluoxetine treatment of poststroke depression: a three-month double-blind placebocontrolled study with an open-label long-term follow up. *Journal of Neurology* 2003;**250**(3):347-51.

Gao 2016 {published data only}

Gao J, Lin M, Zhao J, Bi S, Ni Z, Shang X. Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke. *Clinical Rehabilitation* 2017;**31**(7):71-81.

GlaxoSmithKline 1998 {published data only}

GlaxoSmithKline. An 8-week double-blind placebo controlled parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from depression following stroke. GSK Clinical Study Register www.gsk clinicalstudyregister.com (accessed 31 August 2012).

Guo 2009 {published data only}

Guo R-Y, Su L, Wang CX. Effects of Linggui Bafa on the therapeutic effect and quality of life in patients of poststroke depression. *Chinese Acupuncture & Moxibustion* 2009;**29**(10):785-90.

He 2004 {published data only}

He P. Randomized controlled observation on the effect of early application of fluoxetine in preventing depression after stroke. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(28):6016-7.

He 2005 {*published data only*}

* He Y, Wang X, Xiao C. Prospective study of effects of paroxetine with mental intervention on depression and anxiety after stroke. *Nervous Diseases and Mental Health* 2005;**5**(1):6-13.

Wang X, He Y, Xiao C-L. A clinical trial of paroxetine and psychotherapy in patients with post-stroke depression and anxiety. *Chinese Mental Health Journal* 2005;**19**:564-6.

He 2016 {published data only}

Guo 2012. Multi-center randomized clinical study of antidepressant treatment (fluoxetine) on secondary prevention of ischemic stroke [ChiCTR-TRC-12002078]. www.chictr.org.cn/ showprojen.aspx?proj=7471 (first received 3 April 2012).

* He Y-T, Tang B-S, Cai Z-L, Zeng S-L, Jiang X, Guo Yi. Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in China. *Journal of Stroke and Cerebrovascular Diseases* 2016;**25**(4):761-70.

Hu 2002 {published data only}

Hu Y, Suo A, Xiang L. The comparative study of the effectiveness of fluoxetine on the stroke patients with depressive symptoms. *Shanghai Archives of Psychiatry* 2002;**14**:149-50.

Huang 2002 {published data only}

Huang X-H. The clinical correlation study and the effect of fluoxetine intervention on poststroke depression. *Chinese Journal of Clinical Rehabilitation* 2002;**6**(15):2296-7.

Jia 2005 {published data only}

Jia W. Effect of early intervention on recovery of motor function and recurrent stroke in patients with post-stroke depression. *Chinese Journal of Clinical Rehabilitation* 2005;**9**(12):4-5.

Kim 2011 {published data only}

Kim JS. The preventative effect of escitalopram on depression and related emotional disorders in acute stroke patients, 2011. clinicaltrials.gov/ct2/show/NCT01278498 (first received 19 January 2011). [NCT01278498]

* Kim JS, Lee E-J, Chang D-ll, Park J-H, Ahn SH, Cha J-K, et al. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebocontrolled study. *Lancet Psychiatry* 2017;**4**(1):33-41.

Kong 2007 {published data only}

Kong Y. Fluoxetine for poststroke depression: a randomized placebo controlled clinical trial. *Neural Regeneration Research* 2007;**2**(3):162-5.

Lai 2006 {published data only}

Lai J. The effect of using paroxetine to treat post stroke depression. *Journal of Guangdong Medical College* 2006;**24**(6):585-6.



Li 2004a {published data only}

Li J, He Q-Y, Han M-F. Recent effect of fluoxetine in improving neurologic impairment and preventing post-stroke depression in the early stage. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(7):1208-9.

Li 2004b {published data only}

Li C-M, Jiang X-D, Liao G, Lei J-M, Lan S, Ni F-W. Effect of antidepressant drugs in early period on the recovery of poststroke depression. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(19):3713-5.

Li 2005 {published data only}

Li Y, Wang X, Qian FS. Related factors of post-stroke depression and effect of paroxetine. *Shandong Archives of Psychiatry* 2005;**18**(4):209-10.

Li 2006 {published data only}

Li W-Q, Li D-X. The efficacy of citalopram for post-stroke depression and its effects on stroke rehabilitation. *International Journal of Cerebrovascular Diseases* 2006;**14**(4):275-8.

Li 2008 {published data only}

Li L-T, Wang S-H, Ge H-Y, Chen J, Yue S-W, Yu M. The beneficial effects of the herbal medicine free and easy wanderer plus (FEWP) and fluoxetine on post-stroke depression. *Journal of Alternative and Complementary Medicine* 2008;**14**(7):841-6.

Liu 2006 {published data only}

Liu Y, Xu R. Effect of citalopram treatment on post-stroke depression and neurological functional rehabilitation. *Chinese Journal of Rehabilitation* 2006;**21**(3):174-5.

Marquez Romero 2013 {published data only}

Marquez-Romero JM. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH). www.clinicaltrials.gov/ct2/ show/NCT01737541 (first received 29 November 2012).

Marquez-Romero JM, Arauz A, Ruiz-Sandoval JL, Cruz-Estrada Ede L, Huerta-Franco MR, Aguayo-Leytte G, et al. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebocontrolled, multicenter trial. *Trials* 2013;**14**:77.

Marquez-Romero JM, Reyes-Martínez M, Huerta-Franco MR, Ruiz-Franco A, Silos H, Arauz A. Fluoxetine for motor recovery after acute intracerebral hemorrhage,the FMRICH Trial. Correspondence from Marquez-Romero 2018.

Meara 1998 {published data only}

Meara RJ, Thalanany M, Balonwu V, Hobson P. The treatment of depression after stroke with the selective serotonin reuptake inhibitor sertraline. *Cerebrovascular Diseases* 1998;**8 Suppl 4**:90.

Miao 2004 {published data only}

Miao S-Y, Shi Y-J. Related factors of post-stroke depression and therapeutical effect of citalopram. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(19):3718-9.

Murray 2005 {published data only}

Murray V, Von Arbin M, Bartfai A, Berggren A-L, Landtblom A-M, Lumdmark J, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. *Journal of Clinical Psychiatry* 2005;**66**(6):708-16.

Pan 2018 {published data only}

Pan X-L, Chen H-F, Cheng X, Hu C-C, Wang J-W, Fu Y-M, et al. Effects of paroxetine on motor and cognitive function recovery in patients with non-depressed ischemic stroke: an open randomized controlled study. Brain Impairment Vol. doi: 10.1017/BrImp.2018.6.

Pariente 2001 {published data only}

Guiraud-Chaumeil B, Pariente J, Albucher J-F, Loubinoux I, Chollet F. Rehabilitation after stroke [Recuperation neurologique post-ischemique]. *Bulletin de l'Académie Nationale de Médecine* 2002;**6**:1015-24.

* Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. *Annals of Neurology* 2001;**50**(6):718-29.

Rasmussen 2003 {published data only}

Rasmussen A. Depression and stroke. *Nordic Journal of Psychiatry* 2001;**55**(4):288.

Rasmussen A. Prophylactic treatment for post-stroke depression and comorbidity. *Journal of Psychosomatic Research* 2000;**48**(3):66.

Rasmussen A, Lunde M, Poulsen D, Sørensen K, Qvitzau S, Bech P. A double-blind placebo controlled study of sertraline in the prevention of depression in stroke patients. *European Neuropyschopharmacology* 2002;**12**:231.

* Rasmussen A, Lunde M, Poulsen DL, Sørensen K, Qvitzau S, Bech P. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. *Psychosomatics* 2003;**44**(3):216-22.

Razazian 2014 {published data only}

Razazian N. A survey for assessment of effectiveness of fluoxetine on motor improvement in ischemic stroke patients. www.en.irct.ir/trial/8797 2014.

Restifo 2001 {published data only}

Restifo DA, Lo Prest R, Lanza S, Giuffrida S, D'Aleo G, Rifici Di Bella C, et al. Motor cortex reorganization induced by fluoxetine in poststroke hemiplegic patients undergoing rehabilitation therapy: a study with transcranial magnetic stimulation. *Neurorehabilitation and Neural Repair* 2001;**15**(4):284.

Robinson 2000a {published data only}

Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and post-stroke depression: a placebo controlled trial of antidepressants. *American Journal of Psychiatry* 2003;**160**:1823-9.

Narushima K, Kosier JT, Robinson RG. Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. *Journal of Nervous and Mental Diseases* 2002;**190**:296-303.

* Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. *American Journal of Psychiatry* 2000;**157**(3):351-9.

Robinson 2000b {published data only}

Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and post-stroke depression: a placebo controlled trial of antidepressants. *American Journal of Psychiatry* 2003;**160**:1823-9.

Narushima K, Robinson RG. Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. *Journal of Nervous and Mental Diseases* 2002;**190**:296-303.

* Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. *American Journal of Psychiatry* 2000;**157**(3):351-9.

Robinson 2008 {published data only}

Jorge RE, Acion L, Moser D, Adams HP, Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. *Archives of General Psychiatry* 2010;**67**(2):187-96.

Robinson RG, Arndt S. Incomplete financial disclosure in a study of escitalopram and problem solving therapy for prevention of post-stroke depression. *JAMA* 2009;**301**:1023-4.

* Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression. *JAMA* 2008;**299**(20):2391-400.

Savadi Oskouie 2012 {published data only}

Savadi Oskouie D. Evaluation of the effect of citalopram on three months functional prognosis of acute ischemic stroke patients: a randomized clinical trial. www.en.irct.ir/trial/1766 (first received 22 April 2012).

Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, Hashemilar M, Nikanfar M, Ghazanfari Amlashi S, et al. Efficacy of citalopram on acute ischemic stroke outcome: a randomized clinical trial. *Neurorehabilitation and Neural Repair* 2017;**31**(7):638-47.

Shah 2016 {published data only}

Shah IA, Asimi RP, Kawoos Y, Wani MA, Wani MA, Dar MA. Effect of fluoxetine on motor recovery after acute haemorrhagic stroke: a randomized trial. Journal of Neurology and Neurophysiology 2016; Vol. 7, issue 2. [DOI: 10.4172/2155-9562.1000364]

Song 2006 {published data only}

Song J-G. Effects of fluoxetine hydrochloride on depressive symptoms and P300 after cerebral stroke. *Chinese Journal of Clinical Rehabilitation* 2006;**10**(14):160-2.

Wang 2003 {published data only}

Wang X, Tan Z, Wu Z, Gao J, Feng M. The effects of antidepression therapy on post-stroke depression and neurologic rehabilitation in the elderly patients. *Chinese Journal of Geriatrics* 2003;**22**(5):270-3.

Wen 2006 {published data only}

Wen Z-X. The influence of post-stroke prophylactic antidepression treatment on nerve functional rehabilitation. *Acta Academiae Medicinae Qingdao Universitatis* 2006;**42**(3):253-4.

Whyte 2005 {published data only}

Whyte E. Setraline for prevention post stroke depression and improving rehabilitation outcomes. clinicaltrials.gov/ct2/show/ NCT00177424 (first received 15 September 2005).

Wiart 2000 {published data only}

Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. *Stroke* 2000;**31**(8):1829-32.

Xie 2005 {published data only}

Xie R, Liu J, Quan H. A prospective random clinical contrast study of treatment with sertraline in elderly patients with poststroke depression. *Chinese Journal of Clinical Neuroscience* 2005;**13**(3):294-7.

Xu 2001 {published data only}

Xu J, Tan J, Ou L. A study on treatment of fluoxetine to depression in early recovery stage of cerebral infarction. *Chinese Journal of Rehabilitation Medicine* 2001;**16**(5):281-3.

Xu 2006 {published data only}

Xu J, Wang J, Liu J. Preventive effects of antidepressants on post-stroke depression. *Chinese Mental Health Journal* 2006;**20**(3):186-8.

Yang 2002 {published data only}

Yang J, Zhao Y, Bai S. Controlled study on antidepressant treatment of patients with post-stroke depression. *Chinese Mental Health Journal* 2002;**16**(12):871-2.

Yang 2011 {published data only}

Yang J. Therapeutic effect of paroxetine on patients with early poststroke depression and the serum interleukins. *Chinese Journal of Cerebrovascular Diseases* 2011;**8**(5):235-8.

Ye 2004 {published data only}

* Ye L-X, Wang H, Wang Y-D, Zhong L, Liang D-S, Guo Y. Effect of anti-depressive therapy on the rehabilitation of psychological and neurological function after stroke. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(31):6826-8.

Ye LX. Effect of Paxil and berhomine on post-stroke anxietydepression and neurological recovery. *Chinese Journal of Clinical Rehabilitation* 2006;**10**(6):153-5.



Zhao 2011 {published data only}

Zhao P, Wang J-P. Effects of antidepressants on neurofunctional recovery of post-stroke patients with aphasia. *Journal of Dalian Medical University* 2011;**33**(1):55-7.

Zhou 2008 {published data only}

Zhou Z-l, Liang L-Z, Yan Y-X. Preventive effects of fluoxetine on post-stroke depression. *Chinese Journal of Modern Applied Pharmacy* 2008;**25**(3):263-4.

References to studies excluded from this review

Andersen 1993 {published data only}

Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. *Lancet* 1993;**342**(8875):837-9.

Andersen 2012 {published data only}

Andersen G. Efficacy of escitalopram treatment in acute stroke and the role of specific genotypes in stroke. www.clinicaltrialsregister.eu/ctr-search/search? query=2011-005541-12 (first received 27 February 2012).

Anderson 2002 {published data only}

Anderson C, Hackett M, Carter K, Ni MC. Maximising outcome by overcoming depression in stroke (MOODS) trial. *Cerebrovascular Diseases 2002* 2002;**13(Suppl 3)**:79.

Anonymous 2012 {published data only}

Anonymous 2012. Stroke and depression. *Johns Hopkins Med Letters: Health After 50* 2012;**23**(11):3.

Anonymous 2012b {published data only}

Anonymous. Drug & Device News. *Medical Malpractice Law & Strategy, New York Law Journal Newsletters* 2012;**30**(2):5.

Berends 2009 {published data only}

Berends HI, Nijlant JM, Putten MJ, Movig KL, IJzerman MJ. Single dose of fluoxetine increases muscle activation in chronic stroke patients. Clinical Neuropharmacology 2009; Vol. 32, issue 1:1-5. [also known as Flu 2006]

Choi Kwon 2008 {published data only}

Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS. Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. *Cerebrovascular Diseases* 2008;**26**(3):266-71.

Finkenzeller 2009 {published data only}

Finkenzeller W, Zobel I, Rietz S, Schramm E, Berger M. Interpersonal psychotherapy and pharmacotherapy for poststroke depression. Feasibility and effectiveness. *Der Nervenarzt* 2009;**80**(7):805-12.

Gourab 2015 {published data only}

Gourab K, Schmit BD, Hornby GT. Increased lower limb spasticity but not strength or function following a single-dose serotonin reuptake inhibitor in chronic stroke. *Archives of Physical Medicine and Rehabilitation* 2015;**96**(12):2112-9.

Graffagnino 2002 {published data only}

Graffagnino C. Poststroke depression and functional recovery (SADBRAIN). Duke University Medical Centre 2002.

Ji 2000 {published data only}

Ji QM, Xie LP. Efficacy of fluoxetine in the treatment of 20 patients with depression after stroke. *Herald of Medicine* 2000;**19**(4):329.

Li 2002 {published data only}

Li F, Gu DX, Ceng SH, Xu JW. Effect of paroxetine on prognosis of patients with post cerebral infarction depression. *Chinese Journal of New Drugs and Clinical Remedies*. 2002;**21**(1):11-3.

Liang 2003 {published data only}

Liang Z, Shuliang T. Clinical efficacy of fluoxetine in treatment of patients with depression after acute stroke. *Chinese Journal of Clinical Rehabilitation* 2003;**7**(13):1924-5.

Liu 2004 {published data only}

Liu L-X. Recent effect of drug intervention on poststroke anxiety. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(30):6600-1.

Robinson 2011 {published data only}

Robinson RG, Mikami K, Jang M, Jorge RE. Prevention of anxiety disorder after stroke. *Journal of Neuropsychiatry and Clinical Neurosciences* 2011;**23**(2):18.

Sitzer 2002 {published data only}

Sitzer M, Huff W, Steckel R. Prevention of poststroke depression after acute ischemic stroke using the selective serotonin reuptake inhibitor sertraline (PreDis-study). *Stroke* 2002;**33**(2):651-2.

Sun 2015 {published data only}

Sun YT, Bao YH, Wang SL, Chu JM, Li LP. Efficacy observation on the treatment of post-stroke depression by acupuncture at the acupoints based on ziwuliuzhu and Prozac. *Chinese Acupuncture and Moxibustion* 2015;**355**(2):119-22.

University of Alabama 2013 {published data only}

University of Alabama. RCT of a neuroplasticity agent and CI therapy for severe arm paresis after stroke. clinicaltrials.gov/ ct2/show/NCT01963832 (accessed 5th March 2019).

Xu 2007 {published data only}

Xu B, Zhou WY, Zhang SJ. Observation of effect of Wulung capsule in treating post-stroke depression. *Chinese Journal of Integrated Traditional and Western Medicine* 2007;**27**(7):640-2.

Zhou 2003 {published data only}

Zhou B. Effects of fluoxetine on neurofunctional recovery of non depressed patients after stroke. *Chinese Journal of Clinical Rehabilitation* 2003;**7**(3):374-5.

References to studies awaiting assessment

Carda 2009 {published data only}

Carda S, Cisari C. Effects of clinical and functional outcome of escitalopram in adult stroke patients. clinicaltrials.gov/ ct2/show/NCT00967408 (first received 27 August 2009). [NCT00967408]

Guo 2015 {published data only}

Guo Y. Effect of using fluoxetine at different time windows after ischemic stroke on neurological functional prognosis: a randomized controlled trial. www.chictr.org.cn/ showprojen.aspx?proj=12925 (first received 27 December 2015).

Guo Y, He Y, Tang B, Ma K, Cai Z, Zeng S, et al. Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. *Restorative Neurology and Neuroscience* 2016;**34**(2):177–87.

He 2012 {published data only}

Guo 2012. Multi-center randomized clinical study of antidepressant treatment (fluoxetine) on secondary prevention of ischemic stroke [ChiCTR-TRC-12002078]. www.chictr.org.cn/ showprojen.aspx?proj=7471 (first received 3 April 2012).

He Y, Cai Z, Zeng S, Chen S, Tang B, Liang Y, Chang X, Guo Y. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study. *Clinical Neurology and Neurosurgery* 2018;**168**:1-6.

Jurcau 2016 {published data only}

Jurcau A, Simion A. Improved post-ischaemic stroke recovery over 1 year with escitalopram for 3 months. *European Journal of Neurology. Conference: 2nd Congress of the European Academy of Neurology* 2016;**23**:614.

References to ongoing studies

Anonymous 2005 {published data only}

Anonymous. Influence of escitalopram on the incidence of depression and dementia following acute middle cerebral artery territory infarction. A randomised placebo-controlled double blind study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005266-37 (accessed prior to 12 May 2019).

Chollet 2016 {published data only}

Sattler V, Chollet F. Serotonin Selective Reuptake Inhibitor (SSRI) effects on cerebral connectivity in acute ischemic stroke (RECONISE). www.clinicaltrials.gov/ct2/show/NCT02767999 (first received 11 May 2016).

Cocho 2015 {published data only}

Cocho D. Effect of serotonin and levodopa in ischemic stroke. www.clinicaltrials.gov/ct2/show/NCT02386475 (first received 12 March 2015).

Dike 2019 {published data only}

Dike FO, Ekeh BC, Ogun AS, Ekrikpo EU, Walshak P, Ogunniy AA. Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine. *Journal of Neurology and Stroke* 2019;**9**(1):47-51.

Farokhi 2017 {published data only}

Farokhi F. Evaluation of fluoxetine and standard treatment efficacy on change to side effect of stroke of ischemic strokes in both hemispheres in anterior circulation. www.irct.ir/ trial/17976 (first received 11 October 2017).

FOCUS-Poland 2014 {published data only}

Fluoxetine or Control under Supervision: Poland. Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - EduraCT No: 2014-001335-37 2014.

Fregni 2014 {published data only}

Fregni F. Effects rTMS combined with fluoxetine on motor recovery in stroke patients. www.clinicaltrials.gov/ct2/show/ NCT02208466 (first received 5 August 2014).

Hankey 2011 {published data only}

Hankey G. Assessment oF FluoxetINe In sTroke recoverY (AFFINITY). www.affinitytrial.org/ (accessed 19th February 2019).

Hankey G. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. www.anzctr.org.au/Trial/Registration/ TrialReview.aspx?ACTRN=12611000774921 (first received 22 July 2011).

Karimialavijeh 2017 {published data only}

Karimialavijeh E. Comparison of the effects of citalopram versus fluoxetine on motor recovery after stroke: A double-blind placebo-controlled randomized clinical trial. www.en.irct.ir/ trial/17729 (first received 3 December 2017).

Leibovitch 2018 {published data only}

Leibovitch F. Fluoxetine Opens Window to improve motor recovery after stroke (FLOW). www.clinicaltrials.gov/ct2/show/ NCT03448159 (first received 27 February 2018).

Levitt 2019 {published data only}

Levitt 2019. Depression in hemorrhagic stroke. www.clinicaltrials.gov/ct2/show/NCT03826875 (first received 1 February 2019).

Lundström 2014 {published data only}

Lundström E. Establishing the effect(s) and safety of Fluoxetine initiated in the acute phase of stroke. www.isrctn.com/ ISRCTN13020412 (first received 19 December 2014).

Pastore-Wapp 2016 {published data only}

Pastore-Wapp M, Krammer W. Cortical ischemic stroke and serotonin (CISS). www.clinicaltrials.gov/ct2/show/NCT02865642 (first received 12 August 2016).

Pirzeh 2012 {published data only}

Pirzeh R. A study of sertraline effect on quality of life in stroke inpatients. www.en.irct.ir/trial/11413 (first received 28 November 2012).



Sadaat 2012 {published data only}

Saadat SM. Effect of fluoxetine on functional recovery of patients with cerebrovascular accident following middle cerebral artery trunk obstruction: a randomized clinical trial. www.en.irct.ir/trial/8954 (first received 25 January 2012).

Sahin 2016 {published data only}

Sahin B, Leonhardt AM. Fluoxetine for visual recovery after ischemic stroke (FLUORESCE). www.clinicaltrials.gov/ct2/show/NCT02737930 (accessed 14 April 2016).

Additional references

Allida 2019

Allida S, Patel K, House A, Hackett ML. Pharmaceutical interventions for emotionalism after stroke. *Cochrane Database of Systematic Reviews* 2019, Issue 3. [DOI: 10.1002/14651858.CD003690.pub4]

Deeks 2017

Deeks JJ, Higgins JP, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking metaanalyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**(7109):629-34.

GBD 2015

GBD 2015. Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study. *Lancet* 2016;**388**(10053):1545–602.

GRADE 2013

Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.

GRADEproGDT 2015 [Computer program]

McMaster University (developed by Evidence Prime, Inc.). GRADEpro Guideline Development Tool [Software]. McMaster University (developed by Evidence Prime, Inc.), 2015.

Hatano 1976

Hatano S. Experience from a multicentre stroke register: a preliminary report. *Bulletin of the World Health Organization* 1976;**54**(5):541-53.

Higgins 2017

Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R,

Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.

Johnson 2016

Johnson W, Onuma O, Owolabi M, Sachdev S. Stroke: a global response is needed. *Bulletin of the World Health Organization* 2016;**94**(9):634-634A.

Lang 2004

Lang UE, Jockers-Scherübl MC, Hellweg R. State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. *Journal of Neural Transmission* 2004;**111**(3):387-411.

Lim 2009

Lim C-M, Kim W-W, Park J-Y, Kim C, Yoon SH, Lee J-K. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. *Journal of Neuroscience Research* 2009;**87**(4):1037-45.

Loubinoux 1999

Loubinoux I, Boulanouar K, Ranjeva J-F, Carel C, Berry I, Rascol O, et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. *Journal of Cerebral Blood Flow and Metabolism* 1999;**19**(12):1365-75.

Mantel 1959

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *Journal of the National Cancer Institute* 1959;**22**(4):719-748.

Ming 2005

Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. *Annual Review of Neuroscience* 2005;28:223-50.

Molnar 2008

Molnar FJ, Hutton B, Fergusson D. Does analysis using "last observation carried forward" introduce bias in dementia research?. *CMAJ* 2008;**179**(8):751–753.

Pälvimäki 1994

Pälvimäki E-P, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J. Up-regulation of beta l-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. *Psychopharmacology (Berl)* 1994;**115**(4):543-6.

Review Manager 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Santarelli 2003

Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis antidepressant treatments and animal models of depressive-like behaviour. *Behavioural Pharmacology* 2003;**301**:805-9.



Schmidt 2007

Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behaviour. *Behavioural Pharmacology* 2007;**18**(5-6):391-418.

Schünemann 2017

Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Akl E, Guyatt GH on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing 'Summary of findings' tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.

Shin 2009

Shin TK, Kang MS, Lee HY, Seo MS, Kim SG, Kim CD, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice. *Korean Journal of Physiology and Pharmacology* 2009;**13**(3):257-63.

Sterne 2017

Sterne JA, Egger M, Moher D, Boutron I, editor(s). . Chapter 10: Addressing reporting biases. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.

Taupin 2006

Taupin P. Adult neurogenesis and neuroplasticity. *Restorative Neurology and Neuroscience* 2006;**24**(1):9-15.

Wan 2014

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Medical Research Methodology* 2014;**14**:135.

Wiltrout 2007

Wiltrout C, Lang B, Yan Y, Dempsey RJ, Vemuganti R. Repairing brain after stroke: a review on post-ischaemic neurogenesis. *Neurochemistry International* 2007;**50**(7-8):1028-41.

Yi 2010

Yi ZM, Liu F, Zhai SD. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. *International Journal of Clinical Practice* 2010;**64**(9):1310-7.

Zittel 2008

Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. *Neurorehabilitation and Neural Repair* 2008;**22**(3):311-4. [DOI: 10.1177/1545968307312173]

References to other published versions of this review

Mead 2011

Mead GE, Hankey GJ, Kutlubaev MA, Lee R, Bailey M, Hackett ML. Selective serotonin reuptake inhibitors (SSRIs) for stroke. *Cochrane Database of Systematic Reviews* 2011, Issue 10. [DOI: 10.1002/14651858.CD009286]

Mead 2012

Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. *Cochrane Database of Systematic Reviews* 2012, Issue 11. [DOI: 10.1002/14651858.CD009286.pub2]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Acler 2009	
Methods	Study type: interventional (clinical trial)
	Intervention model: parallel assignment
	Primary purpose: treatment
Participants	20 participants
	Location: Italy
	Setting: inpatient
	Inclusion criteria: first-ever ischaemic stroke, CT or MRI documenting a single monohemispheric lesion, age below 80 years, within 3 months of onset
	Exclusion criteria: major affective disorders, alcohol abuse and dementia leading to unco-operative be- haviour, pacemakers, metal in the head, concomitant neuropathies, systemic vasculopathies, major af- fective disorders



Treatment: 10 people, mean age 65 ± 7 years, 6 men Control: 10 people, mean age 65 ± 7 years, 6 men Interventions Citalopram 10 mg daily Placebo: identical pill daily Duration of freatment: at least 4 months Duration of follow-up: not stated Outcomes Metro: cortex excitability NIHSS Lindmark Scale Bi Placebo: identical pill daily NIHSS Lindmark Scale Bi NO data on death, 61 upset, bleeds or seizures NIHSS No data on death, 61 upset, bleeds or seizures NIHSS Funding source Source of funding not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a stated Risk of bios Support for judgement Risk of loig Computer-generated random numbers Control: blas) Inclear risk Method of allocation concealment not stated Allocation concealment (detection blas) Low risk Stated blinded, placebo was 'an identical pill' Blinding of participants and personnel (perfor- mance blas) Low risk Stated blinded Blinding of participants and personnel (detection blas) Low risk Stated blinded Selective reporting (re- bias) Loucear risk Is is not stated whether da	Acler 2009 (Continued)		
Interventions Citalopram 10 mg daily Placebo: identical pill daily Duration of follow-up: not stated Outcomes Motor cortex excitability NHSS Lindmark Scale Bi BI HDRS BD1 No data on death, GI upset, bleeds or seizures Funding source Source of funding not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Notes Low risk Computer-generated random numbers Allocation concealment (selection bias) Unclear risk Method of allocation concealment not stated Blinding of participants and personnel (perfor- mance bias) Low risk Stated blinded, placebo was 'an identical pill' and personnel (perfor- mance bias) Blinding of outcome as- Alloutcomes Low risk Stated blinded Blinding of outcome as- Alloutcomes Low risk Stated blinded Alloutcomes Unclear risk It is not stated		Treatment: 10 people,	mean age 68 ± 7 years, 6 men
Placebo: identical pill daily Duration of treatment: at least 4 months Duration of follow-up: not stated Outcomes Motor cortex excitability NIHSS Lindmark Scale Bit HDRS BD1 Notation of eating not stated; unclear whether or not a drug company was involved in the study Notes Source of funding not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Notes Low risk Computer-generated random numbers Random sequence generation Low risk Computer-generated random numbers Allocation concealment (selection bias) Low risk Stated blinded, placebo was 'an identical pill' Nance bias) Low risk Stated blinded, placebo was 'an identical pill' Nates Low risk Stated blinded, placebo was 'an identical pill' Natoutomes Low risk <		Control: 10 people, me	ean age 65 ± 7 years, 6 men
Duration of treatment: at least 4 months Duration of follow-up: not stated Dutomes Motor cortex excitability: NHHSS Lindmark Scale Bi HDRS BDI No data on death, GI upset, bleeds or seizures Funding source Source of funding not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Risk of bios Surger of funding not stated; unclear whether or not a drug company was involved in the study Risk of bios Dates of study not stated; unclear whether or not a drug company was involved in the study Risk of bios Computer-generated random numbers Binding of participants Low risk Computer-generated random numbers Incompany for uncease-bias Low risk Stated blinded, placebo was 'an identical pill' Indication concealment (selection bias) Low risk Stated blinded, placebo was 'an identical pill' Binding of outcome as-bias Low risk Stated blinded Selective reporting (reportion ginas) Unclear risk It is not stated whether data from all recruited participants are reported glintition bias, 210 utcomes Selective reporting (re- plina) Unclear risk Sid	Interventions	Citalopram 10 mg daily	у
Duration of follow-up: not stated Outcomes Motor cortex excitability NIHSS Lindmark Scale Bit HDRS HDRS Bit No data on death, GI upset, bleeds or seizures No data on death, GI upset, bleeds or seizures Funding source Source of funding not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Risk of bias Support for judgement Random sequence generation (selection bias) Iun risk Allocation concealment (selection bias) Unclear risk Blinding of participants Low risk Stated blinded, placebo was 'an identical pill' and personnel (performance bias) Stated blinded, placebo was 'an identical pill' and personnel (performance bias) Blinding of outcome as-basisment (detection bias) Low risk Stated blinded Stated blinded, placebo was 'an identical pill' (detection bias) Low risk Stated blinded Blinding of outcome as-basisment (detection bias) Low risk Stated blinded Stated blinded, placebo was 'an identical pill' (detection bias) Low risk Stated blinded Stated blinded personeli (performance) Low risk <td></td> <td>Placebo: identical pill o</td> <td>daily</td>		Placebo: identical pill o	daily
Outcomes Motor cortex excitability NIHSS Lindmark Scale NIHSS Bi HDRS BDI No data on death, GI upset, bleeds or seizures Funding source Source of funding not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated. Any conflicts of interest not stated Risk of bias Euror isik Computer-generated random numbers Random sequence genera- tion (selection bias) Low risk Computer-generated random numbers Allocation concealment (selection bias) Unclear risk Method of allocation concealment not stated Blinding of participants and personnel (perfor- mance bias) Low risk Stated blinded, placebo was 'an identical pill' Alloutcomes Low risk Stated blinded, placebo was 'an identical pill' Blinding of outcome as- sessment (detection bias) Low risk Stated blinded All outcomes Low risk Stated blinded Selective reporting (re- portig blas) Unclear risk Stated blinded Selective reporting (re- porting blas) Unclear risk Stated blinded		Duration of treatment:	at least 4 months
NIHSS Lindmark Scale BI HDRS DDI No data on death, GI uset, bleeds or seizures Funding source Source of funding not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Risk of bios Dates of study not stated; unclear whether or not a drug company was involved in the study Random sequence generation Low risk Support for judgement Rolocation concealment Low risk Computer-generated random numbers Allocation concealment Unclear risk Method of allocation concealment not stated Binding of participants and personnel (perfor- mance bias) Low risk Stated blinded, placebo was 'an identical pill' Binding of outcome as- sessment (detection bias) Low risk Stated blinded Binding of outcome as- sessment (detection bias) Low risk Stated blinded Binding of outcome as- sessment (detection bias) Low risk Stated blinded Binding of outcome as- sessment (detection bias) Low risk Stated blinded Binding of outcome as- sessment (detection bias) Low risk Stated blinded		Duration of follow-up:	not stated
Lindmark Scale BI BI HDRS BDI No data on death, GI upset, bleeds or seizures Funding source Source of funding not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Risk of bias Uthors' judgement Bias Authors' judgement Risk of bias Computer-generated random numbers Rilocation concealment (selection bias) Unclear risk Binding of participants and personnel (performance bias) Stated blinded, placebo was 'an identical pill' Blinding of outcome as sessment (detection bias) Low risk Stated blinded Blinding of outcome as sessment (detection bias) Low risk Stated blinded Blinding of participants and (section bias) Low risk Stated blinded Blinding of outcome as sessment (detection bias) Low risk Stated blinded Blinding of outcome as sessment (detection bias) Low risk Stated blinded Blinding of outcome as sessment (detection bias) Low risk Stated blinded Stated blinded Stated whether data from all recruited participants are reported althoutgh they were assessesed State	Outcomes	Motor cortex excitabili	ty
BI HDRS BDI No data on death, GI u=st. bleeds or seizures Funding source Source of funding not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Risk of bias Juthors' judgement Bias Authors' judgement Rolaccition concealment Low risk Onclear risk Method of allocation concealment not stated Binding of participants Low risk Binding of participants Low risk Stated blinded, placebo was 'an identical pill' Binding of oparticipants Low risk Binding of oparticipants Low risk Stated blinded, placebo was 'an identical pill' Binding of oparticipants Low risk Stated blinded Stated blinded I outcomes Low risk Stated blinded Binding of oparticipants Low risk Stated blinded Stated blinded Jutecar risk Is is not stated whether data from all recruited participants are reported I outcomes Unclear risk Side effects were not reported although they were assessed		NIHSS	
HDRS BDI No data on death, GI upset, bleeds or seizures Funding source Source of funding not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Risk of bios Dates of study not stated; unclear whether or not a drug company was involved in the study Bias Authors' judgement Support for judgement Random sequence genera- for (selection bias) Low risk Computer-generated random numbers Allocation concealment (selection bias) Unclear risk Method of allocation concealment not stated Blinding of participants and personnel (perfor- mance bias) Low risk Stated blinded, placebo was 'an identical pill' Blinding of outcome as- sessment (detection bias) Low risk Stated blinded Slinding of outcome as- NI outcomes Low risk Stated blinded Slinding of outcome ata- (detection bias) Unclear risk It is not stated whether data from all recruited participants are reported Slinding of outcome sessment (detection bias) Unclear risk Side effects were not reported although they were assessed Selective reporting (re- porting bias) Unclear risk Side effects were not reported although they were assessed </td <td></td> <td>Lindmark Scale</td> <td></td>		Lindmark Scale	
BDI No data on death, G I upper Services Funding source Source of funding not stated; unclear whether or not a drug company was involved in the study Notes Dates of study not stated; unclear whether or not a drug company was involved in the study Risk of bias Dates of study not stated; unclear whether or not a drug company was involved in the study Bias Authors' judgement Support for judgement Random sequence genera: Low risk Computer-generated random numbers Allocation concealment Unclear risk Method of allocation concealment not stated Blinding of participants and personnel (performance bias) Low risk Stated blinded, placebo was 'an identical pill' Blinding of outcome as-sessment (detection bias) Low risk Stated blinded Sulcoarones Low risk Stated blinded </td <td></td> <td>BI</td> <td></td>		BI	
No data on death, Gl upset, bleeds or seizuresFunding sourceSource of funding not stated; unclear whether or not a drug company was involved in the studyNotesDates of study not stated; unclear whether or not a drug company was involved in the studyRisk of biasEnterest not statedBiasAuthors' judgementSupport for judgementRandom sequence genera- tion (selection bias)Low riskComputer-generated random numbersAllocation concealment (selection bias)Unclear riskMethod of allocation concealment not statedBlinding of participants and personnel (perfor- mance bias)Low riskStated blinded, placebo was 'an identical pill'Blinding of outcome as- sessment (detection bias)Low riskStated blindedIloucomesUnclear riskIt is not stated whether data from all recruited participants are reported (Altrition bias)IloucomesUnclear riskSide effects were not reported although they were assessed		HDRS	
Funding sourceSource of funding not stated; unclear whether or not a drug company was involved in the studyNotesDates of study not stated. Any conflicts of interest not statedRisk of biasSupport for judgementBiasAuthors' judgementSupport for judgementRandom sequence genera- tion (selection bias)Low riskComputer-generated random numbersAllocation concealment (selection bias)Unclear riskMethod of allocation concealment not statedBlinding of participants and personnel (perfor- mance bias)Low riskStated blinded, placebo was 'an identical pill'Blinding of outcome as- sessment (detection bias)Low riskStated blindedIncomplete outcome data (attritio bias)Unclear riskIt is not stated whether data from all recruited participants are reported (attrition bias)Selective reporting (re- porting bias)Unclear riskSide effects were not reported although they were assessed porting bias)		BDI	
NotesDates of study not stated. Any conflicts of interest not statedRisk of biasAuthors' judgementSupport for judgementBiasAuthors' judgementSupport for judgementRandom sequence generation (selection bias)Low riskComputer-generated random numbersAllocation concealment (selection bias)Unclear riskMethod of allocation concealment not statedBlinding of participants and personnel (performance bias)Low riskStated blinded, placebo was 'an identical pill'Blinding of outcome assessment (detection bias)Low riskStated blindedBlinding of outcomesUnclear riskIt is not stated whether data from all recruited participants are reported (attrition bias)All outcomesUnclear riskIt is not stated whether data from all recruited participants are reported (attrition bias)Selective reporting (reporting (reporting bias)Unclear riskSide effects were not reported although they were assessed porting bias)		No data on death, GI u	pset, bleeds or seizures
Risk of bias Authors' judgement Support for judgement Bias Authors' judgement Support for judgement Random sequence genera- tion (selection bias) Low risk Computer-generated random numbers Allocation concealment (selection bias) Unclear risk Method of allocation concealment not stated Blinding of participants and personnel (perfor- mance bias) Low risk Stated blinded, placebo was 'an identical pill' Blinding of outcome as- sessment (detection bias) Low risk Stated blinded Nethod of allocation concealment all recruited participants are reported It is not stated whether data from all recruited participants are reported Selective reporting (re- porting bias) Unclear risk Side effects were not reported although they were assessed	Funding source	Source of funding not s	stated; unclear whether or not a drug company was involved in the study
BiasAuthors' judgementSupport for judgementRandom sequence genera- tion (selection bias)Low riskComputer-generated random numbersAllocation concealment (selection bias)Unclear riskMethod of allocation concealment not statedBlinding of participants and personnel (perfor- mance bias) All outcomesLow riskStated blinded, placebo was 'an identical pill'Blinding of outcome as- sessment (detection bias)Low riskStated blindedIncomplete outcome data (attrition bias) All outcomesUnclear riskIt is not stated whether data from all recruited participants are reportedSelective reporting (re- porting bias)Unclear riskSide effects were not reported although they were assessed	Notes	Dates of study not stat	ed. Any conflicts of interest not stated
Random sequence generation (selection bias) Low risk Computer-generated random numbers Allocation concealment (selection bias) Unclear risk Method of allocation concealment not stated Blinding of participants and personnel (performance bias) Low risk Stated blinded, placebo was 'an identical pill' Blinding of outcome assessment (detection bias) Low risk Stated blinded Blinding of outcome assessment (detection bias) Low risk Stated blinded Incomplete outcome data (attrition bias) Unclear risk It is not stated whether data from all recruited participants are reported Selective reporting (reporting (reporting bias) Unclear risk Side effects were not reported although they were assessed	Risk of bias		
tion (selection bias)Unclear riskMethod of allocation concealment not stated (selection bias)Blinding of participants and personnel (perfor- mance bias) All outcomesLow riskStated blinded, placebo was 'an identical pill'Blinding of outcome as- sessment (detection bias) All outcomesLow riskStated blindedIncomplete outcome data (attrition bias) All outcomesUnclear riskIt is not stated whether data from all recruited participants are reportedSelective reporting (re- porting bias)Unclear riskSide effects were not reported although they were assessed	Bias	Authors' judgement	Support for judgement
(selection bias)Low riskStated blinded, placebo was 'an identical pill'Blinding of participants and personnel (perfor- mance bias) All outcomesLow riskStated blinded, placebo was 'an identical pill'Blinding of outcome as- sessment (detection bias) All outcomesLow riskStated blindedIncomplete outcome data (attrition bias) All outcomesUnclear riskIt is not stated whether data from all recruited participants are reported (attrition bias) All outcomesSelective reporting (re- porting bias)Unclear riskSide effects were not reported although they were assessed		Low risk	Computer-generated random numbers
and personnel (performance bias) All outcomesLow riskStated blindedBlinding of outcome assessment (detection bias) All outcomesLow riskStated blindedIncomplete outcome data (attrition bias) All outcomesUnclear riskIt is not stated whether data from all recruited participants are reported (attrition bias) All outcomesSelective reporting (re- porting bias)Unclear riskSide effects were not reported although they were assessed		Unclear risk	Method of allocation concealment not stated
sessment (detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-porting bias) Unclear risk Side effects were not reported although they were assessed	and personnel (perfor- mance bias)	Low risk	Stated blinded, placebo was 'an identical pill'
(attrition bias) All outcomes Selective reporting (re- porting bias) Unclear risk Side effects were not reported although they were assessed	sessment (detection bias)	Low risk	Stated blinded
porting bias)	(attrition bias)	Unclear risk	It is not stated whether data from all recruited participants are reported
Other bias Unclear risk –		Unclear risk	Side effects were not reported although they were assessed
	porting bias)		



Methods	Parallel design				
	Analysis: ITT (last observation carried forward), withdrawn owing to becoming depressed, AE, treating practitioner started antidepressant, medical advice, no reason given, not contactable - numbers not in cluded				
Participants	Location: Australia				
	Setting: inpatient				
	Treatment: 55 people, mean \pm SD age 68 \pm 13 years, 67% men				
	Control: 56 people, mean \pm SD age 67 \pm 13 years, 62% men				
	Stroke criteria: acute ischaemic or haemorrhagic stroke, diagnosis by clinical signs (ICD-10) and CT (100% imaged, 10/111 CT scan did not show acute ischaemia); stroke on average < 2 weeks prior to ran- domisation				
	Not depressed (HADS-D had to be over 7)				
	Other entry criteria: not stated				
	Comparability of treatment groups: more participants in treatment group with previous heart attack and stroke, also higher levels of hypertension				
	Exclusion criteria: severe communication difficulties, unstable medical condition, severe cognitive im- pairment and depression (MMSE < 10), taking antidepressants within 4 weeks of stroke, contraindica- tion to sertraline, previous reaction to sertraline, could not speak English				
Interventions	Treatment: sertraline 50 mg daily (night)				
	Control: matched placebo				
	Duration: treatment continued for 24 weeks				
	Duration of follow-up (post-treatment to study end): 28 weeks				
Outcomes	Depression: change in scores from baseline to end of treatment on HDRS, proportion depressed				
	Change in MMSE scores				
	mRS				
	Death				
	Leaving the trial early				
	Check list of possible AEs read out to participant by a research nurse				
Funding source	Funded by an unrestricted grant from Rotary Health Research Fund				
Notes	Recruitment June 2004 to June 2006				
	Conflicts of interest not stated				
Risk of bias					
Bias	Authors' judgement Support for judgement				
Random sequence genera- tion (selection bias)	Low risk Computer-generated random numbers				



Almeida 2006 (Continued)

Allocation concealment (selection bias)	Low risk	Centralised
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Stated in paper, matched placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not stated in paper
Incomplete outcome data (attrition bias) All outcomes	Low risk	Performed last observation carried forward
Selective reporting (re- porting bias)	Low risk	Trial protocol published on www.strokecentre.org/trials
Other bias	Low risk	No other obvious biases

Andersen 1994

Methods	Parallel design
	Analysis (ITT) last observation carried forward and per protocol: death (1 treatment, 1 control) with- drawn owing to AE (6 treatment, 1 control), all excluded from analysis
Participants	Location: Denmark
	Setting: mixed
	Treatment: 33 people, mean \pm SD age 68 \pm 4 years, 36% men
	Control: 33 people, mean ± SD age 66 ± 9 years, 66% men
	Stroke criteria: ischaemic stroke and PICH; diagnosis via clinical signs and CT (100%); stroke 2 to 52 weeks prior to randomisation (average time 12 weeks)
	Depression criteria: HDRS score > 12 (score transformed to appropriate DSM-III-R criteria)
	Other entry criteria: none stated
	Comparability of treatment groups: balanced
	Exclusion criteria: depression within last year, receiving current treatment for depression, severe de- mentia or communication problems, degenerative or expansive neurological disease, decreased con- sciousness
Interventions	Treatment: citalopram 10 mg in participants > 66 years, 20 mg in participants < 67 years daily; dose doubled if no response to treatment within 3 weeks
	Control: matched placebo
	Duration: treatment continued for 6 weeks
	Duration of follow-up (post-treatment to study end): 0



Andersen 1994 (Continued)

Trusted evidence. Informed decisions. Better health.

		protocol on www.strokecentre.org/trials states that mood scores were mea- stroke, this probably refers to the time since stroke at the time of randomisation		
Outcomes	Depression: change in scores from baseline to end of treatment on HDRS			
	Melancholia scale			
	Proportion no longer m	neeting entry criteria (< 13 on HDRS)		
	50% reduction in HDRS	score		
	Additional: leaving the	study early		
	Death			
	AEs (unwanted drug ef scale)	fects were registered and evaluated at the same intervals using a side effect		
	Unable to use: BI, Socia	al Activities Index, MMSE (data not presented)		
Funding source	rg Diocese Research Fo	oundation, Medical Research Foundation for North Jutland County, The Aalgo- undation, Consultant Otorhinolaryngologist Kopp's Foundation and Stine and bundation. Lundbeck Pharma A/S provided the citalopram and placebo; thus we unclear risk'.		
Notes	Recruitment 1 Februar	y 1991 to 29 February 1992. Conflicts of interest not stated		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	Blocks of 4 used		
Allocation concealment (selection bias)	Low risk	Centralised opaque envelopes		
(selection bias) Blinding of participants and personnel (perfor-	Low risk Low risk	Centralised opaque envelopes Matched placebo		
(selection bias) Blinding of participants and personnel (perfor- mance bias) All outcomes Blinding of outcome as- sessment (detection bias)				
(selection bias) Blinding of participants and personnel (perfor- mance bias) All outcomes Blinding of outcome as- sessment (detection bias) All outcomes Incomplete outcome data (attrition bias)	Low risk	Matched placebo		
(selection bias) Blinding of participants and personnel (perfor- mance bias) All outcomes Blinding of outcome as- sessment (detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes Selective reporting (re-	Low risk Unclear risk	Matched placebo Those who were blinded were not stated Although there were dropouts, analysis performed both per protocol and us-		
(selection bias) Blinding of participants and personnel (perfor- mance bias) All outcomes Blinding of outcome as- sessment (detection bias) All outcomes Incomplete outcome data (attrition bias) All outcomes	Low risk Unclear risk Low risk	Matched placebo Those who were blinded were not stated Although there were dropouts, analysis performed both per protocol and us- ing last observation carried forward		



Methods	Multicentre
	Study type: interventional (clinical trial)
	Intervention model: parallel assignment
	Primary purpose: treatment
Participants	642 participants
	Country: Denmark
	Setting: inpatient
	At randomisation number allocated: citalopram n = 319; placebo n = 323
	% male at baseline: citalopram n = 199/319 (62%); placebo n = 222/323 (69%)
	Age at baseline: mean age, citalopram 68 \pm 13 (n = 319); placebo 68 \pm 13 (n = 323)
	Subtype of stroke at baseline: not available
	Severity of stroke at baseline: NIHSS, citalopram 5.3 \pm 5.6; placebo 4.8 \pm 4.8
	Time since stroke onset: mean time from last known 'well' to first treatment 1.7 days (median 1, IQR (to 6)
	Inclusion criteria:
	 First ever ischaemic stroke Age ≥ 18 years
	Exclusion Criteria:
	 Haemorrhagic stroke Dementia or other neurodegenerative disease Antidepressant medical treatment within 6 months of admission Acute need for antidepressant treatment Drug abuse or other conditions that may indicate non-compliant behaviour Liver failure (increased liver enzyme levels up to or more than 2 times upper limit) Renal failure (eGFR below 30 ml/min per 1.73 m²) Hyponatremia (S-potassium below 130 mmol/l) Actively bleeding ulcer Fatal stroke or other severe co-morbidity that markedly decreases expected life span Prolonged corrected QT-interval (QTc above 480 ms) Ongoing treatment with drugs known to prolong the QTc interval
nterventions	Experimental: citalopram 20 mg (10 mg if aged ≥ 65 years or having reduced liver/kidney function) or placebo once daily for 6 months Comparator: ½ to 2 tablets with no intrinsic drug activity per day for 6 months
Dutcomes	
Dutcomes	 Primary outcomes Vascular death, TIA/stroke and myocardial infarction within 6 months Functional status at 6 months (mRS)
	Secondary outcomes within or at 6 months
	Vascular deathDeath of any cause



Random sequence genera- tion (selection bias)	Low risk	Quote: "A computer-generated randomization code was used to randomize patients in blocks of 10."
Allocation concealment (selection bias)	Low risk	Quote: "Citalopram was commercially available (Sandoz, Denmark) and pro- duction of the placebo and randomization was prepared by a pharmacy in- dependently of the investigators (Glostrup Pharmacy, Denmark). The tablets were indistinguishable and were supplied in numbered containers."
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of participant, care provider, and investigator assured and unlikely that the blinding could have been broken
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome assessor assured and unlikely that the blinding could have been broken
Incomplete outcome data (attrition bias) All outcomes	High risk	Attrition/exclusions reported with reasons provided (including did not start or study medication, consent withdrawn, side effects, indication for open label, other reasons (no detail provided)). At < 31 days of study medication, twice as many participants in the citalopram group withdrew consent (n = 29/318 (9%) compared to the placebo group (n = 14/320 (4%)). However, at < 31 days twice as many participants in the placebo group (n = 12/318(4%)) compared to the citalopram group (n = 6/320 (2%) were switched to open label. Attrition/exclusions: 51/319 (16%) in the citalopram group and 39/319 (11%) in the placebo group.



Andersen 2013 (Continued)		The investigators use LOCF in their intention-to-treat analysis. LOCF assumes that missing values are missing completely at random and ignores improve- ments or deteriorations in the participants condition since dropout and there- fore stops improvements or declines in outcome measures. LOCF introduces risk of false or biased conclusions (Molnar 2008)
Selective reporting (re- porting bias)	Low risk	The study protocol is available and all of the study's prespecified (primary and secondary) outcomes that are of interest to the review have been reported in the prespecified way
Other bias	Low risk	The study appears to be free of other sources of bias

Birchenall 2019

Methods	Study type: interventional (clinical trial)			
	Intervention model: parallel assignment			
	Primary Purpose: treatment			
Participants	6 participants			
	Country: France			
	Setting: inpatient			
	At randomisation number allocated: 6 although unclear as to which group			
	% male: not available			
	Age: not available			
	Subtype of stroke: not available			
	Severity of stroke: not available			
	Time since stroke onset: not available			
	Inclusion criteria:			
	 Age 18 to 80 years. Social security affiliation Day 3 to day 15 after stroke or brain haemorrhage Hemiparesia with upper limb motor deficit (Fugl-Meyer score - hand ≤ 10) Informed consent 			
	Exclusion criteria:			
	 NIHSS > 20 Depression (criteria DSM5-R) with MADRS score > 19 History of recurrent bipolar or depressive disorders History of behavior or suicidal idea Family history of extension of the interval QT or congenital long interval QT History of clinical stroke Aphasia preventing correct evaluation of motor and depression scales. Patients treated by antidepressant drugs, IMAO, and neuroleptics in the past month Benzodiazepines within 48 hours preceding inclusion. Intolerance or allergy to fluoxetine (Sandoz[®] 20 mg pill) 			



Birchenall 2019 (Continued)				
	-	disorders preventing oral administration of the treatment		
	 Planned carotid sur Pregnant or breast- 			
	-) and TGP > 2N); severe renal failure (creatinine > 180micromol/l)		
	•	e disease not allowing follow-up		
		other therapeutic study		
	Contraindication to	MRI and TMS		
	Withdrawal criteria: no	ot stated		
Interventions	Experimental: fluoxeti	ne; 1 pill of 20 mg/day, during 3 months		
	Comparator: placebo o	of fluoxetine; 1 pill of 20 mg/day, during 3 months		
Outcomes	Primary outcome:			
	• Slope of the curve of	of recruitment of the MEPs at 3 months.		
	Secondary outcomes r	ecorded at 3 and 6 months:		
	 Slope of recruitmen MEPs) 	t of the MEPs (effect of a first dose of fluoxetine on the slope of recruitment of the		
	• Slope of recruitmer MEPs to month 6)	nt of the MEPs (persistence of fluoxetine effect on the slope of recruitment of the		
	,	ontrol in paretic hand		
	_	control in non-paretic hand		
Funding source	Not stated			
Notes	No published data, unpublished data say 6 patients, none of whom died, so we have used this informa- tion			
	Dates study conducted: February 2014 to August 2015			
	Declarations of Interes	t: none reported.		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	No information available		
Allocation concealment (selection bias)	Unclear risk	No information available		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	No information available		
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No information available		
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information available		



Birchenall 2019 (Continued)

Selective reporting (re- porting bias)	Unclear risk	No information available
Other bias	Unclear risk	No information available

Black-Schaffer 2012

Methods	Study type: interventional (clinical trial)		
	Intervention model: parallel assignment		
	Primary purpose: treatment		
Participants	0 participants (aimed to recruit 25 participants)		
	Country: USA		
	Setting: inpatient		
	At randomisation number allocated: 0		
	% male: not available		
	Age: not available		
	Subtype of stroke: not available		
	Severity of stroke: not available Time since stroke onset: not available		
	Inclusion criteria:		
	 Ischaemic infarction within 15 days Admission NIHSS item 5 score ≥ 2 Able to give informed consent, with surrogate consent acceptable 		
	Exclusion criteria:		
	 Pre-stroke mRS score equal or ≥ 3 Pregnant or lactating Taking an SSRI on admission Taking a medication likely to have adverse interaction with an SSRI Unable to return for follow-up testing days 90, 180 Concurrent medical condition likely to worsen patient's functional status over next 6 months Unable to competently participate in testing for 45 minutes to 2 hours with rest breaks for MRI substudy: contraindication to MRI 		
Interventions	Experimental: fluoxetine 20 mg daily for 90 days starting day 5 to10 after stroke		
	Comparator: placebo participants will take 1 placebo pill daily for 90 days		
Outcomes	Primary outcome measures:		
	• FMMS (baseline to 90 days, baseline to 180 days)		
	Secondary Outcome Measures		
	 Western Aphasia Battery (baseline to 90 days) Behavioral Inattention Test (baseline to 90 days, baseline to 180 days) 		

Black-Schaffer 2012 (Continued)

- FIM (baseline to discharge)
- Fatigue Severity Scale (baseline to 90 days, baseline to 180 days)
- BDI (baseline to 90 days, baseline to 180 days)
- Western Aphasia Battery (baseline to 180 days)
- mRS (baseline to 90 days, baseline to 180 days)

Funding source	Not stated	
Notes	clinicaltrials.gov/ct2/show/NCT01674868	
	Withdrawn - unable to find patients meeting inclusion/exclusion criteria	
	Dates study conducted: April 2013 to December 2015 (estimated completion date)	
	Declarations of Interest: none reported	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Withdrawn: unable to find patients meeting inclusion/exclusion criteria
Allocation concealment (selection bias)	Unclear risk	Withdrawn: unable to find patients meeting inclusion/exclusion criteria
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Withdrawn: unable to find patients meeting inclusion/exclusion criteria
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Withdrawn: unable to find patients meeting inclusion/exclusion criteria
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Withdrawn: unable to find patients meeting inclusion/exclusion criteria
Selective reporting (re- porting bias)	Unclear risk	Withdrawn: unable to find patients meeting inclusion/exclusion criteria
Other bias	Unclear risk	Withdrawn: unable to find patients meeting inclusion/exclusion criteria

Brown 1998

Methods	Parallel design
	Analysis: per protocol: 1 withdrawn (treatment), excluded from analysis
Participants	Diagnosis: stroke, time from stroke to randomisation not reported
	Randomised 10 to treatment and 10 to control
	Treatment: 9 completed treatment, mean \pm SD age 61.4 \pm 8.6 years, 55% men
	Control: 10 people completed placebo, mean \pm SD age 63.7 \pm 5.4 years, 60% men

Brown 1998 (Continued)		emotionalism of at least 4 weeks' duration assessed during semi-structured in- ed Lawson and MacLeod rating scale, in addition to frequency of outbursts		
	Exclusion criteria: cognitive impairment, dysphasia, major depressive disorder			
Interventions	Treatment: fluoxetine 20 mg daily			
	Control: matched place	ebo		
	Duration: 10 days			
	Duration of follow-up:	(end of treatment to end of study) 0		
Outcomes	Used leaving the study	early		
	Unable to use data fror sented)	n HDRS, Lawson and MacLeod Scale, self-rating scales (mean and SD not pre-		
	Also reported emotion	al outbursts; we have not used these in our analyses		
	AEs: not presented			
Funding source	Funder not stated			
Notes	Dates of study not state	ed; conflicts of interest not stated		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Bias Random sequence genera- tion (selection bias)	Authors' judgement	Support for judgement Randomisation method not stated		
Random sequence genera-				
Random sequence genera- tion (selection bias) Allocation concealment	Unclear risk	Randomisation method not stated		
Random sequence genera- tion (selection bias) Allocation concealment (selection bias) Blinding of participants and personnel (perfor- mance bias)	Unclear risk Unclear risk	Randomisation method not stated Randomised by independent statistician		
Random sequence genera- tion (selection bias) Allocation concealment (selection bias) Blinding of participants and personnel (perfor- mance bias) All outcomes Blinding of outcome as- sessment (detection bias)	Unclear risk Unclear risk Low risk	Randomisation method not stated Randomised by independent statistician States blinding, matched placebo		
Random sequence genera- tion (selection bias) Allocation concealment (selection bias) Blinding of participants and personnel (perfor- mance bias) All outcomes Blinding of outcome as- sessment (detection bias) All outcomes Incomplete outcome data (attrition bias)	Unclear risk Unclear risk Low risk Low risk	Randomisation method not stated Randomised by independent statistician States blinding, matched placebo States blinding		

Burns 1999

Methods

Parallel design



curns 1999 (Continued)	Analysis: ITT: 2 withdra	wn and 1 death (treatment), 1 death (placebo), last value carried forward	
Participants	Diagnosis: stroke.		
	Months from stroke: median (range) 10.5 months (1 ± 156) in sertraline group and 5.5 months (1.5 ± 48) in the control group Treatment: 14 people		
	Control: 14 people		
	Exclusion criteria: less than 1 month since stroke, depression or dementia using the DSM III-R criteria		
Interventions	Treatment: sertraline 5	0 mg daily	
	Control: matched place	ebo	
	Duration: treatment co	ntinued for 8 weeks	
	Duration of follow-up: ported so could not be	2 weeks off treatment. All scores became non-significant (though data not re- used in the analysis)	
Outcomes	Able to use:		
	 diminished tearfuln leaving the study ea death AEs Method of collecting Al 	clinician's interview based impression of change ess rly Es was not stated	
		BI, MMSE (data not presented)	
Funding source	Funded by an unrestricted personal grant from Pfizer, the manufacturers of sertraline		
Notes	Dates of study not state	ed, conflicts of interest not stated	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Blocks of 4 using list produced by medical statistics department	
Allocation concealment (selection bias)	Unclear risk	Not stated	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Matched placebo	
Blinding of outcome as- sessment (detection bias)	Unclear risk	Run-out was single-blind, treatment was double-blind, but unclear whether outcome assessors were blind	
All outcomes			



Burns 1999 (Continued) All outcomes		
Selective reporting (re- porting bias)	Low risk	Trial details published on www.strokecentre.org/trials, although unable to use data from MADRS
		Given that the main aim was to explore effect on emotionalism, this is unlikely to have biased results
Other bias	Unclear risk	Placebo group younger, uncertain influence on bias
		Statistical analysis was carried out independently by the Applied Statistics Re- search Unit in Canterbury

Chen 2005a

Methods	To observe the changes of neurotransmitter in people with post-stroke depression by using En- cephalofluctuography Technology, and observe the effect of antidepression treatment on the activity of neurotransmitter	
Participants	48 participants with post-stroke depression	
Interventions	Treatment: 24 people received citalopram 20 mg plus usual care, or fluoxetine if side effects such as nausea, emesis	
	Control: 24 people usual care alone	
Outcomes	Encephalofluctuography technology	
	Level of sympathin and 5-hydroxytryptamine at 4 weeks and 3 months after treatment started	
Funding source	Not stated	
Notes	No data from our endpoints of interest, so data not included in a meta-analysis	
	Recruitment March 2001 to December 2001	
	Conflicts of interest not stated	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Randomly divided" but method not stated
Allocation concealment (selection bias)	Unclear risk	Method not stated
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not described
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described



Chen 2005a (Continued)

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (re- porting bias)	Unclear risk	Unclear
Other bias	Unclear risk	Unclear

Chen 2005b

Methods	Parallel group			
	Analysis: according to allocated treatment group			
Participants	Country: China			
	Setting: inpatient			
	Stroke criteria: first ever stroke, onset time ≤ 7 days, haemorrhagic and ischaemic, clinical diagnosis plus confirmation by imaging (though not clear whether a stroke lesion had to be present), at least 1 limb with muscle power grade 3 or less, Bl ≤ 50, no consciousness disturbance			
	Mood criteria: HAMD > 16			
	Treatment: 40 people, mean age 63.5 years, 29 men			
	Control: 38 people, mean age 65.8 years, 25 men			
	No difference in baseline depression and BI between treatment and control group			
	Excluded: severe cardiac, hepatic and renal organic diseases, psychiatric disorders			
Interventions	Treatment: paroxetine 20 mg daily plus routine stroke medication, nerve nutritional agents, acupunc- ture and rehabilitation			
	Control: routine stroke medication, nerve nutritional agents, acupuncture and rehabilitation			
	Duration of treatment: 12 weeks			
	Duration of follow-up (post-treatment to study end): 0 weeks			
Outcomes	HAMD			
	BI			
	Death			
	Number completing the trial			
	AEs not reported			
Funding source	No description of funding			
Notes	_			
Risk of bias				
Bias	Authors' judgement Support for judgement			



Chen 2005b (Continued)

Random sequence genera- tion (selection bias)	Unclear risk	Method not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	Dropouts: none
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	No obvious risks, baseline similar

Chen 2001

Methods	Randomised trial	
	Aim: to observe effects of integrative Chinese herb YuLeShu and fluoxetine on the depressive symp- toms and rehabilitation of neurological impairment in patients with post-stroke depression	
Participants	Country: China	
	Setting: not described	
	Participants: internal carotid system cerebral infarction or haemorrhage within previous 2 months	
	Fluoxetine: 19 people, mean age 61.71 ± 8.13 years, 8 men	
	Control: 18 people, mean age 62.85 ± 7.32 years, 7 men	
	Depression: diagnosis of depression according to DSM-IV	
	Inclusion criteria: HDRS ≥ 20 but < 35 and/or Zung SDS ≥ 41	
	Exclusion criteria: HDRS > 35, previous depression, aphasia, severe cardiac, pulmonary, hepatic and re nal diseases, previous stroke	
Interventions	3 groups: fluoxetine plus usual care versus YuLeShu plus usual care versus usual care. We are using the fluoxetine plus usual care versus usual care alone in the comparison	
Outcomes	HDRS	
	Zung SDS	
	BI	
	Scandinavian Neurological Stroke Scale (also known as CSS)	



Chen 2001 (Continued)

Stated no side effects, but not clear which side effects were sought, or how they were sought. They were reported at 4, 8 and 12 weeks after treatment

Funding source	Funded by a local scientific academic fund, drug company not involved	
Notes	-	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "using a computer", but method not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	High risk	Dropouts: 2 people dropped out of the fluoxetine group, 1 dropped out of the YuLeShu group and 2 dropped out of the control group
Selective reporting (re- porting bias)	Unclear risk	Protocol not published
Other bias	Unclear risk	Reported that of the people who completed the tests, there were no differ- ences in baseline
		No comment on whether there were differences in baseline for the entire group

Chen 2002

Methods	Parallel group (3 groups: doxepin, paroxetine, placebo; we used the paroxetine and placebo data in ou review)	
	Aim: treat depression and determine effect on neurological function	
Participants	Country: China	
	Setting: unclear	
	Stroke diagnosis: diagnostic criteria of the 4th National Meeting of the Cerebrovascular Diseases proved by CT or MRI	
	Time since stroke: not known	
	Depression diagnosis: Classification and Diagnosis of Psychosis in China (2nd edition)	
	Treatment: 24 people, age and gender not given	

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright @ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Chen 2002 (Continued)				
	Control: 24 people, age and gender not given			
	Exclusion: pre-stroke mental disease, cognition disorder (MMSE < 24), marked deterioration in depres- sion during treatment (HAMD > 24) or suicide mood, intolerance to drug			
Interventions	Treatment: paroxetine	20 mg 3 times per day		
	Control: placebo guvita	amine once per day		
	Duration of treatment: 8 weeks			
		post-treatment to study end): unclear: follow-up is performed 'after treatment' 8 weeks (so post-treatment to study end = 0)		
Outcomes	HAMD			
	BI			
	CSS			
	Death/side effects/leav	ving the trial early		
	Method of reporting side effects not stated			
Funding source	Funder not stated, unclear if there was drug company involvement			
Notes	-			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	Method not described		
Allocation concealment (selection bias)	Unclear risk	Not described		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Placebo was used, but unclear if this was matching		
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described		
Incomplete outcome data (attrition bias) All outcomes	High risk	Dropouts: 4 in placebo and 0 in paroxetine		
Selective reporting (re- porting bias)	Unclear risk	No protocol available		
Other bias	Unclear risk	Demographic data not provided, so we cannot determine whether the base- line was balanced		



Methods	Parallel design		
	-	and augment rehabilitation	
	Analysis: according to a	llocated treatment group	
Participants	Location: China		
	Setting: inpatient		
	Treatment: 25 people		
	Control: 32 people		
	Whole group (including group): 132 (mean age 6	non-depression group, depression control group and depression treatment 52 ± 12 years, 79 men)	
		e or PICH, clinical diagnosis plus confirmation on brain imaging (not clear that a present), clear consciousness	
	Depression diagnosis (a	t 2 weeks after stroke onset): psychiatric interview, DSM IV criteria	
	Excluded: major psychological trauma history in previous 1 year, severe mental retardation, severe im- pairment of lingual expression or comprehension, major complicated medical event in previous 1 year		
Interventions	Treatment: fluoxetine 20 mg daily		
	Control: no fluoxetine		
	Duration of treatment: 6 months		
	Duration of follow-up (post-treatment to study end): 6 months		
Outcomes	SSS		
	ADL		
	HAMD		
	Zung SDS		
	Zung SAS		
	No deaths, none left trial early		
	No data on AEs		
Funding source	No description of funding		
Notes	-		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Method not described	
Allocation concealment (selection bias)	Unclear risk	Not described	



Cheng 2003 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	59 participants were diagnosed to have depression by symptoms but only 57 were included in the results table
Selective reporting (re- porting bias)	High risk	No protocol, no report of the results of the self-rating anxiety scale
Other bias	Unclear risk	No clear description of differences between the treatment and control group

Chollet 2011

Methods	Randomised parallel-group trial	
Participants	Location: France	
	Setting: stroke units	
	Inclusion criteria: aged 18 to 85 years with FMMS of 55 or less, acute ischaemic stroke with hemiparesis or hemiplegia, 5 to 10 days after stroke onset, unclear if there had to be a visible lesion on brain imag- ing	
	Treatment: 59 people, mean ± SD age 66.4 ± 11.7 years; 63% men	
	Control: 59 people, mean \pm SD age 62.9 \pm 13.4 years; 59% men	
	Comparability of treatment groups: total FMMS score fluoxetine 17.1 compared with 13.4 in placebo Previous stroke more common in the fluoxetine group; fluoxetine group had more diabetes	
	Exclusions: clinical depression or treatment with antidepressants, MADRS > 19, aphasia severe enough to mask detection/assessment of depression, pregnancy, patient on neuroleptics/benzodiazepines, owing to undergo carotid endarterectomy, other major diseases that would prevent follow-up	
Interventions	Treatment: fluoxetine 20 mg daily for 90 days	
	Control: identical capsules to active drug	
	Duration of treatment: 90 days	
	Duration of follow-up (treatment end to study end): 0 days	
Outcomes	Primary outcome: the mean change of FMMS score between inclusion (day 0) and day 90 after the start of the study drug	
	Secondary endpoints were NIHSS, mRS and MADRS measured at days 0, 30 and 90	
Funding source	Funded by French national programme for clinical research: the sponsor had no involvement in stud design, data collection, data analysis, data interpretation or writing the report	

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)



Chollet 2011 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Balanced by centre with an allocation based on a block size of 4 generated with a computer random-number generator
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Identical capsules for control arm
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	All study site investigators and all investigators were masked to treatment al- location
Incomplete outcome data (attrition bias) All outcomes	Low risk	Dropouts: 2 participants died (1 in each group) and 3 dropped out - not stated how missing outcome data were dealt with
Selective reporting (re- porting bias)	Low risk	Trial protocol published on www.strokecentre.org/trials, all outcomes were reported
Other bias	Unclear risk	Note difference in baseline: it is not clear what effect this had on results, so we have classified this as 'unclear risk'

Dam 1996	
Methods	Parallel design
	Analysis: per protocol: withdrawn because of AEs (2 treatment), all excluded from analysis
Participants	Location: Italy
	Setting: unclear
	Treatment: 18 people, mean \pm SD age 68 \pm 9 years, 44% men
	Control: 17 people, mean ± SD age 68 ± 5.5 years, 44% men
	Stroke criteria: ischaemic, unilateral MCA territory stroke, diagnosis via clinical signs and CT (100%), stroke 1 to 6 months prior to randomisation (average time 3 months)
	Other inclusion criteria: unable to walk
	Comparability of treatment groups: balanced
	Exclusion: history of major affective disorders; alcohol abuse; or a history or evidence or both of severe heart, lung, kidney or liver diseases or mental deterioration
Interventions	Treatment: fluoxetine 20 mg daily
	Control: matched placebo
	Duration: treatment continued on average 74 \pm 6 days, duration not reported for control group



Dam 1996 (Continued)	Duration of follow-up (treatment end to study end): 0	
Outcomes	Depression: change in scores from baseline to end of treatment on HDRS	
	Additional: graded neurological scale (HSS), BI	
	Leaving the study early	
	Death	
	AEs including seizures - unclear if these were reported systematically	
Funding source	Funding source not stated	
Notes	Dates of recruitment and conflicts of interest not stated	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	No description
Allocation concealment (selection bias)	Unclear risk	No description
Blinding of participants and personnel (perfor-	Low risk	Quote: "Examining neurologists blind to treatment".
and personnel (perior- mance bias) All outcomes		Comment: Unclear if this refers to outcome assessors or the neurologist caring for the participant. However, placebo was 'matched' so this is low risk
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	See above
Incomplete outcome data (attrition bias) All outcomes	High risk	2/35 dropouts, per-protocol analysis
Selective reporting (re- porting bias)	Low risk	Trial available, including results on www.strokecentre.org/trials - all specified outcome measures were reported
Other bias	Unclear risk	Baseline characteristics similar in the 2 groups

Feng 2004

Methods	Aim: to study the influence of Jieyu Huoxue decoction on rehabilitation of patients with depression af- ter cerebral infarction
Participants	Country: China
	4 groups: fluoxetine plus usual care, Jieyu Huoxue decoction plus usual care, usual care in people with depression, usual care in people with no depression
	We are using data from 'fluoxetine plus usual care' versus 'usual care in people with depression'
	Setting: mixed inpatient and outpatient



Feng 2004 (Continued)				
		nic stroke within 1 month of stroke onset, clinical diagnosis plus confirmation by whether a visible lesion was needed to make a diagnosis		
	Depression: psychiatric	c interview using DSM IV, Zung SDS ≥ 41		
	Included those with no	previous psychiatric history		
	54 participants with po	ost-stroke depression were randomised		
	18 received fluoxetine tion	plus usual care, 18 received usual care only and 18 received Jieyu Huoxue decoc-		
	Of the 54 participants v	with depression randomised, mean age: 71.5 \pm 6.7 years, 24 men		
	Excluded: previous stro eases	oke, previous depression, and severe cardiac, pulmonary, hepatic and renal dis-		
Interventions	Treatment: fluoxetine 2	20 mg daily plus usual stroke care		
	Control: usual stroke care			
	Duration of treatment:	60 days		
	Duration of follow-up (post-treatment to study end): 0 weeks		
Outcomes	Zung SDS			
	ADL - although score not referenced, so not used in analysis			
	MESSS			
	Reported side effects in fluoxetine group but not in the control group			
	Unclear how side effects were collected			
Funding source	Funding source not stated			
Notes	-			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	Method not stated		
Allocation concealment (selection bias)	Unclear risk	No description		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo		
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	No blinding		
Incomplete outcome data (attrition bias) All outcomes	High risk	8 participants dropped out (2 in fluoxetine group, 2 in the depression control group, 1 in the Jieyu Huoxue decoction, 3 in no-depression control)		

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright @ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Feng 2004 (Continued)

Selective reporting (re- porting bias)	Unclear risk	No protocol	
Other bias	Unclear risk	Baseline balanced	

FOCUS Trial Collaboration 2018

Methods	Multicentre RCT			
	Study type: interventional (clinical trial)			
	Primary purpose: treatment			
Participants	3127 participants			
	Country: UK			
	Setting: inpatient			
	At randomisation number allocated: N = 3127: fluoxetine (n = 1564); placebo (n = 1563)			
	% male: fluoxetine (62%); placebo (61%)			
	Age: mean age: fluoxetine = 71·2 ± 12.4; placebo = 71·5 ± 12.1			
	Subtype of stroke:			
	 Total anterior circulation infarct: fluoxetine (20%); placebo (20%) Partial anterior circulation infarct: fluoxetine (36%); placebo (35%) Lacunar infarct: fluoxetine (20%); placebo (18%) Posterior circulation infarct: fluoxetine (12%); placebo (15%) Uncertain: fluoxetine (2%); placebo (2%) 			
	Severity of stroke: NIHSS, Median (IQR) fluoxetine (6 (3 to 11)); placebo (6 (3 to 11))			
	Time since stroke onset: mean days: fluoxetine 6.9 \pm 3.6; placebo 7.0 \pm 3.6			
	Inclusion criteria			
	 Age > 18 years Brain imaging consistent with intracerebral haemorrhage or ischaemic stroke Randomisation can be performed between 2 and 15 days after stroke onset Persisting focal neurological deficit is present at the time of randomisation 			
	Exclusion criteria			
	 Subarachnoid haemorrhage Unlikely to be available for follow up at 12 months Patient and/or carer unable to understand spoken or written English Other life-threatening illness Pregnant or breast-feeding or of child bearing age not taking contraception History of epileptic seizures Attempted suicide or self-harm Allergy or contra indication to fluoxetine Taken a monoamine oxidase inhibitor in last 5 weeks Current or recent depression requiring treatment with selective serotonin reuptake inhibitor 			



Trusted evidence. Informed decisions. Better health.

FOCUS Trial Collaboration 2018 (Continued)

Interventions	Experimental: 20 mg orally once daily for 6 months		
	Comparator: matching placebo orally once daily for 6 months		
Outcomes	Primary outcome:		
	• mRS at 6 months		
	Secondary outcome m	easures:	
	 Deaths from all causes at 6 and 12 months Modified Rankin scale at 12 months Stroke Impact Scale Euroquol 5D-5L Mental Health Inventory 5 Vitality subscale of SF36 (as an assessment of fatigue) Diagnosis of depression Other adverse events Adherence to the trial medication Health and social care resources used during follow-up 		
Funding source	MHRA approval grante	d. Start-up phase funded by The Stroke Association. Main phase funded by NIHR	
Notes	ISRCTN83290762. Recruitment 10 September 2012 to 31 March 2017. Authors declared no conflicts of interest		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Quote: "Patients were randomly assigned in a 1:1 ratio to receive fluoxetine or placebo, by use of a centralised randomization system."	
Allocation concealment (selection bias)	Low risk	Quote: "Patients were randomly assigned in a 1:1 ratio to receive fluoxetine or placebo, by use of a centralised randomization system."	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Quote: "Patients, their families, and the health-care team including the phar- macist, staff in the coordinating centre, and anyone involved in outcome as- sessments were all masked to treatment allocation by use of a placebo cap- sule that was visually identical to the fluoxetine capsules even when broken open."	
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Quote: "Patients, their families, and the health-care team including the phar- macist, staff in the coordinating centre, and anyone involved in outcome as- sessments were all masked to treatment allocation by use of a placebo cap- sule that was visually identical to the fluoxetine capsules even when broken open."	
Incomplete outcome data (attrition bias) All outcomes	Low risk	For the primary outcome of mRS at 6 months data were available for fluoxe- tine n = 1553/1564 (99.3%) and placebo n = 1553/1563 (99.3%)	
Selective reporting (re- porting bias)	Low risk	The study protocol is available and all of the study's prespecified (primary and secondary) outcomes that are of interest in the review have been reported	



Fruehwald 2003			
Methods	Parallel design		
	Analysis: per protocol:		
	Withdrawals: death (1 treatment), withdrawn owing to AEs (1 treatment, 2 control), all excluded from analysis		
Participants	Location: Austria		
	Setting: inpatients		
	Treatment: 28 people, mean \pm SD age 65 \pm 14 years, 46% men		
	Control: 26 people, mean \pm SD age 64 \pm 14 years, 71% men		
	Stroke criteria: ischaemic stroke and PICH; diagnosis via clinical signs and CT (100%); stroke on average 11 days prior to randomisation		
	Depression criteria: psychiatric interviews, HDRS score > 15		
	Other entry criteria: not stated		
	Comparability of treatment groups: non-significant trend towards more women and right-sided stroke in treatment group		
	Exclusion criteria: MMSE < 20, more than mild communication deficit, diseases of the central nervous system and previous neurodegenerative or expansive neurological disorders		
Interventions	Treatment: fluoxetine 20 mg daily, dose escalation at 4 weeks if HDRS score > 13		
	Control: matched placebo		
	Duration of treatment: 12 weeks		
	Duration of follow-up (end of treatment to study end): 15 months		
Outcomes	Depression: change in scores from baseline to end of treatment of HDRS, BDI and CGI (item 1)		
	Proportion of responders (< 13 HDRS)		
	Additional: SSS		
	Death		
	AEs (selected data)		
	Unable to use: RS, BI, MMSE (data not presented at follow-up)		
	AEs data on dizziness, nausea and cephalalgia (data not presented by group)		
Funding source	The medication was supplied by Lannacher Heilmittel, Lannach, Austria		
Notes	Recruitment 1 June 1998 to 31 Decmeber 1998. Conflicts of interest not stated		
Risk of bias			
Bias	Authors' judgement Support for judgement		
Random sequence genera- tion (selection bias)	Low risk Computerised randomisation, using random permutated block design		



Fruehwald 2003 (Continued)

Allocation concealment (selection bias)	Low risk	Centralised concealment
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	States blinded, used matching placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	States blinded
Incomplete outcome data (attrition bias) All outcomes	High risk	4/54, per protocol analysis
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	Baseline balanced
		All participants were randomly assigned to either fluoxetine or placebo treat- ment by the drug company independently of the research teams and the study centres

Gao 2016

Sao 2016				
Methods	Study type: interventional (clinical trial)			
	Primary purpose: treatment			
Participants	274 participants			
	Country: China			
	Setting: outpatient			
	At randomisation number allocated: N = 274, citalopram (n = 91); placebo (n = 91); cognitive behaviour- al therapy (n = 92)			
	% male: 51.8%			
	Age: mean age, citalopram 66.0 \pm 7.3 (n = 91); placebo 67.2 \pm 9.6 (n = 91); cognitive behavioural therapy 64.9 \pm 8.0 (n = 92)			
	Subtype of stroke: not available			
	Severity of stroke: not available			
	Time since stroke onset: acute ischaemic stroke within the previous 7 days			
	Inclusion criteria:			
	 Age ≥ 18 First ever ischaemic stroke meeting World Health Organization (WHO) diagnostic criteria confirmed by MRI No history of depression No antidepressant use prior to the study 			

Gao 2016 (Continued)	Exclusion criteria:
	 No consent Premorbid stroke related impairment BI < 10
Interventions	Experimental: citalopram 20 mg per day for a minimum of 3 months + general discussions
	Comparator 1: placebo + general discussions
	Comparator 2: placebo + cognitive behavioural therapy
Outcomes	 Depressive symptoms (17-item Hamilton Depression Scale (HAMD17), Bech-Rafaelsen Melancholia Scale (MES)) at 3 months.
	 Drug side-effects (Udvalg for Kliniske Undersogelser side-effect scale at 2, 4, and 6 weeks, and 3 months
	Performance in ADL (BI) at 3 months
	Functional impairment (FIM scale) at 3 months
Funding source	Natural Science Foundation of China [81100243, 81171131, 81272564, 81272795, 81100893, 81172197, and 81372484], the Natural Science Foundation of Liaoning Province in China [No. L2013296], and Liaoning Science and Technology Plan Projects [No. 2011225020]
Notes	This trial was particular in that recruitment happened at 4 different time points: at 0 months, 3 months, 6 months and 9 months from discharge. Inclusion criteria required that participants suffered from post- stroke depression. Participants were invited to complete the BDI and those with a score > 10 were in- cluded, provided other criteria were met
	Group 'placebo + general discussions' and 'citalopram + general discussions were included. No signifi- cant differences observed in the 2 included groups
	Dates study conducted: Participants enrolled between October 2011 and June 2013
	Declarations of Interest: none reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "Randomization into one of three intervention groups was undertaken by an independent researcher using computer-generated random number se- quences"
Allocation concealment (selection bias)	Low risk	Quote: "that were prepared in advance and placed in consecutively num- bered, sealed, opaque envelopes."
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Study described as "single blind". Quote: "The researcher successively opened the envelopes corresponding to different time periods and determined the intervention by patient number." Quote: "The study therapists acted as clinical evaluators." Quote: "The study therapists were asked not to divulge any treatment informa-
Blinding of outcome as- sessment (detection bias)	High risk	Comment: Care providers, investigator and outcome assessors were all aware of allocation. Quote: "The study therapists acted as clinical evaluators."

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright @ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Gao 2016 (Continued) All outcomes		Quote: "The study therapists were asked not to divulge any treatment informa- tion to their patients."
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "in Group A [placebo + general discussions], one patient violated pro- tocol in the second time period, one could no longer be reached, and one left the study owing to stroke recurrence in the third time period; in Group B [citalopram + general discussions], persistent side-effects from the drugs led five patients to leave the study (two owing to orthostatic dizziness, one owing to palpitation, and two owing to constipation)" Comment: Attrition reported for each intervention group and reasons given Group A (placebo + general discussions) 3/91 = 3% attrition
		Group B (citalopram + general discussions) 5/91 = 5% attrition Overall = 4% attrition
Selective reporting (re- porting bias)	Unclear risk	There is no study protocol available. Therefore insufficient information to judge yes or no
Other bias	Low risk	The study appears to be free from other sources of bias

GlaxoSmithKline 1998

Methods	Parallel group		
	Analysis: according to treatment group		
Participants	Location: not stated		
	Setting: not stated		
	Stroke criteria: "documented diagnosis of stroke within 12 months prior to screening"		
	Mood: MADRS score > 17		
	Treatment: 112 people, age 64.3 ± 11.4 years, 61 men		
	Control: 117 people, 65.6 ± 10.5 years, 64 men		
	Excluded: concurrent psychiatric disorders, concurrent psychotropic pharmacotherapy, patients who posed a suicidal risk, patients with substance abuse/dependence, concurrent psychotropic pharma-cotherapy, MMSE < 24, participating in another clinical trial, serious medical condition or clinically sig nificant finding on screening or baseline evaluation that would preclude the administration of paroxet tine and an intolerance to paroxetine		
nterventions	Treatment: paroxetine 20 to 50 mg daily		
	Control: placebo (not stated whether matching)		
	Duration of treatment: 8 weeks		
	Duration of follow-up (treatment to study end): 0 weeks		
Outcomes	Change from baseline to endpoint in MADRS		
	Proportion of participants scoring < 8 on the MADRS total score at the endpoint (we used this in our analysis)		
	Changes from baseline to endpoint on the RI		

GlaxoSmithKline 1998	(Continued)
	Change from baseline to endpoint on RS score
	Change from baseline to endpoint on the Clinical Global Improvement Severity of Illness Score (CGI-S Proportion of responders based on CGI-Global Improvement (CGI-G) score (score of < 4) at endpoint
	GI side effects reported, but unclear whether these are 'events' or 'participants', so we cannot use these data. It is not clear how the side effects were collected
	Withdrawal from study
Funding source	Source of funding not stated, but we assume it was funded by GlaxoSmithKline
Notes	Study period 29 August 1998 to 15 October 1999. Conflicts of interest not stated. Study number PAR625. Date updated: 11 March 2005
Risk of bias	

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Randomisation method not described
Allocation concealment (selection bias)	Unclear risk	Allocation concealment: not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Blinding not described, used placebo but not stated whether identical
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Blinding not described
Incomplete outcome data (attrition bias) All outcomes	High risk	20 in each group dropped out
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	Insufficient information to make clear judgement

Guo 2009	
Methods	Parallel group, 3-arm trial, comparing sertraline plus routine care versus routine care versus acupunc- ture plus routine care. We are using the sertraline plus routine care versus routine care in this review
	Aim: to treat depression
	Analysis: according to allocated treatment
Participants	Country: China
	Setting: unknown
	Stroke criteria: first ever stroke, clinical diagnosis plus relevant lesion on imaging, age ≥ 60 years old

Guo 2009 (Continued)	Depression criteria: HA	MD score ≥ 8, no depression prior to stroke
	Treatment: 40 people,	mean age 67.6 ± 12.43 years, 23 men
	Control: 40 people, me	an age 64.5 ± 12.07 years, 22 men
	aphasia, sensory apha	disorders or family psychiatric disorders, severe cognitive impairment, global sia, apraxia, severe cardiac, hepatic, renal, lung or other severe somatic disorder, ance, severe deafness, family or patient unable to comply
Interventions	Treatment: sertraline 5 chotherapy)	50 mg daily plus stroke care (acute, secondary prevention, rehabilitation and psy-
	Control: stroke care (ad	cute, secondary prevention, rehabilitation and psychotherapy)
	Duration of treatment:	6 weeks
	Duration of follow-up:	(treatment end to study end): 6 months
Outcomes	HAMD	
	NIHSS	
	FIM (reported cognition	n and mobility scores only)
	SF-36	
	AEs not reported	
Funding source	Funded by a local scier	ntific academic fund
Notes	_	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Random-number table
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Outcome assessor blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts, analysed by allocated treatment
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Low risk	No obvious risk, balance baseline



He 2004

e 2004				
Methods	Parallel group			
	Analysis: according to t	treatment allocation		
Participants	Location: China			
	Setting: inpatient			
		athological types of stroke, clinical diagnosis plus confirmation by imaging (did lesion was needed to make the diagnosis), first ever stroke		
	Depression diagnosis: ' ment	'HAMD scores'. Translation of paper: did not have to have depression at recruit-		
	Treatment: 36 people,	mean age 70.8 \pm 6.7 years, 25 men		
	Control: 35 people, me	an age 70.4 ± 6.8 years, 23 men		
	Exclusion: psychiatric o	disorders, dysphasia, consciousness disturbance, agnosia, severe dementia		
Interventions	Treatment: fluoxetine 2	20 mg daily plus usual stroke care		
	Control: usual stroke ca	are		
	Duration of treatment:	8 weeks		
	Duration of follow-up (treatment end to study end): 0			
Outcomes	HAMD			
	SSS			
	No description of how	side effects were collected		
Funding source	Funded by local scientific academic fund			
Notes	Reported that there were no AEs, so we have assumed no seizures or GI side effects			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	Not described		
Allocation concealment (selection bias)	Unclear risk	Not described		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo		
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Quote: "Outcome assessors blind"		
Incomplete outcome data (attrition bias)	High risk	13 dropped out after randomisation		



He 2004 (Continued) All outcomes

Selective reporting (re- porting bias)	Unclear risk	No protocol	
Other bias	Low risk	Balanced baseline, no obvious risks	

Methods	Parallel design. 3 groups: paroxetine, paroxetine plus psychotherapy, control. We are using paroxetine	
methous	and control data in this review	
	Analysis: according to treatment group	
Participants	Location: China	
	Setting: inpatient	
	Stroke criteria: first ever stroke; ischaemic and haemorrhagic, timing: "acute", clinical diagnosis plus confirmation by imaging (though not clear whether a stroke lesion had to be present or not)	
	Mood criteria: meets ICD-10 organic depression and organic anxiety diagnostic criteria on psychiatric interview, HAMD score ≥ 17 and HAMA score ≥ 14	
	Treatment: 27 people, mean age 62.4 ± 6.1 years, 14 men	
	Control: 27 people, mean age 63.2 ± 5.7 years, 16 men	
	Exclusion: previous psychiatric disorder, antidepressants and "nerve block agents" in recent 3 months severe cognitive impairment, aphasia, severe cardiac, hepatic and renal function impairment, allergy to paroxetine, severe suicidal behaviour	
Interventions	Treatment: paroxetine 20 mg plus routine stroke treatment	
	Control: routine stroke treatment	
	Duration of treatment: 6 weeks	
	Duration of follow-up: end of treatment to study end: 0	
Outcomes	SSS	
	BI	
	HAMD	
	НАМА	
	TESS	
	Also reported GI upset and dizziness. They did not list any seizures in the list of AEs, so we are assuming no seizures in either groups	
	Unclear how side effects were collected	
Funding source	Funded by a local scientific academic fund	
Notes	The authors mentioned using the SDS and the SAS for evaluation, but they did not report the res SDS and SAS	



He 2005 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Method not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts, analysed according to treatment group
Selective reporting (re- porting bias)	High risk	No protocol, the authors mentioned using the SDS and the SAS for evaluation but they did not report the results
Other bias	Low risk	Balanced baseline

He 2016

Methods	Study type: interventional (clinical trial)
	Primary purpose: prevention
Participants	374 participants
	Country: China
	Setting: inpatient
	At randomisation numbers allocated: N = 300
	Experimental group 1: fluoxetine immediately after enrolment n = 100; comparator group 1: fluoxetine 7 days after enrolment n = 100; comparator group 2: no fluoxetine n = 100
	% male: unclear
	Age: experimental, unclear; comparator 1, unclear; comparator 2, unclear
	Subtype of stroke: unclear
	Severity of stroke NIHSS score at baseline: unclear
	Experimental: unclear
	Comparator 1: unclear
	Comparator 2: unclear



He 2016 (Continued)

Time from stroke onset: within 1 week after onset of cerebral infarction

Inclusion criteria:

- ICD-10 diagnostic criteria for acute cerebral infarction
- Age 18 to 80 years
- First onset of stroke within 1 week
- NIHSS score > 2
- Stroke related impairment
- Informed consent by patients or legal representative

Exclusion criteria:

- Coma
- Haemorrhagic stroke
- Previous neurological impairment
- Use of antidepressants over previous 3 months
- Use of benzodiapines over previous 2 weeks
- Self-harm, suicidal ideation or need for antidepressants
- Abnormal liver enzymes or creatinine levels
- Gastrointestinal disorders affect drug absorption seriously
- Life-threatening illness (e.g. malignancy)
- Allergic
- Mental health disorders
- Pregnant or breast feeding
- Allergic
- Enrolled in another interventional clinical research trial within previous 3 months
- Scheduled endovascular intervention

Withdrawal criteria:

	Unblinding Serious adverse reactions or anophylactic check		
	 Serious adverse reactions e.g. anaphylactic shock Need for immediate stroke-related surgery 		
	Complications		
	Antidepressant use		
	 Self-harm, suicidal intention, urgent need for antidepressants 		
	Withdrawal from the study		
Interventions	Experimental: 20 mg of fluoxetine a day for 90 days and conventional therapy		
	Comparator: conventional therapy		
Outcomes	Primary outcome at days 15, 90 and 180		
	NIHSS score		
	Secondary outcome at days 90 and 180		
	BI score		
Funding source	This study was funded by Science and Technology Department of Guangdong, China (grant number: 2011B031800130), Science and Technology Innovation Committee of Shenzhen, China (grant num- ber: 201101020), and Health and Family Planning Committee of Shenzhen, China (grant number: 201501009). It was registered on the Chinese Clinical Trial Registry (number: ChiCTR-TRC-12002078)		
Notes	Dates study conducted: Unclear. Either from June 2011 to December 2012 (ChiCTR-TRC-12002078) or		

He 2016 (Continued)

from December 2015 to June 2016 (ChiCTR-IPR - 15007658)

Declarations of Interest: none reported

Trial registration detail (ChiCTR-TRC-12002078) does not match but rather matches ChiCTR-IPR - 15007658.

Baseline demographic and clinical characteristics for each group not presented, but rather the baseline demographic and clinical characteristics for those completing the trial (i.e. a subset of all those randomised at baseline) are presented

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "Table of random numbers"
Allocation concealment (selection bias)	Unclear risk	Insufficient information on method of allocation concealment to judge yes or no
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Insufficient information to permit judgement yes or no
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Quote: "The evaluator was banned from participation in the treatment or from querying of the randomisation data."
Incomplete outcome data (attrition bias) All outcomes	High risk	For the primary outcome of NIHSS score at 15, 90 and 180 days there was 8/187 (4%) lost to follow-up in the experimental group; 16/187 (15%) in the comparator group. Twice as many participants in the comparator group (16/187(9%)) compared to the fluoxetine group (8/187 (4%)) were lost to follow-up. Attrition and exclusions were not fully reported
		> 5% lost to follow-up
Selective reporting (re- porting bias)	High risk	The trial registration number/protocol does not match the study design pre- sented, but rather matches ChiCTR-IPR - 15007658
Other bias	High risk	The baseline data presented in table 1: comparison of data at baseline be- tween control group and the treatment group are not true baseline charac- teristics (i.e. at randomisation). The data presented in table 1 are the baseline characteristics of all those completing the trial which is a subgroup of all par- ticipants randomised. We cannot tell if there is whether there was any baseline imbalance in important demographic or clinical characteristics

 Hu 2002

 Methods
 Parallel design

 Aim: to study effect of antidepressants on depressive symptoms and nervous function

 Participants
 Country: China

 Setting: inpatient



Hu 2002 (Continued)	
	Stroke criteria: all pathological stroke types, clinical diagnosis plus confirmation by imaging (though unclear whether a relevant lesion had to be visible), onset of stroke 0.5 to 2 months, no obvious aphasia
	Depression: according to CCMD-II-R
	Treatment: 42 people, mean age 61.4 ± 3.6 years, 32 men
	Control: 30 people, mean age 60 ± 4.8 years, 23 men
Interventions	Treatment: fluoxetine 20 mg daily
	Control: no other antidepressant
	Duration of treatment: 8 weeks
	Duration of follow-up (end of treatment to study end): 0
Outcomes	HAMD
	MESSS
	However, these data were not usable, as they were reported as proportions above or below "decre- ment levels"
	Reported side effects but unclear how this was done
	None left the trial early
Funding source	Source of funding not stated
Notes	-
Risk of bias	

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Randomisation method not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	Balanced baseline, no other obvious risks



Huang 2002

Methods	Parallel design		
	Aim: efficacy and tolera	ance of fluoxetine in early post-stroke depression	
	Analysis: according to t	treatment group	
Participants	Country: China		
	Setting: inpatient		
	Stroke criteria: first ever stroke, with single unilateral lesion, clinical diagnosis with imaging consistent with stroke, both ischaemic and haemorrhagic, recruited 2 weeks after stroke onset		
	Depression criteria: CCMD II-R depression diagnosis		
	Treatment: 40 people,	age and gender not stated	
	Control: 40 people, age	e and gender not stated	
		tment and control groups were selected from a group of 168 first-ever acute erage age of 62 ± 8.1 years, 76 men	
Interventions	Treatment: fluoxetine 2	20 mg daily	
	Control: placebo		
	Duration of treatment:	4 weeks	
	Duration of follow-up (treatment end to study end): 0		
Outcomes	HAMD		
	CSS		
	Did not report death		
	Unclear how AEs were reported: no obvious AEs were found, but they did not specifically report seizures		
Funding source	Source of funding not stated		
Notes	-		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Method not stated	
Allocation concealment (selection bias)	Unclear risk	Method not stated	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Placebo used, but unclear if identical	
Blinding of outcome as- sessment (detection bias)	Unclear risk	Not described	



Huang 2002 (Continued) All outcomes

Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts, analysed according to treatment group
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	No description of the differences between treatment and control group in baseline characteristics

Jia 2005

Parallel design
Aim: to determine the effect of early intervention for post stroke depression on movement after 3 months of stroke
Country: China
Setting: inpatient
Inclusion: aged 40 to 75 years, all pathological types of stroke, clinical diagnosis plus confirmation by imaging (did not state whether a relevant lesion had to be present to make a diagnosis), able to give in- formed consent
Depression diagnosis: Zung SDS > 41 for screening for depression, HDRS for evaluation of the depres- sion severity level
Treatment: 92 people randomised, 90 accepted allocation, mean age 55.6 \pm 6.5 years, 60 men
Control: 92 people randomised, 90 accepted allocation, mean age 55.1 \pm 6.8, 55 men
Excluded: organic psychiatric disorders such as Alzheimer's disease or degenerative disease, functional disorders such as schizophrenia and affective disorders
Treatment: either fluoxetine or sertraline (given sertraline if also had anxiety) plus routine stroke care
Control: routine stroke care
Duration of treatment: 3 months
Duration of follow-up: 3 years but the authors did not describe the extent of neurological function dam- age and HAMD scores in the third year
HAMD
Extent of neurological damage
Recurrent stroke
Death
Did not report AEs
Source of funding not stated
-



Jia 2005 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	No blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Dropouts: 6 in treatment group (2 refused allocation), 4 in control group (2 re- fused allocation)
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	Balanced baseline

(im 2011			
Methods	Multicentre		
	Study type: interventional (clinical trial)		
	Intervention model: parallel assignment		
	Primary purpose: prevention		
Participants	478 participants		
	Country: South Korea		
	Setting: inpatient. At neurology departments in 17 university hospitals throughout South Korea		
	At randomisation number allocated: N = 478, escitalopram (n = 241); placebo (n = 237)		
	% male at baseline: unclear		
	Age at baseline: unclear		
	Subtype of stroke at baseline: unclear		
	Severity of stroke at baseline: unclear		
	Time since stroke onset: acute ischaemic stroke or intracerebral haemorrhage within the previous 21 days		
	Inclusion criteria:		



Kim 2011 (Continued)

- Age > 20 years
- Patients with acute stroke (ischaemic stroke or cerebral haemorrhage) confirmed by neuroimaging within 21 days after stroke onset
- Patients with haemorrhagic transformation of infarcted tissue will not be included, but if investigators judge the risk of bleeding is small (i.e. reduced amount of blood in follow-up neuroimaging) those patients can be enrolled
- Patients with MRS ≥ 2 on screening
- Patients without definite history of depression
- Patients who fulfil the following criteria in the K-MADRS test: The combined score of the 9th question (pessimistic thoughts) and the 10th question (suicidal idea) ≤ 7 The score of the 10th question < 6
- Patients without serious communication problem
- Consent

Exclusion criteria

- MRS 0 or 1 on screening
- History of depression or have taken antidepressants
- Diagnosis of bipolar disorder or other psychiatric disorders
- Severe dementia or aphasia and unable to communicate
- Taken migraine medication on screening or expected to take migraine medication frequently due to severe migraine
- Suicidal ideation on screening test or those who express their wish to be treated for depression
- Depression requiring treatment diagnosed by physician
- SSRI medication required for other reasons
- Taken antiepileptic drugs on screening
- History of traumatic brain injury, brain tumour, or other brain disease (except stroke) within 30 days prior to screening
- Uncommon causes of stroke (e.g. subarachnoid haemorrhage, venous thrombosis, arteriovenous malformation, or Moyamoya disease)
- · Bleeding diathesis, haemophilia, or thrombocytopenia
- Severe concomitant illness (e.g. liver disease, renal disease, malignancy)
- Patients with abnormal blood tests, renal insufficiency, heart failure
- Pregnant or breastfeeding
- Participating in another clinical (interventional) trial

Withdrawal criteria: not stated

Interventions	Experimental: escitalopram: first week 5 mg, 2nd week ~ 12 week: 10 mg	
	Comparator: "sugar pill". First week 5 mg, 2nd week ~ 12 week: 10 mg	
Outcomes	Primary outcomes collected at 3 months	
	 Occurrence rate of depression (Montgomery-Asberg Depression Scale (MADRS) score ≥16) 	
	Secondary outcomes:	
	Prevention of depression at 3 months	
	Prevention of emotional incontinence (modified Kim's criteria) at 3 and 6 months	
	Prevention of anger proneness (modified Spielberger trait anger scale) at 3 and 6 months	
	 Recovery of neurologic dysfunction (NIHSS, mRS Barthel Index, motor function test from Hemispheric Stroke Scale at 3 months 	
	Improvement of cognitive function (Montreal Cognitive Assessment (MoCA) at 3 and 6 months	
	Improvement of quality of life (Stroke Specific Quality of Life scale) at 3 and 6 months	
	Improvement of caregiver burden (Sense of Competence Questionnaire scores) at 3 and 6 months	

Kim 2011 (Continued)

Funding source	Dong-A Pharmaceutical Company, grants from the Ministry for Health, Welfare, and Family Affairs, South Korea
Notes	NCT01278498
	Baseline demographic and clinical characteristics for each group not presented, but rather the baseline demographic and clinical characteristics for those completing the trial (i.e., a subset of all those ran- domised at baseline) are presented.
	Dates study conducted: January 2011 to December 2015.

Declarations of Interest: none reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "Eligible patients were enrolled by investigators at each centre, and randomly assigned in a 1:1 ratio using a web-based system to the escitalopram group or the placebo group after being assigned a subject number. Randomi- sation was done with random permuted blocks of sizes four to six, and was stratified by centre. The placebo was identical in appearance to escitalopram"
Allocation concealment (selection bias)	Low risk	Quote: "Eligible patients were enrolled by investigators at each centre, and randomly assigned in a 1:1 ratio using a web-based system to the escitalopram group or the placebo group after being assigned a subject number. Randomi- sation was done with random permuted blocks of sizes four to six, and was stratified by centre"
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Quote: "The placebo was identical in appearance to escitalopram"
		Quote: "The individual treatment code was stored separately by the main medical statistician (E-JL) and two designated statisticians. All investigators including interviewers and assessors of the outcome, participants, and care providers were masked to treatment assignment throughout the study. The code could be unblinded only with the approval of the steering committee."
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Quote: "All investigators including interviewers and assessors of the out- come, participants, and care providers were masked to treatment assignment throughout the study. The code could be unblinded only with the approval of the steering committee."
Incomplete outcome data (attrition bias) All outcomes	High risk	The following participants were excluded from the 'full analysis set' post-ran- domisation from both escitalopram group and placebo group:
		 did not take at least 1 dose of study medication (escitalopram = 4, placebo = 6) did not undergo at least 1 assessment of the primary endpoint (escitalopram = 27, placebo = 36) Reasons for attrition were reported (withdrew consent, violated protocol, considered for treatment for depression, death). Numbers were similar in both groups At 12 weeks, escitalopram group 67/241 (28%) attrition and placebo 73/237(31%) attrition



Kim 2011 (Continued)		It is not clear how missing data were imputed for the intention-to-treat analy- sis; Quote: "we used latest available records for analysis."
Selective reporting (re- porting bias)	Low risk	The study protocol is available and all the study's prespecified (primary out- comes and secondary outcomes) that are of interest in the review have been reported in the prespecified way.=
Other bias	High risk	The baseline data presented in table 1: comparison of data at baseline be- tween control group and the treatment group are not true baseline charac- teristics (i.e. at randomisation). The data presented in table 1 are the baseline characteristics of all those completing the trial which is a subgroup of all par- ticipants randomised. We cannot tell if there is whether there was any baseline imbalance in important demographic or clinical characteristics

Kong 2007 Methods Parallel Aim: to study whether fluoxetine could prevent post-stroke depression and improve neurological function Participants Country: China Setting: inpatient Stroke: met diagnostic criteria of various cerebrovascular diseases formulated in the 4th National Cerebrovascular Disease conference and confirmed as stroke by CT or MRI, all hemiplegic, within 7 days of onset HAMD score of no depression Treatment: 48 people, mean age 64 ± 7 years, 60% men Control: 42 people, mean age 62 ± 7 years, 57% men Exclusion: major depression, current antidepressants, allergy to fluoxetine, substance abuse, bipolar disorder, schizophrenia, MMSE ≤ 23/30, substance abuse, obvious liver and renal deficit Interventions Treatment: fluoxetine 20 mg daily Control: matching placebo capsules Duration of treatment: 8 weeks Duration of follow-up (end of treatment to end of study): 0 Outcomes HAMD ΒI NIHSS Reported "somatic side effects and hyponatraemia" but not death or other side effects Authors state that "side effect rating was assessed at each visit" but unclear how this was done Source of funding not stated. Fluoxetine and placebo were supplied by Lilly Pharmaceutical Company Funding source Notes _



Kong 2007 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Computer-generated table of random digits
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Identical capsules, participants blinded
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	States that researchers were blinded
Incomplete outcome data (attrition bias) All outcomes	High risk	17/90 dropouts
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	Balanced baseline

Lai 2006

-di 2006			
Methods	Parallel design		
	Analysis: analysed according to allocated treatment groups		
Participants	Location China		
	Setting: inpatients		
	Treatment: 40 people		
	Control: 40 people		
	Total: mean age 60 \pm 14 years, 43 men		
	Stroke criteria: unclear stroke types, clinical diagnosis plus brain imaging (though not clear that stroke lesion had to be present), acute stroke		
	Depression criteria: HAMD at least 7, or Zung SDS > 53, but no clear description about using which scale for inclusion criteria		
	Other entry criteria: none stated		
	Comparability of treatment groups: unclear		
	Exclusion criteria: unclear		
Interventions	Treatment: paroxetine 20 mg daily		
	Control: placebo		



Lai 2006 (Continued)			
	Duration: treatment co	ntinued for 2 months	
	Duration of follow-up (end of treatment to end of study): 0		
Outcomes	Depression: HAMD, Zur	ng SDS (abnormal if the score is > 53)	
	Additional: Zung SAS (a	bnormal is the score is > 50)	
	Death		
_	The author described t	hat they recorded AEs but they did not report any AEs	
Funding source	Source of funding not s	tated	
Notes	-		
B ¹ 1 1 1			
Risk of bias			
Risk of bias Bias	Authors' judgement	Support for judgement	
	Authors' judgement Unclear risk	Support for judgement Method not stated	
Bias Random sequence genera-			

Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	No participant dropped out
Selective reporting (re- porting bias)	High risk	No protocol, stated that they would evaluate side effects but these were not reported
Other bias	Unclear risk	Demographic details at baseline not described

Li 2004a

Methods	Parallel group	
	Aim: to study effects of fluoxetine on neurological impairment and post-stroke depression	
Participants	Location: China	
	Setting: inpatient	
	Stroke: inclusion: all pathological types, clinical diagnosis plus confirmation by imaging that relevant lesion visible, CSS 16 to 30	
	Depression criteria: HAMD scores \geq 17 and DSM IV diagnostic criteria	



Li 2004a (Continued)			
	Treatment: 33 people,	mean age 60.33 years, 24 men	
	Control: 34 people, me	an age 60.44 years, 23 men	
	Excluded severe psych	iatric disorders, severe cardiac, pulmonary, hepatic and renal disease	
Interventions	Treatment: fluoxetine 20 mg daily plus routine acute stroke care		
	Control: routine acute	stroke care	
	Duration of treatment: 4 weeks		
	Duration of follow-up (end of treatment to end of study): 0	
Outcomes	CSS		
	Depression incidence		
	Laboratory monitoring	parameters	
	AEs (method of reporting not stated)		
Funding source	Source of funding not stated		
Notes			
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Computer random numbers	
Allocation concealment (selection bias)	Low risk	Opaque sealed envelopes	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo	
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described	
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts	
Selective reporting (re- porting bias)	Unclear risk	No protocol	
Other bias	Unclear risk	Balanced baseline	

Li 2004b

Methods

Parallel design



Li 2004b (Continued)	Aim: to treat depression				
Participants	Country: China				
	Setting: inpatient				
	Stroke criteria: ischaemic stroke, clinical diagnosis plus imaging confirmation (though not clear that a relevant lesion had to be seen), stroke onset time ≤ 7 days				
	Depression criteria: HAMD score ≥ 8				
	Treatment: 37 people, age 48 to 87 years, 17 men				
	Control: 36 people, age 53 to 82 years, 15 men				
	Exclusion: previous depression or psychiatric interview, dementia (according to MMSE scores), aphasia severe cardiac, pulmonary, hepatic, renal function impairment, consciousness disturbance				
Interventions	Treatment: fluoxetine 20 mg daily plus usual stroke care				
	Control: usual stroke care				
	Duration: 8 weeks				
	Duration of follow-up (treatment end to study end): 0				
Outcomes	HAMD				
	CSS (cannot use as reported as a categorical variable)				
	MMSE (reported as a dichotomous variable)				
	BI (reported as a dichotomous variable)				
	Data for continuous variables not provided				
	Death reported				
	Side effects in treatment group only reported, not control group. Method of reporting side effects not stated				
Funding source	Source of funding not stated				
Notes	Note that the sum of numbers in each category of HAMD at 8 weeks in the control group adds up to 30, not 32				
Risk of bias					
					

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Method not described
Allocation concealment (selection bias)	Unclear risk	Method not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo



Li 2004b (Continued)		
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	High risk	Dropouts: 6 in treatment and 4 in control group
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	Baseline balanced

Li 2005

Methods	Parallel design			
	Improvement of post-stroke depression and augmentation of rehabilitation			
Participants	Country: China			
	Setting: inpatient			
	Stroke criteria: all stroke, clinical diagnosis plus confirmation on imaging (though not clear whether a relevant lesion had to be present)			
	Depression according to CCMD-II-R			
	Treatment: 74 participants			
	Control: 74 participants			
	Participaients in the treatment and control groups were selected from a group of 368 stroke patients with an average age of 57 ± 11.8 years, age range 33 to 84 years, 240 men			
	Excluded: previous psychiatric disorders, severe dementia, aphasia, consciousness disturbance			
Interventions	Treatment: paroxetine 20 mg daily plus routine stroke treatment			
	Control: routine stroke treatment			
	Duration of treatment: 4 weeks			
	Duration of follow-up (end of treatment to study end): 0			
Outcomes	HAMD			
	SSS			
	Deaths			
	Side effects not recorded			
Funding source	Source of funding not stated			
Notes	-			
Risk of bias				



Li 2005 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Randomisation method not described
Allocation concealment (selection bias)	Unclear risk	No description
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not stated whether blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	Analysed according to allocated treatment group, no participant dropped out
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	No description of differences between treatment and control group

Li 2006

Methods	Parallel group		
Participants	All pathological types of stroke, CT or MRI needed for diagnosis		
	Inclusion criteria: depression diagnosed by Chinese Classification of Mental Disorders 3 and HAMD ≥ 18 no previous organic brain disorder, and no previous psychiatric history, clear consciousness, no com- prehension problems, normal language, first acute stroke, first episode of depression		
	Treatment: 52 people, mean ± SD age 61.12 ± 10.25, 32 men		
	Control: 53 people, mean ± SD age 60.89 ± 9.12, 35 men		
Interventions	Treatment: citalopram 20 mg daily plus usual care		
	Control: usual care		
	Duration of treatment: 12 weeks		
	Duration of follow-up (end of treatment to end of study): 0		
Outcomes	HDRS (also known as HAMD)		
	ВІ		
	CSS		
	MMSE		
	Side effects reported according to the participant's complaints and observation, no description of who recorded AEs; and reported only for the treatment group		

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright @ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Li 2006 (Continued)

Funding source

Source of funding not stated

Notes _ **Risk of bias** Bias **Authors' judgement** Support for judgement Random sequence genera-Unclear risk No description tion (selection bias) Allocation concealment Unclear risk No description (selection bias) Blinding of participants High risk No placebo and personnel (performance bias) All outcomes Blinding of outcome as-Unclear risk No description sessment (detection bias) All outcomes Incomplete outcome data High risk 2 dropouts in treatment group, 4 in control group. 1 in treatment group died, (attrition bias) and 2 in the control group died (i.e. > 5%) All outcomes Selective reporting (re-Unclear risk No protocol

	porting bias)		
-	Other bias	Unclear risk	Baseline balanced

Li 2008

.1 2008		
Methods	Parallel trial, 3 (fluoxetine versus "free and easy wandering" versus placebo), we are using the fluoxe tine versus placebo comparison in this review	
Participants	Country: China	
	Setting: unclear	
	Stroke criteria: by neuroimaging, ischaemic or PICH	
	Depression diagnosis: "each patient was evaluated by a psychiatrist", HAMD > 20 included	
	Fluoxetine group: 60 people, mean age 69.2 \pm 3.5 years, men 41.6%	
	Control: 30 people, mean age 67.8 ± 3.9 years, men 56.7%	
	Excluded psychiatric illness other than depression, antidepressants within previous 2 weeks, MMSE • 23, severe aphasia	
Interventions	Treatment: fluoxetine 20 to 40 mg daily	
	Control: placebo	
	Duration of treatment: 8 weeks	



Li 2008 (Continued)

	Duration of follow-up (treatment end to study end): 0
Outcomes	HAMD
	BI
	Description of why participants left the trial early
	AEs (reported by participant or observed/elicited by physician at each visit)
Funding source	Funded by the Natural Science Foundation of Shandong Province, People's Republic of China. None of authors had financial ties with the companies producing the medications in this study
Notes	Note twice as many in fluoxetine as in control group
	study conducted between March 2006 to September 2007. None of the authors or departments in- volved in the study had financial ties with the companies producing the medications used in this study

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Computer-generated random numbers
Allocation concealment (selection bias)	Unclear risk	Unclear
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Paper states blinded, used placebo (though unclear if matching)
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	4/90 dropped out (< 5%)
Selective reporting (re- porting bias)	Unclear risk	No placebo
Other bias	Low risk	Balanced baseline

Liu 2006

Methods	Parallel design
	Aim: to study effect of citalopram on post-stroke depression and neurological functional rehabilitation
Participants Country: China	
	Setting: inpatient
	Stroke criteria: stroke during "recovery phase" at 6 to 9 months, NIHSS score \geq 13, HAMD score \geq 17



Liu 2006 (Continued)	60 people randomised.	, of whom 38 were men, mean age 60.7 \pm 8.6 years. Demographics for treatment		
	and control groups we			
	Treatment: 30 people,	age and gender not stated		
	Control: 30 people, age and gender not stated			
	Exclusion criteria: prev	ious psychiatric disorder, dementia, aphasia, consciousness disturbance		
Interventions	Treatment: citalopram	20 mg daily plus routine stroke care		
	Control: routine stroke	care		
	Duration of treatment:	6 weeks		
	Duration of follow-up (treatment end to study end): 0		
Outcomes	HAMD			
	NIHSS			
	BI			
	Death			
Funding source	Source of funding not s	tated		
Notes	AEs not reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	Method not described		
Allocation concealment (selection bias)	Unclear risk	Not described		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo		
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not stated		
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts		
Selective reporting (re- porting bias)	Unclear risk	No protocol		
Other bias	Unclear risk	Baseline balance reported by authors		



Methods	Multicentre				
	Study type: interventional (clinical trial)				
	Primary purpose: supportive care				
Participants	32 participants				
	Country: Mexico				
	Setting: inpatient				
	At randomisation number allocated: N = 32: fluoxetine (n = 15); placebo (n = 17)				
	% men: 50%				
	Age: mean age 55.1 ± 12.2				
	Subtype of stroke: not available				
	Severity of stroke: NIHSS, Median (IQR): fluoxetine (12 (5)); placebo (14 (5))				
	Time since stroke onset: within 10 days				
	Inclusion criteria:				
	 Age > 18 years Patients who had an acute intracerebral haemorrhage within the past 10 days causing hemipare or hemiplegia FMMS scores of ≤ 55 Written informed consent 				
	Exclusion criteria:				
	 NIHSS score > 20 Premorbid disability, evidenced by residual motor deficit from a previous stroke Comprehension deficit or severe aphasia Previous diagnosis of depression or one of the following:Hospital Anxiety and Depression Scale score ≥ 11 points; taking antidepressant drugs 2 weeks before inclusion Use of neuroleptic drugs or benzodiazepines 2 weeks before inclusion Other life-threatening illnesses 				
	Withdrawal criteria:				
	 Detection of eligibility violations Poor compliance (< 90%) or noncompliance Use of any medication or treatment during the trial that could affect the study results Occurrence of a serious adverse event: participant has an acute reaction (allergy, shock) to the investigational product participant develops depression, evidenced by HAD score ≥ 11 points at visit participant withdraws consent or is unco-operative 				
Interventions	Experimental: fluoxetine 20 mg orally once daily for 90 days				
	Comparator: matching placebo orally once daily for 90 days				
Outcomes	Primary outcome				
	• FMMS score (baseline and 90 days): change from baseline in FMMS score at 90 days				
	Secondary outcomes				



Marquez Romero 2013 (Conti	 BI (baseline and 90 days): change from baseline in BI at 90 days mRS (baseline and 90 days): change from baseline in mRS at 90 days NIHSS (baseline and 90 days): change from baseline in NIHSS at 90 days 		
Funding source	Psicofarma S.A. de C.V.		
Notes	NCT01737541		
	Terminated (study recruitment was suspended due to lack of funding)		
	Dates study conducted: November 2012 to August 2014		
	Declarations of Interest: none reported		

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "A pharmaceutical laboratory (Psicofarma™ S.A. de C.V.) will be respon- sible for the manufacture and randomization of the investigational product, which will be achieved using a web-based randomization program. This pro- gram will be set to assign participants equally to each site at a ratio of 1:1."
Allocation concealment (selection bias)	Low risk	Quote: "Each of the sites will be assigned 22 participants. The manufacturer will then deliver the pre-randomized bottles containing the investigational product to each recruiting center. Study subjects who satisfy the eligibility cri- teria at each recruiting center will receive the investigational product corre- sponding to a consecutive number assigned according to their entrance to the study."
Blinding of participants and personnel (perfor-	Low risk	Quote: "Fluoxetine and placebo tablets will be identical in form, color, odor and packaging."
mance bias) All outcomes		"Both the investigator and the subject will be blinded to the assignment of the study drugs. The manufacturer of the tablets will label the investigational drugs by the randomization code number. The labeled experimental products will be provided to the recruiting centers by the manufacturer. An envelope containing all randomization codes will be delivered to the principal investiga- tor and will be kept sealed until the conclusion of the trial."
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of participants and key study personnel ensured, and unlikely that blinding could have been broken
Incomplete outcome data (attrition bias)	Low risk	Aimed to recruit 44 per group (total of 88) 35 in each group + 20% to allow for predicted 20% loss to follow-up
All outcomes		Actual enrolment N = 32. Quote: "Two patients (one in each group) did not take any medication returning the unopened bottles at visit 1 and had to be excluded from analysis."
		Comment: Report includes data from 30 participants (14 participants in the fluoxetine group and 16 in the placebo group)
Selective reporting (re- porting bias)	Low risk	The study protocol is available and all of the study's prespecified (primary and secondary) outcomes that are of interest in the review have been reported
Other bias	Low risk	The study appears to be free of other sources of bias



Meara 1998

Methods	Parallel design			
	Analysis: unclear			
Participants	Location: Wales, UK Setting: inpatient			
	Treatment: unclear			
	Control: unclear Stroke criteria: ischaen	nic stroke > 11 weeks prior to randomisation		
	Depression criteria: GDS (15-item) score > 4			
	Other entry criteria not stated			
	Exclusion criteria: moderate to severe dementia, severe aphasia, communication difficulties, poorly controlled epilepsy			
Interventions	Treatment: sertraline 5	0 mg daily, dose escalation to 100 mg for non-responders at 2 weeks		
	Control: matched placebo			
	Duration: treatment continued for 6 weeks			
Outcomes	Depression: change in scores from baseline to end of treatment on GDS Unable to use GDS, BI, MMSE, FAI, FAST			
	Leaving trial early			
	Death			
	AEs			
Funding source	Source of funding not stated			
Notes	Contacted author for more details but no response			
	We could not use the data in our meta-analysis			
	Dates of study not stated. Conflicts not stated			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	Method not described		
Allocation concealment (selection bias)	Unclear risk	Not described		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Double-blind reported, those who were blind not described		
Blinding of outcome as- sessment (detection bias)	Unclear risk	Double-blind reported, those who were blind not described		



Meara 1998 (Continued) All outcomes

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (re- porting bias)	Unclear risk	Insufficient data to make a judgement
Other bias	Unclear risk	Insufficient data to make a judgement

Miao 2004

Methods	Parallel group			
	9 not allocated (5 in treatment group refused allocation, 4 in the control group refused allocation)			
Participants	Country: China			
	Setting: mixed inpatient and outpatient			
	All stroke pathological types, clinical diagnosis plus confirmation by imaging that a relevant lesion was visible, 2 to 8 months after stroke, clear consciousness, no comprehension problem, 1 lesion in 1 hemi- sphere, normal language comprehension			
	Mood: depression after stroke onset, HAMD score \geq 20			
	Participants: 90 randomised, 34 in each group at treatment end			
	Treatment: 34 people, age 58.16 ± 8.49 years, 19 men			
	Control: 34 people, age 62.45 ± 8.24 years, 18 men			
	Exclusion criteria: other organic brain disorders and other aetiologies-related depression			
Interventions	Treatment: citalopram 20 mg daily plus usual stroke care			
	Control: usual stroke care			
	Duration of treatment: 6 weeks			
	Duration of follow-up (treatment end to study end): 0			
Outcomes	HAMD			
	SDS			
	Efficacy			
	Death			
	AEs (only in the citalopram group)			
	Method of recording AEs was not stated			
Funding source	Source of funding not stated			
Notes	-			
Risk of bias				



Miao 2004 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera-	Unclear risk	Quote: "Simple random sampling"
tion (selection bias)		Comment: no further description given
Allocation concealment (selection bias)	Unclear risk	Allocation not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding described
Incomplete outcome data (attrition bias) All outcomes	High risk	9 not allocated after randomisation, 13 dropouts
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	Baseline balanced

Murray 2005				
Methods	Parallel design			
	Analysis: ITT (last observation carried forward) and per-protocol: death (2 control), no efficacy (16 treatment, 22 control), withdrawn owing to AE (8 treatment, 5 control), withdrew consent (1 control), all excluded from analysis			
Participants	Location: Sweden			
	Setting: mixed			
	Treatment: 62 people, mean \pm SD age 71 \pm 10 years, 52% men			
	Control: 61 people, mean \pm SD age 71 \pm 10 years, 44% men			
	Stroke criteria: all subtypes, diagnosis by WHO criteria and CT (100%); stroke 3 to 367 days prior to ran- domisation (average time 128 days)			
	Depression criteria: psychiatric interview (DSM-IV, major and minor) and MADRS > 9			
	Other entry criteria: > 17 years of age, stroke within the previous 12 months			
	Comparability of treatment groups: significant trend towards more left-hemisphere lesion strokes in treatment group			
	Exclusion criteria: under 18 years of age, severely impaired communication, apparent difficulties ad- hering to study protocol, acute myocardial infarction, other psychiatric illnesses other than depression, significant risk of suicide, antidepressants during the month after randomisation, current use of psy- chotropic medication or opiate analgesic drugs			



Murray 2005 (Continued)	Participants with < 20%	% reduction in MADRS score at 6 weeks were excluded		
Interventions	Treatment: sertraline 50 mg daily; possible dose escalation to 100 mg after 4 weeks			
	Control: matching plac	cebo		
	Duration of treatment:	26 weeks		
	Duration of follow-up:	(treatment end to study end): 0		
Outcomes	Depression: change in	scores from baseline to end of treatment on MADRS		
	Additional: leaving the study early			
	Death			
	Unable to use: Scandinavian Supervision Stroke Scale, BI, Stroke Unit Mental Status, Examination so- cial performance, treatment costs, mortality, relative's situation, neuropsychological performance, neurological recovery (data not presented)			
	AEs (selected data presented) using a modified version of the Udvalg for Kliniske Undersogelser side effect rating scale			
Funding source	Funded by an unrestricted grant, study drug and placebo from Pfizer AG Sweden and grants from the AFA Insurances and Marianne and Marcus Wallenberg Foundation			
Notes	Recruitment September 1998 to January 2001. Conflicts stated; some of the authors have received grants from pharmaceutical companies			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Low risk	Block randomisation		
Allocation concealment (selection bias)	Low risk	Centralised randomisation		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	States blinding and used matching placebo		
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	States blinding		
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT as well as per protocol		
Selective reporting (re- porting bias)	High risk	No protocol, paper stated that ADL data and SSS data were collected, but these were not reported		
Other bias	Unclear risk	Balanced baseline except that more participants had left hemisphere brain le sion in sertraline group than in placebo group (statistically significant)		



Methods	Study type: interventional (clinical trial)			
	Primary purpose: treatment			
Participants	170 participants			
	Country: China			
	Setting: inpatient			
	At randomisation number allocated: 170, paroxetine (n = 85); usual care (n = 85)			
	% male: paroxetine (71.8); usual care (unclear)			
	Age: mean age paroxetine = 65.6 ± 7.56; placebo = unclear			
	Subtype of stroke: not stated.			
	Severity of stroke: NIHSS, Median (IQR): paroxetine 8 (6 – 10); usual care (unclear)			
	Time since stroke onset: within 1 week			
	Inclusion criteria:			
	 Age between 50 and 80 years old Diagnostic criteria met (Fourth National Cerebrovascular Disease Conference) and confirmation b MRI Ability to participate in assessments within 1 week of stroke onset FMMS score of < 55 points Montreal Cognitive Assessment score of < 26 points Exclusion criteria			
	 NIHSS score > 20 points Aphasia History of pre-stroke depression and taken antidepressants or benzodiazepines HAMD score >7 points Receipt of thrombolytic therapy Complications such as infection, bed sores, or heart failure that might affect rehabilitation Withdrawal criteria: not stated 			
Interventions	Experimental: orally administrated paroxetine at dosages of 10 mg/day during week 1 and 20 mg/day thereafter, for a total treatment duration of 3 months			
	Comparator: usual care			
Outcomes	Outcomes were collected at 15, 90 and 180 days			
	 Movement assessed using FMMS Cognitive impairment assessed using the Montreal Cognitive Assessment Depression assessed using HAMD 			
Funding source	No grant funding from any grant funding agency, commercial or not-for-profit organisations.			
Notes	There is no study protocol/trial register reference.			
	Baseline sociodemographic and clinical characteristics are provided only for those who completed the study.			

Pan 2018 (Continued)

The authors state that one of the inclusion criteria is Montreal Cognitive Assessment (MOCA) score of < 26 points. In the Results section they state that there were "72 cases of cognitive impairment" (i.e. a MoCA score of < 26 points) in the comparator group and 82 in the experimental group at days 15, 90 and 180. This suggests that either that the inclusion criteria were not strictly adhered to or if 100% of participants had a MoCA score of < 26 points at baseline then 10/82 participants in the comparator group and 3/85 in the experimental group have improved on the MoCA between days 0 and 15

Dates study conducted: participants recruited between January 2012 and June 2014

Declarations of Interest: none reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "Random number table"
Allocation concealment (selection bias)	Unclear risk	Insufficient information to judge yes or no
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Insufficient information to judge yes or no
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Quote: "All scale evaluators were trained and tested by the main investigator and were blind to the group assignment."
Incomplete outcome data (attrition bias) All outcomes	Low risk	All data available for all participants in the experimental group (n = 85/85) and data available for (n = 82/85) participants in the comparison group for the Fugl–Meyer Motor Scale and the HAMD score
		For the MOCA (see 'Other bias' below)
		< 5% overall loss to follow-up
Selective reporting (re- porting bias)	Unclear risk	There is no study protocol/trial register reference, so insufficient information to judge yes or no.
Other bias	High risk	The authors state that one of the inclusion criteria is Montreal Cognitive As- sessment (MoCA) score of < 26 points. In the Results section they state that there were "72 cases of cognitive impairment" (i.e., a MoCA score of < 26 points) in the comparator group and 82 in the experimental group at days 15, 90 and 180. This suggests that either that the inclusion criteria were not strictly adhered to or, if 100% of participants had a MoCA score of < 26 points at base- line then 10/82 participants in the comparator group and 3/85 in the experi- mental group have improved on the MoCA between days 0 and 15. The results 'Comparison of MoCA scores' and table 3 suggests otherwise

Pariente 2001

Methods	Prospective double-blind cross-over placebo-controlled study of 8 people with pure motor hemiparesis
Participants	Lacunar ischaemic stroke, assessed by brain CT



Pariente 2001 (Continued)	Quote: "Early phase of recovery"		
Interventions	Single dose of fluoxetine		
Outcomes	fMRI (raw data provide	d)	
	Finger tapping (presen	ted as a graph, no raw data)	
	NIHSS, motricity index	, BI, trunk control test, Ashworth scale, somatosensory scale (no data)	
Funding source	Source of funding not s	stated	
Notes	activation in the ipsi-le	e data in our meta-analyses. The authors reported that fluoxetine led to hyper- esional (i.e. on the same side as the stroke lesion) primary motor cortex during a fluoxetine significantly improved motor skills of the affected side	
	Dates of recruitment n	ot given. Conflicts not stated	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Randomisation code kept at the centre and broken at the end of the study	
Allocation concealment (selection bias)	Low risk	Randomisation code kept at the centre and broken at the end of the study	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Double-blind, placebo given	
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Double-blind	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on fMRI appears complete	
Selective reporting (re- porting bias)	Unclear risk	Data on clinical outcomes were not reported	
Other bias	Unclear risk	Balanced baseline	
asmussen 2003			
Methods	Parallel design		
	Analysis: ITT (last observation carried forward) and per-protocol: details of those excluded from analy-		

Analysis: ITT (last observation carried forward) and per-protocol: details of those excluded from analyses (35 treatment, 35 control) unclear Location: Denmark

Setting: unclear

Participants

Treatment: 70 people, mean \pm SD age 72 \pm 9, 50% men

asmussen 2003 (Continued)	Control: 67 people, me	an ± SD age 68 ± 11, 51% men		
	Stroke criteria: ischaen to randomisation	nic and PICH; diagnosis by clinical signs and symptoms; stroke 0 to 4 weeks prio		
	Other entry criteria: no	t stated		
	Comparability of treatr	nent groups: participants in treatment group older on average		
Interventions		0 mg daily; at any time after 2 weeks dose could be increased in 50 mg incre- ily; average dose 62.9 mg daily		
	Control: matched place	ebo		
	Duration of treatment: 12 months			
	Duration of follow-up (end of treatment to end of study): 0		
Outcomes	Depression: change in	scores from baseline to end of treatment on HDRS		
	Proportion scoring > 2	on the CGI or > 16 on the GDS at end of treatment		
	Additional: leaving the	study early. Did not report death		
	Unable to use: HDRS, GDS, aphasia severity rating scale, European Stroke Scale, MMSE, Cambridge Cog- nitive Examination, SF-36, BI (data not presented)			
	AEs (detailed data not presented) evaluated by using the Udvalg for Kliniske Undersogelser Side Effect Rating Scale			
	Did not report death			
Funding source	Funding from Pfizer A/S, Gert Jorgensen legat and the Brain Cause. It is unclear whether the drug com- panies had input into the design and analysis of the study			
Notes	Recruitment January 1996 to May 1998. Conflicts not stated			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	Method not stated		
Allocation concealment (selection bias)	Unclear risk	Method not stated		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Matched placebo		
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not stated		
Incomplete outcome data (attrition bias) All outcomes	Low risk	Used ITT analysis and last observation carried forward		

Rasmussen 2003 (Continued)

Selective reporting (re- porting bias)	Low risk	Trial details published on www.strokecentre.org/trials
Other bias	Unclear risk	Those given sertraline were slightly older (by 4 years) but this is unlikely to in- troduce bias
		There was no significant difference between groups

Razazian 2014

	Study type: interventional (clinical trial)			
	Primary purpose: treatment			
Participants	172 participants			
	Country: Iran (Islamic Republic of)			
	Setting: inpatient			
	At randomisation number allocated: fluoxetine n = 86; placebo n = 86			
	% male: unclear			
	Age: fluoxetine group = unclear; placebo = unclear			
	Subtype of stroke: not available			
	Severity of stroke: not available			
	Time since stroke onset: not available			
	Inclusion criteria			
	 Middle cerebral artery stroke (documented with imaging) Hemiplegia, monoplegia or paresis No coma Consent Suitable for discharge Not admitted to Intensive care unit 			
	Exclusion criteria			
	 Death from any cause during study Irregular use of drugs Irregular return for re-examinations Seizures Severe diarrhoea, vomiting, Severe insomnia Metabolic disorder History of psychiatric disorder or severe depression prior to stroke SAH, lobar ICH, brain tumour or stroke in other vascular territories Use of any MAOI, selegiline, cyproheptadine 			
	Withdrawal criteria: not stated			

Razazian 2014 (Continued)	Compository placebo fl		
	Comparator: placebo fluoxetine for 90 days		
	All participants receive	d 30 sessions of routine physiotherapy during the rehabilitation period	
Outcomes	Primary outcomes collected at day 45 and day 90		
	Motor deficit (BI)Psychiatric disorder	(HDRS)	
Funding source	Kermanshah University	of Medical Sciences.	
Notes	IRCT201312088323N7		
		and clinical characteristics for each group not presented, but rather the baseline cal characteristics for those completing the trial (i.e. a subset of all those ran- re presented	
Dates study conducted: participants recruited between June 2013 a		: participants recruited between June 2013 and September 2014	
	Declarations of Interest: none reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera-	Unclear risk	Quote: "random permuted blocks".	
tion (selection bias)		Comment: Insufficient information about the block randomisation to permit judgement	
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement of yes or no	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Quote: "placebo that was identical to the active drug in appearance and pack- aging"	
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement of yes or no	
Incomplete outcome data (attrition bias) All outcomes	High risk	13% attrition at 90 days. 13% (n = 11/86) from the experimental group and 13% (n = 11/86) from the comparator group were excluded form the full set analysis at 90 days follow-up. Reasons for attrition reported	
Selective reporting (re- porting bias)	Low risk	Protocol available and all the study's prespecified outcomes that are of inter- est to the review have been reported in a prespecified way	
Other bias	High risk	The baseline data presented in table 1: patients demographic characteristics and risk factors and not true baseline characteristics (i.e. at randomisation). The data presented in table 1 are the characteristics of the full analysis set which is a subgroup of all participants randomised. We cannot tell if there is whether there was any baseline imbalance in important demographic or clini- cal characteristics	



Restifo 2001				
Methods	Double-blind study			
Participants	10 participants with disabling hemiplegia owing to hemispheric ischaemic stroke in territory of left MCA			
Interventions	Treatment: fluoxetine 2	20 mg daily for 3 months plus usual care (including Bobath rehabilitation)		
	Control: usual care incl	Control: usual care including Bobath rehabilitation		
Outcomes	Transmagnetic stimula	ation to establish motor reorganisation		
	The authors reported that fluoxetine might modulate the primary motor cortex reorganisation			
Funding source	Source of funding not stated			
Notes	Abstract only, full pape stated	er could not be found by our searches. Dates of study and conflicts of interest not		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "Random allocation", method not described		
Allocation concealment (selection bias)	Unclear risk	Quote: "Random allocation", method not described		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	A placebo was used, not clear if it was matching		
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Unclear from abstract		
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear from abstract		
Selective reporting (re- porting bias)	Unclear risk	Unclear from abstract		
Other bias	Unclear risk	Unclear from abstract		

Robinson 2000a

RODITISOTI 2000a	
Methods	Parallel design
	Comparison of fluoxetine, nortriptyline and placebo. We are using the fluoxetine and placebo data
	Analysis: per protocol, number excluded from analyses varied
	Data provided for depressed and non-depressed separately. We are labelling the depressed group as Robinson 2000a (this trial), and the non-depressed group as Robinson 2000b
Participants	Location: USA and Argentina

Robinson 2000a (Continued)			
	Setting: mixed		
	Treatment: 23 people v	with depression, mean \pm SD age 65 \pm 14 years; 17 men	
	Control: 17 people with	h depression, mean ± SD age 73 ± 10 years; 9 men	
	Stroke criteria: all subt cruitment, 18 to 85 yea	ypes, diagnosis by clinical signs and CT (100%), stroke within 6 months of re- irs of age	
	Stroke on average 16 w	veeks (fluoxetine) and 6 weeks (placebo) prior to randomisation	
	injury, prior history of a	er significant medical illness, severe comprehension deficit, prior history of head other brain disease (with the exception of stroke), participants on antidepres- etine) were allowed to stop their antidepressant for a 2-week washout period	
Interventions	Treatment: fluoxetine : (3 weeks)	10 mg daily (3 weeks), 20 mg daily (3 weeks), 30 mg daily (3 weeks), 40 mg daily	
	Control: matched place	ebo	
	Duration: treatment co	ontinued for 12 weeks	
	Duration of follow-up (end of treatment to end of study): 0	
Outcomes	Depression: change in	scores from baseline to end of treatment on HDRS	
	Additional: MMSE, JHF	I	
	Death		
	AEs (method of reporti	ng these was not stated)	
Funding source		s and grants from the Raul Carrea Institute of Neurological Research and Funda- ili Lilly and company supplied the fluoxetine and placebo	
Notes	Note difference in time	e since stroke between treatment groups	
	Dates of recruitment not stated. Conflicts not stated		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Random-number table	
Allocation concealment (selection bias)	Low risk	Concealment held by independent person	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Matched placebo	
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not stated	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Per-protocol and ITT analyses	



Robinson 2000a (Continued)

Selective reporting (re- porting bias)	Low risk	Protocol published www.strokecentre.org/trials
Other bias	Unclear risk	Imbalance in treatment groups for time since stroke and gender

Robinson 2000b Methods Parallel design Comparison of fluoxetine, nortriptyline and placebo. We are using the fluoxetine and placebo data Analysis: per protocol, number excluded from analyses varies Data provided for depressed and non-depressed separately. We are labelling the depressed group as Robinson 2000a, and the non-depressed group as Robinson 2000b (this trial) Participants Location: USA and Argentina Setting: mixed Treatment: 17 non-depressed people, mean ± SD age 66 ± 13 years, 15 men Control: 16 non-depressed people, mean ± SD age 67 9 years, 12 men Stroke criteria: all subtypes, diagnosis by clinical signs and CT (100%), stroke within 6 months of recruitment, aged 18 to 85 years of age Stroke on average 8 weeks (treatment) and 5 weeks (control) prior to randomisation Comparability of treatment groups: unclear Exclusion criteria: other significant medical illness, severe comprehension deficit, prior history of head injury, prior history of other brain disease (with the exception of stroke), participants on antidepressants (other than fluoxetine) were allowed to stop their antidepressant for a 2-week washout period Interventions Treatment: fluoxetine 10 mg daily (3 weeks), 20 mg daily (3 weeks), 30 mg daily (3 weeks), 40 mg daily (3 weeks) Control: matched placebo Duration: treatment continued for 12 weeks Duration of follow-up (end of treatment to end of study): 0 Outcomes Depression: change in scores from baseline to end of treatment on HDRS Additional: MMSE, JHFI Death AEs (method of reporting these was not stated) Funding source Funded by NIMH grants and grants from the Raul Carrea Institute of Neurological Research and Fundacion Perez Companc. Eli Lilly and company supplied the fluoxetine and placebo Notes Note difference in time since stroke between groups Dates of recruitment not stated. Conflicts of interest not stated **Risk of bias**



Robinson 2000b (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Random-number table
Allocation concealment (selection bias)	Low risk	Concealment held by independent person
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Matched placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT and per-protocol
Selective reporting (re- porting bias)	Low risk	Trial on www.strokecentre.org/trials
Other bias	Unclear risk	Note imbalance in time since stroke and in gender.

Robinson 2008	
Methods	Parallel group, 3-arm (escitalopram, placebo, problem-solving therapy group). We are using the esci- talopram versus placebo arm in this review
	Analysis: ITT
Participants	Country: USA
	Setting: mixed: neurology department and newspaper advertisements
	Stroke criteria: ischaemic or haemorrhagic stroke not because of complications of intracranial aneurysm or intracranial vascular malformation; within 3 months of index stroke
	Mood: excluded if DSM IV for major or minor depression or HAMD > 17
	Treatment (escitalopram): 59 people, mean \pm SD age 61.2 \pm 13.7, 38 men
	Control (matched placebo): 58 people, mean \pm SD age 63.9 \pm 11.1, 37 men
	Exclusion: acute coronary syndrome, neurodegenerative disorders, DSM IV criteria for alcohol or sub- stance abuse
Interventions	Treatment: escitalopram 5 to 10 mg (depending on age - lower dose given to > 65 years old)
	Control: matched placebo
	Duration of treatment: 12 months
	Duration of follow-up (treatment end to study end): 0
Outcomes	Diagnosis of depression



Robinson 2008 (Continued)

Trusted evidence. Informed decisions. Better health.

Robinson 2008 (Continued)				
	HAMD (dichotomised)			
	FIM (though no raw dat	ta provided in the paper for meta-analysis)		
	Social functioning examination			
	Repeatable Battery for	Repeatable Battery for Neuropyschological Status		
	The lowa subset provic	led detailed information about cognition		
	Participants, family members and primary care physicians were asked about AEs at 3 monthly intervals or sooner if an individual reported an AE using a standardised checklist			
Funding source	Grant RO1MH-65134. A quent letter to the Jou panies, and that 1 of th	s that "This work was supported solely by National Institute of Mental Health Il the study medications were purchased using NIMH grant funds." In a subse- rnal, the authors disclosed honoraria and expenses from pharmaceutical com- te authors owned Pfizer stock. However, the authors stated that the design and xpenses of the study were supported by monies, materials or any intellectual in- stories		
Notes	The escitalopram group had significantly more diabetes than the placebo group			
	Financial disclosures: see above			
	Recruitment: 9 July 2003 to 1 October 2007			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Low risk	Randomised blocks of 3, 6 and 9		
Allocation concealment (selection bias)	Unclear risk	Not described		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Identical placebo		
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Outcome assessors were blind		
sessment (detection bias) All outcomes Incomplete outcome data	Low risk Low risk	Outcome assessors were blind ITT analyses, all participants used in analysis		
sessment (detection bias) All outcomes				
sessment (detection bias) All outcomes Incomplete outcome data (attrition bias)		ITT analyses, all participants used in analysis		

There was more diabetes in the escitalopram group than placebo group

Savadi Oskouie 2012

Methods

Other bias

Study type: interventional (clinical trial)

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review) Copyright @ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Unclear risk



Savadi Oskouie 2012 (Continued)

Participants	144 participants			
	Country: Islamic Republic of Iran			
	Setting: inpatient			
	At randomisation number allocated: N = 144; citalopram (n = 72); placebo (n = 72)			
	% male at baseline: citalopram n = unclear; placebo n = unclear			
	Age at baseline: citalopram (n = unclear); placebo (n = unclear)			
	Subtype of stroke at baseline: unclear			
	Severity of stroke at baseline: unclear			
	Time since stroke onset: within 7 days			
	Inclusion criteria:			
	 Acute ischaemic stroke No previous use of citalopram or other antidepressants in the month prior to stroke onset Pre-stroke NIHSS < 20 No depression MADRS > 18 			
	Exclusion criteria:			
	 Request of patients to leave the study Previous chronic disease likely to interfere with assessment of effects of citalopram including: chror infections, liver or kidney failure, cancer Previous stroke-related disability Pregnancy or breastfeeding or any conditions that makes follow-up impossible Severe loss of consciousness Thrombolytic therapy Endarterectomy Depression (MADRS > 18) 			
	Withdrawal criteria: not stated			
nterventions	Experimental: oral citalopram 20 mg once daily			
	Comparator: placebo			
Dutcomes	Primary outcome			
	50% reduction in NIHSS score at 3 months compared to baseline			
	Secondary outcome			
	 mRS score at 3 months 50% reduction in NIHSS (motor) score at 3 months compared to baseline 50% reduction in NIHSS (language) score at 3 months compared to baseline Mortality 			
Funding source	Neurosciences Research Center (NSRC) of Tabriz University of Medical Sciences			
Notes	IRCT201203192150N2			

Savadi Oskouie 2012 (Continued)

Baseline demographic and clinical characteristics for each group not presented, rather the baseline demographic and clinical characteristics for those completing the trial (i.e. a subset of all those randomised at baseline) are presented.

Dates study conducted: May 2012 to January 2014

Declarations of Interest: none reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: "A total of 144 patients were randomized through an allocation se- quence based on 2 blocks with size of 72, generated with a computer random number generator."
Allocation concealment (selection bias)	Low risk	Quote: "Allocation was concealed using the sequentially numbered black envelopes."
Blinding of participants and personnel (perfor-	Unclear risk	Not explicitly stated that key study personnel and care providers were blinded, although implied by
mance bias) All outcomes		Quote: "The blinding code remained confidential until the end of the study."
		Quote: "placebo of the same shape and full packaging during the first day after hospital admission."
Blinding of outcome as- sessment (detection bias)	Unclear risk	Not explicitly stated that outcome assessors were blinded, although perhaps implied by the fact
All outcomes		Quote: "The blinding code remained confidential until the end of the study."
Incomplete outcome data (attrition bias) All outcomes	High risk	Primary outcome data were available for 58 (81%) of the citalopram group and 50 (69%) of the placebo group. Reasons for attrition are reported but there are differences between groups: number of participants in the placebo group (n = 11) dead compared to the citalopram group (n = 4). 3 times the number of participants in the placebo group were depressed (n = 6) compared to the citalopram group (n = 2). Did not want to continue (placebo group (n = 5), citalopram group (n = 8).
		Intention-to-treat analyses were carried out (suppl table) assuming that 1. those lost to follow-up had a poor outcome (i.e. did not improve their NIHSS scores from baseline) and 2. those participants in the placebo group who did not want to continue had a good outcome.
		Overall loss of > 5%
Selective reporting (re- porting bias)	Low risk	The study protocol is available and all the study's prespecified (primary out- comes and secondary outcomes) that are of interest in the review have been reported in the prespecified way
Other bias	High risk	The baseline data presented in table 1: comparison of demographic and base- line variables and not true baseline characteristics (i.e. at randomisation). The data presented in table 1 are the characteristics of the full analysis set at 3 months which is a subgroup of all participants randomised. We cannot tell if there is whether there were any baseline imbalance in important demographic or clinical characteristics. However, given that approximately 3 times the num- ber of participants in the placebo group (n = 11) died compared to the citalo- pram (n = 4) and 3 times the number of participants in the placebo group were depressed (n = 6) compared to the citalopram group (n = 2), this suggests that

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright @ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Savadi Oskouie 2012 (Continued)

there may have been important group differences in clinical characteristics at baseline

Methods	Study type: interventional (clinical trial)				
	Primary purpose: supportive care				
Participants	89 participants				
	Country: India				
	Setting: inpatient				
	At randomisation number allocated: N = 89: fluoxetine (n = 45); placebo (n = 44)				
	% male: unclear				
	Age: unclear				
	Subtype of stroke: unclear				
	Severity of stroke: unclear				
	Time since stroke onset: within 5 to 10 days				
	Inclusion criteria:				
	 Age 18 to 80 years old Patients who had an acute ICH within the past 5 to 10 days causing hemiparesis or hemiplegia FMMS scores of 55 or less 				
	Exclusion criteria:				
	 NIHSS score > 20 Diagnosis of depression MADRS score > 19 points Premorbid disability, evidenced by residual motor deficit from a previous stroke Use of neuroleptic drugs or benzodiazepines 4 weeks before inclusion Other life-threatening illnesses that would prevent follow-up Pregnancy Withdrawal criteria: not stated 				
nterventions	Experimental: fluoxetine 20 mg orally once daily for 90 days				
	Comparator: matching placebo orally once daily for 90 days				
Dutcomes	Primary outcome				
	• FMMS score (baseline and 90 days): change from baseline in FMMS score at 90 days				
Funding source	Not stated				
Notes	Baseline demographic and clinical characteristics for each group not presented, rather the baseline demographic and clinical characteristics for those completing the trial (i.e. a subset of all those ran- domised at baseline) are presented				



Shah 2016 (Continued)

Declarations of Interest: none reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Insufficient information about the sequence generation process to permit judgement of yes or no
Allocation concealment (selection bias)	Unclear risk	Insufficient information about the method of allocation concealment to per- mit judgement of yes or no
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	"Patients, attendants, study staff and investigators were masked to treatment allocation." However, "matching was done on a 1:1 basis for age, sex, severi- ty of stroke " which suggests that some key study personnel were not blinded and this non-blinding is likely to introduce bias
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement of yes or no
Incomplete outcome data (attrition bias) All outcomes	High risk	3/45 (7%) participants in the fluoxetine and 2/44 (5%) in the placebo group were lost to follow-up. Reasons for attrition/exclusion not reported. 6% lost to follow-up
Selective reporting (re- porting bias)	Unclear risk	No study protocol available. Insufficient information to permit judgement of yes or no
Other bias	High risk	The use of matching suggests a matched case control design rather than an RCT design.
		We cannot tell whether there was any baseline imbalance in important demo- graphic or clinical characteristics

Song 2006

0	
Methods	Aim: to evaluate changes in depression and cognitive impairment in people with post-stroke depres- sion treated with fluoxetine
	Parallel trial
Participants	Country: China
	Setting: inpatient
	Stroke diagnosed by clinical criteria and "proved on CT" (though not clear if lesion had to be visible)
	Depression: diagnosed in accordance with the CCMD-II-R
	Treatment: 41 people, mean age 51 \pm 7 years, 25 men), time since stroke: 3.5 days
	Control: 41 people, mean age 50 \pm 8 years, 24 men), time since stroke: 3.7 days
	Excluded: previous mental disorders, previous "neurological disorder", if other psychiatric drugs had been taken, these had to be stopped for 1 week before fluoxetine was administered
Interventions	Treatment: fluoxetine 20 mg daily
	Control: placebo (although not stated whether this was identical to fluoxetine)

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright @ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Song 2006 (Continued)	Duration of treatment: 6 weeks	
	Duration of follow-up (treatment end to study end): 0	
	Side effects not reporte	ed
Outcomes	SDS	
	p300 (an event-related	potential)
	Although the stated aim was to assess cognitive impairment, it is not clear how this was measured	
Funding source	Source of funding not stated	
Notes	Recruitment December 1999 to June 2003. Conflicts of interest not stated	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Method not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Placebo - but not clear whether identical
Blinding of outcome as- sessment (detection bias)	Unclear risk	Not described

All outcomes		
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts
Selective reporting (re- porting bias)	Unclear risk	Unclear
Other bias	Unclear risk	Balanced baseline

Wang 2003	
Methods	Parallel design
	3-arm trial: routine care, fluoxetine plus routine care, amitriptyline plus routine care. We are using the routine care and fluoxetine plus routine care in this analysis
	Aim: to observe effects of antidepressant therapy on post-stroke and neurological rehabilitation in the elderly
Participants	Country: China
	Setting: inpatient

Random sequence genera- tion (selection bias)	Unclear risk	Method not described	
Bias	Authors' judgement	Support for judgement	
Risk of bias			
Notes			
Funding source	Source of funding not stated		
	AEs not recorded		
	Neurological function impairment score Bl		
Outcomes	HAMD		
	Duration of follow-up (treatment end to study end): 6 to 9 months	
	Duration of treatment: 12 to 24 weeks		
	Control: usual stroke ca	are	
Interventions	Treatment: fluoxetine 20 to 80 mg daily (start at 20 mg/day, increase dosage at 3 weeks if peutic effect and no AE), plus usual stroke care		
	Excluded: psychiatric c	lisorder history, severe cardiac, pulmonary, hepatic and renal diseases	
	Control: 56 people, me	ean age 74.9 ± 20.8 years, 29 men	
	Treatment: 64 people,	mean age 75.6 ± 19.7 years, 39 men	
	Depression diagnosed	according to CCMD-II-R diagnostic criteria, HAMD ≥ 18	
Wang 2003 (Continued)	Stroke criteria: ischaemic stroke, clinical diagnosis plus confirmation by imaging (although not clear whether a stroke lesion had to be present)		
Wang 2003 (Continued)			

Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	High risk	13 dropped out of fluoxetine group, and 9 dropped out of control group
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	Baseline appeared balanced but no statistical comparison between groups



Ven 2006			
Methods	Parallel trial		
	Aim: to explore effects of prophylactic antidepression therapy on nerve functional rehabilitation after stroke		
	Analysis: according to treatment group		
Participants	Country: China		
	Setting: inpatient		
	Stroke criteria: acute stroke of all pathological subtypes, clinical diagnosis plus confirmation by imag- ing (although not clear whether a stroke lesion had to be present)		
	Treatment: 42 people, mean age 56.8 years, men 19		
	Control: 42 people, me	an age 57.2 years, men 16	
	Excluded those with primary psychiatric impairment and premorbid mood disorders, pre-existing neu- rological disease causing confusion, severe systematic diseases and pulmonary, hepatic and renal fail- ure		
Interventions	Treatment: fluoxetine 20 mg daily plus routine stroke care		
	Control: routine stroke care		
	Duration of treatment: 8 weeks		
	Duration of follow-up (end of treatment to end of study): 0		
Outcomes	HAMD		
	MESSS		
	AEs (method of obtaining data not stated)		
	Death		
Funding source	Source of funding not stated		
Notes	-		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Method not described	
Allocation concealment (selection bias)	Unclear risk	Not described	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo	
Blinding of outcome as- sessment (detection bias)	Unclear risk	Not described	



Wen 2006 (Continued) All outcomes

Incomplete outcome data (attrition bias) All outcomes	Low risk	Analysed according to treatment group, no dropouts
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	Balanced baseline

Whyte 2005

Methods	Study type: interventional (clinical trial)				
	Primary purpose: prevention				
Participants	Number of participants: unclear				
	Country: USA				
	Setting: inpatient				
	At randomisation number allocated: unclear				
	% male: unclear				
	Age: unclear				
	Subtype of stroke: unclear				
	Severity of stroke: unclear				
	Time since stroke onset: unclear				
	Inclusion criteria:				
	 Age > 40 years old Ischaemic stroke within 3 months of study entry Admitted to a UPMC hospital for acute inpatient treatment or rehabilitation of stroke English-speaking Women willing to use an effective form of birth control throughout the study 				
	Exclusion criteria				
	 Major depressive episode (DSM-IV-TR criteria) History of any bipolar disorder Psychotic or history of a psychotic disorder Alcohol or substance abuse or dependence (DMS-IV TR criteria) within 3 months of study entry Current treatment with antidepressant medication for any reason (e.g. anxiety disorder, neuropathic pain) Primary haemorrhagic stroke Language impairment severe enough to prevent assessment CNS disease other than prior stroke or psychiatric illness (e.g. head trauma, multiple sclerosis, HIV with CNS involvement) 				
	 Pulse < 50 or > 100 beats per minute Significant hyponatraemia (Na < 130 meq) Current hypothyroid state 				



Whyte 2005 (Continued)	 Medically unstable including symptoms of delirium History of sensitivity to sertraline Pregnant or breastfeeding 		
Interventions	Experimental: sertraline 12.5 mg/d for 3 days, increased to 25 mg/d for 4 days, then 50 mg/d for 7 days, then increased to 75 mg/d. Target dose = 75 mg per day for the remainder of participation in the study		
	Comparator: matched	placebo	
Outcomes	Primary outcome collected at 12 months:		
	Major depression at 12 months		
	Secondary outcomes collected at 12 months:		
	 Severity of depressive symptoms post-stroke as measured by the HDRS Level of disability as measured by the FIM 		
Funding source	None stated		
Notes	Terminated (recruitment goals could not be met). Last update 27 June 27 2014		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Insufficient information to permit judgement	
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Insufficient information to permit judgement	
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement	
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement	
Selective reporting (re- porting bias)	Unclear risk	Insufficient information to permit judgement	
Other bias	Unclear risk	Insufficient information to permit judgement	

Wiart 2000

Methods

Purpose: to treat early depression

Parallel design



Wiart 2000 (Continued)	Analysis: ITT (last obser tion (1 treatment)	vation carried forward), withdrawn owing to AE (1 treatment), protocol viola-	
Participants	Location: France		
	Setting: unclear		
	Treatment: 16 people, r	nean ± SD age 66 ± 7 years, 65% men	
	Control: 15 people, mea	n ± SD age 66 ± 12 years, 40% men	
		ic stroke and PICH, diagnosis by clinical signs and CT (100%); stroke on average group) and 48 \pm 20 days (control group)	
	Depression criteria: psychiatric interview (ICD-10 criteria) and MADRS score > 19		
	Other entry criteria: all a	antidepressant or neuroleptic drugs stopped 10 days prior to enrolment	
	Comparability of treatm	nent groups: balanced	
		e psychiatric problems which required hospitalisation, severe aphasia, previous impairment, chronic alcoholism, chronic associated handicapping pathology, xetine	
Interventions	Treatment: fluoxetine 2	0 mg daily	
	Control: matched place	bo	
	Duration of treatment: 45 days		
	Duration of follow-up (treatment end to study end): 0		
Outcomes	Depression: change in scores from baseline to end of treatment of MADRS, 50% reduction in MADRS score		
	Additional: FIMs		
	MMSE		
	Motricity Index		
	Leaving the study early		
	Death		
	AEs ("evaluated qualitatively and quantitatively". Complete blood count, liver test and rer test were carried out at each assessment visit)		
Funding source	Lilly France Laboratory	provided methodological and financial support	
Notes	Dates of recruitment not stated. Conflicts of interest not stated		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Method of randomisation not stated	
Allocation concealment (selection bias)	Unclear risk	Method not stated	



Wiart 2000 (Continued)

Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Quote: "Identical white capsules" given
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Method of blinding not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	Used last observation carried forward
Selective reporting (re- porting bias)	Low risk	Trial published on www.strokecentre.org/trials. The primary outcome was reported
Other bias	Unclear risk	Baseline balanced

Xie 2005

Methods	Aim: to study the effect of treatment with sertraline in elderly patients with post-stroke depression
	Parallel study
Participants	Country: China
	Setting: unclear
	Recruited "clinically stable stroke patients with post-stroke depression"
	No other inclusion and exclusion criteria given
	Mood: Zung SDS score ≥ 40 or GDS score 5 to 10
	Treatment: 65 people, mean age 69.8 years, 29 men
	Control: 65 people, mean age 70.7 years, 27 men
	Time since stroke: mean 87.8 days, range 48 to 142 days
Interventions	Treatment: sertraline 50 mg/day plus usual stroke care
	Control: usual stroke care
	Duration of treatment: 12 weeks
	Duration of follow-up: 0
Outcomes	Zung SDS, GDS, ADL score
	AEs were not reported
Funding source	Local scientific academic fund funded the study
Notes	_
Risk of bias	



Xie 2005 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Method not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	No clear description between treatment and control

Xu 2001

ku 2001	
Methods	Parallel
	Aim: to study the effect of fluoxetine on depression in early recovery stage of cerebral infarction
Participants	Country: China
	Setting: outpatient in rehabilitation clinic
	Stroke: first acute cerebral infarction, no description of the diagnostic criteria and the need for imaging confirmation, excluded large cerebral infarction or lacunar infarction (clinical condition too severe or too mild); onset to recruitment time mean 30 days
	Zung SDS ≥ 40
	Treatment: 32 people
	Control: 31 people (no details of participant characteristics)
	Excluded if previous antidepressants
Interventions	Treatment: fluoxetine 20 mg daily plus usual stroke care
	Control: usual stroke care
	Duration of treatment: 8 weeks
	Duration of follow-up (treatment end to study end): 0
Outcomes	Zung SDS
	ADL (BI)



Xu 2001 (Continued)		
	Neural function deficie	nt
	Death	
	AEs not reported	
Funding source	Source of funding not s	stated
Notes	-	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Method not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	High risk	10/62 dropouts
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	No clear description of stroke criteria and imaging

Xu 2006

Mathada	Devallel group
Methods	Parallel group
	Aim: to test whether early prophylactic antidepressant treatment by paroxetine has any beneficial in- fluence on the rate of post-stroke depression and rehabilitation
Participants	Country: China
	Setting: inpatient
	Stroke criteria: stroke onset time ≤ 3 days, age ≤ 75 years old, no previous psychiatric disorders, no ob- vious cognitive impairment or aphasia
	Depression diagnosis was not mentioned as an inclusion criteria, so we assumed that patients did not have to have depression to enter the trial
	Treatment: 32 people, mean age 65 ± 12 years, 17 men
	Control: 32 people, mean age 63 ± 11 years, 16 men

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright @ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Xu 2006 (Continued)	Exclusion: no severe he none met criteria for de	epatic or renal impairment, DSM IV depression not stated as an inclusion, but epression initially	
Interventions	Treatment: paroxetine 20 mg daily		
	Control: placebo		
	Duration of treatment:	12 weeks	
	Duration of follow-up (treatment end to study end): 0	
Outcomes	MESSS		
	ADL		
	Post-stroke diagnosis i	ncidence of depression according to DSM IV	
	AEs not recorded		
Funding source	Study funded by local s	scientific academic fund	
Notes	The number of particip 28/29)	pants in Table 1 (p187) were wrong (paroxetine/placebo: N = 32/32 should be N =	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "Sequence numbers"	
Allocation concealment (selection bias)	Unclear risk	Not described	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Placebo used, but unclear if it was matched	
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described	
Incomplete outcome data (attrition bias) All outcomes	High risk	7 participants dropped out	
Selective reporting (re- porting bias)	Unclear risk	No protocol	
Other bias	Low risk	Baseline balance	
Yang 2002			
Methods	Parallel group		
	Aim: to study effects of antidepressant in treatment of people with post-stroke depression		

Yang 2002 (Continued)		
Participants	Country: China	
	Setting: inpatients and	loutpatients
	haemorrhagic stroke).	ry phase of stroke (2 to 6 months after ischaemic stroke, and 1.5 to 6 months after We included this in the 3 to 6 month group. Clinical diagnosis of stroke (not stat- on by imaging was needed)
	Depression: HAMD > 7	
	Treatment: 64 people,	mean age 64 ± 3 years, 40 men
	Control: 57 people, me	ean age 63 ± 5 years, 32 men
Interventions	Treatment: paroxetine	20 mg daily plus stroke treatment and rehabilitation
	Control: stroke treatme	ent and rehabilitation
	Duration of treatment:	4 months
	Duration of follow-up:	0
Outcomes	Death	
	They collected data on	HAMD and CSS but did not report these data
	ADL score: did not state	e which one, so not used
	AEs not reported	
Funding source	Source of funding not r	reported
Notes	-	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Method not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	High risk	11/121 (9%) dropouts
Selective reporting (re- porting bias)	High risk	No protocol. The paper stated that ADL data and depression data were collect- ed, but these data were not reported



Yang 2002 (Continued)

Other bias

Unclear risk

No baseline differences between groups, no other obvious source of bias

Methods	Aim: to treat early post	-stroke depression	
Participants	Country: China		
	Setting: inpatient		
		types, clinical diagnosis plus confirmation of lesion on imaging, no previous logical disorders, age < 75 years old, stroke onset time < 72 hours, NIHSS score: 4	
	Mood: HAMD ≥ 8		
	Treatment: 20 people, mean age 64 \pm 8 years, 8 men		
	Control: 22 people, me	an age 64 ± 10 years, 13 men	
		ween abstract (20 in treatment and 22 in control, but in tables of results, there I 20 in control). We have used the data from the abstract	
	tive substance induced communication, severe	sychiatric disorder, functional depression, psychoactive substance and addic- psychiatric disorders, infectious disease, severe cognitive impairment to affect aphasia to affect communication, severe cardiac, pulmonary, hepatic and re- nt, previous organic brain disease such as brain tumour, or symptomatic stroke,	
Interventions	Treatment: paroxetine 20 mg daily plus usual stroke care		
	Control: usual stroke care		
	Duration of treatment: at least 3 months		
	Duration of follow-up: 0		
Outcomes	HAMD score, IL-1β and IL-6 level		
	Death		
	AEs not reported		
Funding source	Source of funding: loca	l scientific academic fund	
Notes	-		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Quote: "Case sequence" randomisation	
Allocation concealment (selection bias)	Unclear risk	Not described	

Yang 2011 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Low risk	No difference in baseline

Methods	Aim: to investigate whether antidepressive therapy is needed for people with post-stroke depression of not, and the effect of different antidepressive drugs on the rehabilitation of psychological and neuro- logical function after stroke
	3 groups: paroxetine, imipramine and control. We are using the paroxetine versus control arm in this review
Participants	Country: China
	Setting: inpatient
	Stroke: all pathological subtypes, clinical diagnosis plus confirmation by imaging (did not state whether a visible lesion was needed to make the diagnosis), no positive psychiatric disorders or family history, clear consciousness, no comprehension problem
	Mood: inclusion criteria: HAMD score > 21, HAMA scale > 14
	Treatment: 30 people, age 58.04 ± 8.28 years, 22 men
	Control: 30 people, age 59.21 ± 9.52 years, 17 men
	Exclusion criteria: severe cardiac, hepatic and renal diseases, multiple infarcts or haemorrhage
Interventions	Treatment: paroxetine 20 mg/day plus acute stroke routine care and rehabilitation
	Control: acute stroke routine care plus rehabilitation
	Duration of treatment: 12 weeks
	Duration of follow-up (end of treatment to end of study): 0
Outcomes	Chinese Neurological Impairment Scale, modified BI, HAMD, HAMA, Therapeutic Effect for Depression and Neurologic Function
	Death, Gl upset
	Method of recording side effects not stated
Funding source	Source of funding not stated



Ye 2004 (Continued)

Notes

Inconsistent description about the number of recruitment and randomisation between abstract (N = 90) and result part (N = 93) of the text. The number for final analysis is consistent in the text

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Used "number table" - but unclear if this was a random number table
Allocation concealment (selection bias)	Low risk	The study designer did not involve in assessment and treatment, the assessors did not know the allocation
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	The participants were blinded. Not clear if those delivering the treatment were blind, but no placebo used
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Assessors were blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Only 1 dropped out in paroxetine group
Selective reporting (re- porting bias)	Unclear risk	No protocol
Other bias	Unclear risk	Different numbers reported to have been recruited and randomised, baseline similar

Zhao 2011

Methods	Study type: interventional (clinical trial)
	Primary purpose: treatment
Participants	Country: People's Republic of China
	Setting: inpatient
	At randomisation number allocated: N = 82: fluoxetine (n = 41); placebo (n = 41)
	% male: 58.5
	Age: mean age 65 ± 12
	Subtype of stroke: Ischaemic stroke: 61/82 (74%); haemorrhagic stroke: 21/82 (26%)
	Severity of stroke: MESSS: fluoxetine 23.2 \pm 6.2 (n = 37); placebo 22.8 \pm 5.8 (n = 34)
	Time since stroke onset: within 10 days
	Inclusion criteria:
	Consistent with the Diagnostic Criteria for Cerebrovascular Disease formulated by the Fourth National

Conference of Chinese Medical Association in 1995, and prove with brain CT or MRI



Zhao 2011 (Continued)	 Obvious aphasia an Age 75 years old or l Without previous ps No severe cognitive Exclusion criteria: none Withdrawal criteria: no 	sychiatric illness impairment e
Interventions	Experimental:fluoxetin	ne 20 mg daily for 12 weeks
	Comparator: no fluoxe	tine
Outcomes	Outcomes collected atSeverity of stroke (MPerformance in ADL	
Funding source	Not available	
Notes	Dates study conducted	l: 2008 to 2010
	Declarations of Interes	t: none reported
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	The participants were randomised into 2 groups (with fluoxetine or without fluoxetine) according to the sequence number and a block randomisation table
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement of yes or no
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Insufficient information to permit judgement of yes or no
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement of yes or no
Incomplete outcome data (attrition bias) All outcomes	High risk	Attrition rate of fluoxetine group vs control group was 4/41 (9.8%) vs 7/41 (17.1%)
		> 5% loss to follow-up
Selective reporting (re- porting bias)	Unclear risk	No trial protocol available. Insufficient information to permit judgement of yes or no
Other bias	Low risk	The study appears to be free from other sources of bias

Zhou 2008

Methods

Aim: to study effect of early paroxetine on post-stroke depression and rehabilitation

Zhou 2008 (Continued)	Parallel design		
	Analysis: according to t	treatment groups	
Participants	Country: China		
	Setting: inpatient		
	Stroke criteria: all strok	ke, clinical diagnosis plus confirmation by imaging (though not clear if a relevant visible), stroke onset time ≤ 7 days, no obvious cognitive impairment, no obvi-	
	HAMD score < 8		
	Treatment: 36 people,	mean age 63 ± 9.3 years, 16 men	
	Control: 40 people, me	an age 61 ± 9.6 years, 19 men	
		chiatric disorders, severe hepatic and renal impairment, taking agents with ob- fluoxetine in recent 1 month	
Interventions	Treatment: fluoxetine 2	20 mg daily plus acute stroke routine medication	
	Control: acute stroke re	outine medication	
	Duration of treatment:	8 weeks	
	Duration of follow-up: 0		
Outcomes	No raw data provided f MESSS)	for any of the following outcomes: diagnosis of depression (CCMD-3, HAMD, ADL,	
	Reported no deaths in	either group. Unclear how data on side effects were collected	
Funding source	Source of funding not s	stated	
Notes	_		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Method not described	
Allocation concealment (selection bias)	Unclear risk	Not described	
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	No placebo	
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not described	
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts, analysed according to allocated treatment group	

Cochrane Library	Trusted evidence. Informed decisions. Better health.	Cochrane Database of Systematic Reviews
Zhou 2008 (Continued) Selective reporting (reporting bias)	High risk	No protocol, no raw data provided for several of the outcomes
Other bias	Low risk	Baseline similar

ADL: activities of daily livingAE: adverse events; AE: adverse event; BDI: Beck Depression Inventory; BI: Barthel Index; CCMD-II-R: Chinese Classification of Mental Disorders, second edition, revised; CCMD-3: Chinese Classification of Mental Disorders-3; CGI: Clinical Global Impressions Scale; CSS: Chinese Stroke Scale; CT: computerised tomography; CTIMP: Clinical Trial of an Investigational Medical Product; EEG: electroencephalogram; FAI: Frenchay Activities Index; FAST: Frenchay Aphasia Screening Test; FIM: Functional Independence Measure; FMMS: Fugl-Meyer Motor Scale; fMRI: functional magnetic resonance imaging; GDS: Geriatric Depression Scale; GI: gastrointestinal; HADS: Hospital Anxiety and Depression Scale; HAMA: Hamilton Anxiety scales; HAMD/HDRS: Hamilton Depression Rating Scale; HSS: Hemispheric Stroke Scale; ICD: International Classification of Diseases; ICH: intracerebral haemorrhage; IL: interleukin; ITT: intention-to-treat; IQR: interquartile range; JHFI: Johns Hopkins Functioning Inventory; LOCF: last-observation-carried-forward; MADRS: Montgomery-Åsberg Depression Rating Scale; MAOI: mono-amino-oxidase inhibitor; MCA: middle cerebral artery; MEP: motor evoked potentials; MESSS: Modified Edinburgh-Scandinavian Stroke Scale; MMSE: Mini-Mental State Examination; MRI: magnetic resonance imaging; mRS: modified Rankin score; NIHSS: National Institutes of Health Stroke Scale; PASE: Physical Activity Scale for the Elderly; PICH: primary intracerebral haemorrhage; RS: Rankin score; SAH: subarachnoid haemorrhage; SAS: Zung Self-rating Anxiety Scale; SD: standard deviation; SDS: Zung Self-rating Depression Scale; SF-36: Short Form-36; SSS: Scandinavian Stroke Scale; TESS: Treatment Emergent Symptom Scale; TIA: transient ischaemic attack; WHO: World Health Organization

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Andersen 1993	Cross-over design: double-blind placebo-controlled cross-over protocol as follows: 7 days initial baseline registration, 21 days citalopram or placebo (randomised), 7 days wash-out, 7 days base- line registration, and cross-over to second 21-day treatment period
Andersen 2012	The trial never started
Anderson 2002	The trial never started
Anonymous 2012	Unable to find publication after extensive searching
Anonymous 2012b	Unable to find publication after extensive searching
Berends 2009	Mean time from stroke onset to fluoxetine was 39.1 months
Choi Kwon 2008	Participants more than 1 year post-stroke
Finkenzeller 2009	SSRI plus active intervention (psychotherapy) versus active treatment (psychotherapy) alone. This trial had been included in the original 2012 review but due to the potential interaction between the SSRI and psychotherapy we decided to exclude it in this update
Gourab 2015	Time of stroke onset > 12 months
Graffagnino 2002	Previously listed in 'Studies awaiting classification' (Mead 2012). Unable to access any full publi- cation and we received no response from the author. Given the insufficient information to assess eligibility and, owing to the length of time since the study abstract (2002) was published, we have now excluded this study. CRSREF: 3340767
Ji 2000	SSRI plus active intervention versus active treatment alone
Li 2002	There is no random component in the sequence generation process

Study	Reason for exclusion
Liang 2003	There is no random component in the sequence generation process. This had been included in the 2012 review but on review of the methodology the review authors decided to exclude this for the update
Liu 2004	SSRI plus active intervention versus active treatment alone
Robinson 2011	Ineligible outcomes: prevention of generalised anxiety disorder
Sitzer 2002	Previously listed in 'Studies awaiting classification' (Mead 2012). Unable to access any full publi- cation and we received no response from the author. Given the insufficient information to assess eligibility and, owing to the length of time since the study abstract (2002) was published, we have now excluded this study
Sun 2015	Mean time since onset 19.2 \pm 3.5 months. No placebo or usual-care control group (prozac, acupunc-ture, and prozac plus acupuncture)
University of Alabama 2013	Study withdrawn (not funded)
Xu 2007	This had been included in the 2012 review but it compares fluoxetine plus wulung capsule vs wu- lung capsule alone. Wulung capsule is an active comparator so we have therefore excluded this tri- al for this update
Zhou 2003	There is no random component in the sequence generation process. This trial had been included in the 2012 version of the review but for this update we excluded it

RCT: randomised controlled trial SNR: serotonin–norepinephrine reuptake inhibitor SSRI: selective serotonin reuptake inhibitor

Characteristics of studies awaiting assessment [ordered by study ID]

Carda 2009	
Methods	Study type: interventional (clinical trial)
	Estimated enrolment: 200 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: quadruple (participant, care provider, investigator, outcomes assessor)
	Primary purpose: treatment
Participants	Country: Italy
	Setting: inpatient
	Inclusion criteria:
	> 18 yearsfirst ischaemic or haemorrhagic stroke
	Exclusion criteria:
	unstable medical conditionsunable to understand study aims and procedures



Carda 2009 (Continued)	 severe aphasia other progressive neurological disease previous or concomitant psychiatric illness not willing to participate
Interventions	Experimental: escitalopram and rehabilitation. Escitalopram given 5 mg once a day for the first week, 10 mg once a day from the second to fourth week, and 20 mg daily until the 6th month Comparator: placebo and rehabilitation
Outcomes	 Primary outcome collected at 2 and 6 months FIM Secondary outcomes collected at 2 and 6 months: MMSE MMSE Trunk Control Test Canadian Stroke Scale Motricity Index Token test Token test Stroop Test Stroop Test Wisconsin Card Sorting test Verbal Fluency Raven's Matrices Test Trail Making A-B Test Center for Epidemiological Studies Depression Scale
Notes	clinicaltrials.gov/ct2/show/NCT00967408 Contacted author Prof Cisari; response received; data being analysed

C	2015	
1110	7015	
u u	2020	

Guo 2015	
Methods	Study type: interventional (clinical trial)
	Actual enrolment: 300
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: single (outcomes assessor)
	Primary purpose: prevention
Participants	Country: China
	Setting: inpatient
	At randomisation numbers allocated: N = 300
	Experimental group 1: fluoxetine immediately after enrolment n = 100 Comparator group 1: fluoxetine 7 days after enrolment n = 100 Comparator group 2: no fluoxetine n = 100
	% male: unclear



Guo 2015 (Continued)

Age: Experimental, unclear; Comparator 1, unclear; Comparator 2, unclear

- Subtype of stroke: unclear
- Severity of stroke NIHSS score at baseline: unclear
- Experimental: unclear
- Comparator 1: unclear
- Comparator 2: unclear

Time from stroke onset: within 1 week after onset of cerebral infarction

Inclusion criteria:

- ICD-10 diagnostic criteria for acute cerebral infarction
- Age 18 to 80 years
- First onset of stroke within 1 week
- NIHSS > 2
- Stroke-related impairment
- · Informed consent by participants or legal representative

Exclusion criteria:

- Coma
- Haemorhagic stroke
- Previous neurological impairment
- Use of antidepressants over previous 3 months
- Use of benzodiazepines over previous 2 weeks
- Self-harm, suicidal ideation or need for antidepressants
- Abnormal liver enzymes or creatinine levels
- Gastrointestinal disorders affect drug absorption seriously
- Life-threatening illness (e.g. malignancy)
- Allergic
- Mental health disorders
- Pregnant or breast feeding
- Allergic
- Enrolled in another interventional clinical research trial within previous 3 months

Withdrawal criteria:

- Unblinding
- Serious adverse reactions e.g. anaphylactic shock
- Need for immediate stroke-related surgery
- Complications
 - Antidepressant use
 - Self-harm, suicidal intention, urgent need for antidepressants
 - Withdrawal from the study

InterventionsExperimental: 20 mg of fluoxetine per day for 90 days given immediately after enrolment and conventional therapy of cerebral infarctionComparator 1: 20 mg of fluoxetine a day for 90 days given 7 days after enrolment and conventional therapy of cerebral infarctionComparator 2: no fluoxetine and conventional therapy of cerebral infarctionOutcomesPrimary outcome at days 15, 90 and 180

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright $\ensuremath{\mathbb S}$ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Guo 2015 (Continued)	NIHSS score		
	Secondary outcome at days 90 and 180		
	Bl score		
Notes	ChiCTR-TRC-15007658		
	xuanyi_guo@163.com		
	Baseline demographic and clinical characteristics for each group not presented, but rather the baseline demographic and clinical characteristics for those completing the trial (i.e. a subset of all those randomised at baseline) are presented		

lethods	Study type: interventional (clinical trial)
	Actual enrolment: 404
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: single (outcomes assessor)
	Primary purpose: prevention
Participants	Country: China
	Setting: inpatient
	At randomisation numbers allocated: N = 404
	Experimental group: fluoxetine n = 202
	Comparator group n = 202
	% male: 70.5%
	Age: Experimental: 61.14 ± 10.48 ; Comparator 62.72 ± 11.86
	Subtype of stroke: unclear
	Severity of stroke NIHSS score at baseline:
	Experimental: Median 6 (IQR 4, 8)
	Comparator: Median 5 (IQR 3, 8)
	Time since stroke onset: mean days, fluoxetine 4.28 \pm 1.89; placebo 4.08 \pm 2.15
	Inclusion criteria:
	 ICD-10 diagnostic criteria for acute cerebral infarction Age 18 to 80 years within 1 week of stroke onset Written informed consent by participants or legal representatives
	Exclusion criteria:
	• Coma



He 2012 (Continued)	 History of stroke Pregnant or breast feeding Self-injury, suicidal intention or depression and need for antidepressants History of peptic ulcer or gastritis
	 Life-threatening illness (e.g. cardiac insufficiency, malignancy) Use of antidepressants over previous 3 months Use of benzodiazepines over previous 2 weeks Allergic Enrolled in another interventional clinical research trial within previous 3 months
	 Withdrawal criteria: Violation of randomisation or blinding rules during the follow-up Serious adverse reactions, such as anaphylactic shock Serious infections or medical complications. Antidepressants use Self-injury, suicidal intention or depression and need for antidepressants Withdrawal from the study (participant or legal relatives)
Interventions	Experimental: 20 mg of fluoxetine a day for 90 days and conventional therapy Comparator: conventional therapy
Outcomes	 Recurrence rate of cerebral infarction within 3 years Improvement of NIHSS, hypertension, diabetes, hyperlipids at day 90
Notes	ChiCTR-TRC-12002078 xuanyi_guo@163.com

Jurcau 2016	
Methods	Study type: interventional (clinical trial)
	Actual enrolment: 89
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: unclear
	Primary purpose: treatment
Participants	Country: Romania
	Setting: inpatient
	At randomisation numbers allocated: N = 89
	Experimental group: escitalopram = 43
	Comparator group: ?secondary preventive treatment = 46
	% male: unclear
	Age: unclear



Jurcau 2016 (Continued)	
	Subtype of stroke: unclear
	Severity of stroke: unclear
	Time since stroke onset: unclear
	Inclusion criteria: unclear
	Exclusion criteria: unclear
	withdrawal criteria: unclear
Interventions	Experimental: escitalopram 10 mg/day for 12 weeks
	Comparator: ?secondary preventive treatment = 46
Outcomes	Outcomes collected at 3, 6 and 12 months post-stroke
	• NIHSS
	• BI
	• MMSE
	• BDI
	• HAM-D17
Notes	Does not appear to be a clinical trial register number

BDI: Beck Depression Inventory BI: Bathel Index FIM: Functional Independence Measure HAM-D17: Hamilton Depression Scale MMSE: Mini-Mental State Examination NIHSS: National Institutes of Health Stroke Scale od: once daily

Characteristics of ongoing studies [ordered by study ID]

Anonymous 2005

1011y111003 2003	
Trial name or title	Influence of escitalopram on the incidence of depression and dementia following acute middle cerebral artery territory infarction. A randomised, placebo-controlled, double-blind study
Methods	Study type: interventional (clinical trial)
	Estimated enrolment: 60 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: double (detail unclear)
	Primary purpose: prevention
Participants	Country: Germany
	Setting: inpatient
	Inclusion criteria
	Acute MCA territory infarctionAiming to recruit 60 over 3 years



nonymous 2005 (Continued)	 Within 7 days of stroke onset Prepared to and considered able to follow the whole trial period
	Exclusion criteria:
	 Dementia Recurrent major depression Major stroke Alcohol and drug dependency Pregnancy, breastfeeding Participating in other trials of medicinal products Impaired liver/kidney disease Life expectancy less than 6 months
	Aiming to recruit 60 participants
Interventions	Experimental: escitalopram
	Comparator: placebo
Outcomes	Depression (MADRS) after 180 days
	Incidence of dementia after 180 days (Clinical Dementia Rating scale)
	Severity of dementia
	Zarit Burden Interview
	Incidence of depression (Depression Visual Analogue Scale)
	Severity of post-stroke depression
	Quality of life (SF-36)
	Bayer Activities of Daily Living score
	NPI
Starting date	MHRA approval 7 April 2006; start date not known
Contact information	Not available. National Competent authority is Germany-BFarm
	Sponsor Name: Central Institute for Mental Health, Mannheim, Division of Gerontopsychiatry
Notes	Details available on EudraCT website
	www.clinicaltrialsregister.eu/ctr-search/trial/2005-005266-37/DE

Trial name or title	Resting state MRI connectivity in acute ischemic stroke: Serotonin Selective Reuptake Inhibitor (SSRI) in enhancing motor recovery: a placebo controlled study
Methods	Study type: interventional (clinical trial)
	Estimated enrolment: 60 participants
	Allocation: randomised
	Intervention model: parallel assignment



Chollet 2016 (Continued)	
	Masking: double (participant, investigator)
	Primary purpose: treatment
Participants	Country: France
	Setting: inpatient
	Inclusion criteria:
	 Age 18 years to 85 years First-ever ischaemic stroke Cortical or subcortical stroke NIHSS > 12 or motor NIHSS > 6 at inclusion MRI-proved ischaemic stroke Exclusion criteria: pregnant or breast-feeding alcoholism ongoing SSRI treatment or interruption < 1 month allergic reaction after SSRI administration MRI contraindication NIHSS > 22 Severe aphasia Coma
Interventions	Experimental: 20 mg of fluoxetine capsule a day from day 0 to day 90 and have fMRI
	Comparator: cellulose placebo a day from day 0 to day 90 and have fMRI
Outcomes	Primary outcome at 90 days
	Intracerebral connectivity in the motor network between fluoxetine and placebo group.
	Secondary outcome at 90 days
	 Intracerebral connectivity in the motor network between good responder participants (defined by 8 points gain on the NIHSS, assessed between day 0 and day 30 and between day 0 and day 90, or 2 points gain on the mRS assessed between day 0 and day 30 and between day 0 and day 90) Intracerebral connectivity in the motor network between non-responder participants
Starting date	January 2016
Contact information	Virginie Sattler, Dr sattler.v@chu-toulouse.fr
	François Chollet, MD PhD chollet.f@chu-toulouse.fr
Notes	NCT02767999

Cocho 2015

Trial name or title	Effect of serotonin and levodopa in ischemic stroke (SELEIS)
Methods	Study type: interventional (clinical trial)
	Estimated enrolment: 240 participants



Allocation: randomised Intervention model: parallel assignment Masking: single (outcomes assessor) Primary purpose: treatment Participants Country: Spain Setting: inpatient Inclusion criteria: • Age > 18 years • NIPSS to 20 points • mRS < 3 prior to stroke • Participants without prior cognitive impairment or depressive syndrome • Assigned treatment initiated within the first 5 days of stroke • Participants without prior cognitive impairment or depressive syndrome • Apsiai • Prior myocardial or cerebral haemorrhage • TIA • History of cognitive impairment or prior depressive syndrome • mRS 3 or higher • Life-threatening illness that is likely to reduce 1-year survival • Use of levodopa, an antidepressant or neuroleptic Ativie comparator: placebo Active comparator: placebo Active comparator: sinemet plus 100 mg isomet plus + citalopram 20 mg Outcomes Rankin Scale at 12 months Starting date 1 January 2015 Contact information Delores Cocho dcocho@thag.es Notes NCT02386475	Cocho 2015 (Continued)	
Masking: single (outcomes assessor)Primary purpose: treatmentParticipantsCountry: SpainSetting: inpatientInclusion criteria:· Age > 18 years· NHSS 5 to 20 points· mRS < 3 prior to stroke		Allocation: randomised
Primary purpose: treatment Participants Country: Spain Setting: inpatient Inclusion criteria: - Age>18 years NIHSS 5 to 20 points - mRS < 3 prior to stroke		Intervention model: parallel assignment
Participants Country: Spain Setting: inpatient Inclusion criteria: Inclusion criteria: Age > 18 years NIHSS 5 to 20 points mRS < 3 prior to stroke Participants without prior cognitive impairment or depressive syndrome Assigned treatment initiated within the first 5 days of stroke Exclusion criteria: Aphasia Prior myocardial or cerebral haemorrhage TIA History of cognitive impairment or prior depressive syndrome mRS 3 or higher Life-threatening illness that is likely to reduce 1-year survival Use of levodopa, an antidepressant or neuroleptic Aiming to recruit 240 participants. Active comparator: placebo Interventions Placebo comparator: placebo Active comparator: interplus 100 mg Sinemet plus + citalopram group Outcomes Rankin Scale at 12 months Starting date 1 January 2015 Contact information Dolores Cocho dcoho@fhag.es		Masking: single (outcomes assessor)
Setting: inpatientInclusion criteria:• Age > 18 years• NIHSS 5 to 20 points• mRS < 3 prior to stroke• Participants without prior cognitive impairment or depressive syndrome• Assigned treatment initiated within the first 5 days of strokeExclusion criteria:• Aphasia• Prior myocardial or cerebral haemorrhage• TIA• History of cognitive impairment or prior depressive syndrome• mRS 3 or higher• Life-threatening illness that is likely to reduce 1-year survival• Use of levodopa, an antidepressant or neurolepticAiming to recruit 240 participants.InterventionsPlacebo comparator: placeboActive comparator: citalopram 20 mgActive comparator: sinemet plus 100 mgSinemet plus + citalopram groupOutcomesRankin Scale at 12 monthsStarting date1 January 2015Contact informationDolores Cocho dcocho@fhag.es		Primary purpose: treatment
Inclusion criteria:Age > 18 yearsNIHSS 5 to 20 pointsmRS < 3 prior to stroke	Participants	Country: Spain
Age > 18 yearsNIHSS 5 to 20 pointsmRS < 3 prior to stroke		Setting: inpatient
 NIHSS 5 to 20 points mRS < 3 prior to stroke Participants without prior cognitive impairment or depressive syndrome Assigned treatment initiated within the first 5 days of stroke Exclusion criteria: Aphasia Prior myocardial or cerebral haemorrhage TIA History of cognitive impairment or prior depressive syndrome mRS 3 or higher Life-threatening illness that is likely to reduce 1-year survival Use of levodopa, an antidepressant or neuroleptic Aiming to recruit 240 participants. Interventions Placebo comparator: placebo Active comparator: citalopram 20 mg Active comparator: sinemet plus 100 mg Sinemet plus + citalopram group Outcomes Rankin Scale at 12 months I January 2015 Contact information Dolores Cocho dcocho@fhag.es		Inclusion criteria:
 Aphasia Prior myocardial or cerebral haemorrhage TIA History of cognitive impairment or prior depressive syndrome mRS 3 or higher Life-threatening illness that is likely to reduce 1-year survival Use of levodopa, an antidepressant or neuroleptic Aiming to recruit 240 participants. Placebo comparator: placebo Active comparator: citalopram 20 mg Active comparator: sinemet plus 100 mg Sinemet plus + citalopram group Outcomes Rankin Scale at 12 months Starting date January 2015 Contact information Dolores Cocho dcocho@fhag.es 		 NIHSS 5 to 20 points mRS < 3 prior to stroke Participants without prior cognitive impairment or depressive syndrome
 Prior myocardial or cerebral haemorrhage TIA History of cognitive impairment or prior depressive syndrome mRS 3 or higher Life-threatening illness that is likely to reduce 1-year survival Use of levodopa, an antidepressant or neuroleptic Aiming to recruit 240 participants. Interventions Placebo comparator: placebo Active comparator: citalopram 20 mg Active comparator: sinemet plus 100 mg Sinemet plus + citalopram group Outcomes Rankin Scale at 12 months Starting date January 2015 Contact information Dolores Cocho dcocho@fhag.es 		Exclusion criteria:
Interventions Placebo comparator: placebo Active comparator: citalopram 20 mg Active comparator: sinemet plus 100 mg Sinemet plus + citalopram group Outcomes Rankin Scale at 12 months Starting date 1 January 2015 Contact information Dolores Cocho dcocho@fhag.es		 Prior myocardial or cerebral haemorrhage TIA History of cognitive impairment or prior depressive syndrome mRS 3 or higher Life-threatening illness that is likely to reduce 1-year survival
Active comparator: citalopram 20 mgActive comparator: sinemet plus 100 mgSinemet plus + citalopram groupOutcomesRankin Scale at 12 monthsStarting date1 January 2015Contact informationDolores Cocho dcocho@fhag.es		Aiming to recruit 240 participants.
Active comparator: sinemet plus 100 mg Sinemet plus + citalopram groupOutcomesRankin Scale at 12 monthsStarting date1 January 2015Contact informationDolores Cocho@fhag.es	Interventions	Placebo comparator: placebo
Sinemet plus + citalopram groupOutcomesRankin Scale at 12 monthsStarting date1 January 2015Contact informationDolores Cocho@fhag.es		Active comparator: citalopram 20 mg
Outcomes Rankin Scale at 12 months Starting date 1 January 2015 Contact information Dolores Cocho@fhag.es		Active comparator: sinemet plus 100 mg
Starting date 1 January 2015 Contact information Dolores Cocho@fhag.es		Sinemet plus + citalopram group
Contact information Dolores Cocho dcocho@fhag.es	Outcomes	Rankin Scale at 12 months
	Starting date	1 January 2015
Notes NCT02386475	Contact information	Dolores Cocho@fhag.es
	Notes	NCT02386475

Dike 2019

Trial name or title	Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine
Methods	Study type: interventional (clinical trial)
	Estimated enrolment : 40 participants
	Allocation: randomised

Dike 2019 (Continued)	
	Intervention model: parallel assignment
	Masking: double (participant, outcomes assessor)
	Primary purpose: treatment
Participants	Country: Nigeria
	Setting: inpatient
	Inclusion criteria:
	 18 to 85 years of age Ischaemic stroke, unilateral, supra-tentorial confirmed by neuroimaging Presentation within first 14 days of stroke onset NIHSS score ≤ 16 Hemiparesis or hemiplegia FMMS ≤ 55 Informed consent Exclusion criteria: Haemorrhagic stroke on CT Glasgow coma score < 8 NIHSS score > 16 Cardiovascular/metabolic/respiratory instability: hypertensive emergency or hypotension/ac dosis or alkalosis/RR > 24 cycles per minute Previous central/peripheral nerve injury Current use of a medication likely to have an adverse interaction with fluoxetine Concurrent medications interacting with SSRI Substantial premorbid disability Depression (MADRS score > 19) Current use of antidepressant medication Pregnancy
	Aiming to recruit 60 participants
Interventions	Experimental: 20 mg fluoxetine for 30 days plus standard treatment
	Comparator: standard treatment
Outcomes	Primary outcome:
	Changes in FMMS at day 14 and day 30
	Secondary outcome
	 NIHSS at day 30 mRS at day 30
Starting date	1 January 2015
Contact information	Dike Franklin, Abak Road, Uyo, 530001, Nigeria
	frankincense4m@yahoo.com
Notes	PACTR201412000967245

Farokhi 2017

Trial name or title	Evaluation of fluoxetine and standard treatment efficacy on change to side effect of stroke of is- chaemic strokes in both hemispheres in anterior circulation
Methods	Study type: interventional (clinical trial)
	Estimated enrolment: 60 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: unclear
	Primary purpose: treatment
Participants	Islamic Republic of Iran
	Inclusion criteria:
	Age 40 to 70 years
	No previous history ischaemic stroke
	 Diagnosis of stroke confirmed by imaging Within 2 to 7 days of stroke onset
	Exclusion criteria:
	Not available during study periodHistory of side effect of fluoxetine and other antipsychotic drugs
	 Pregnant or breast feeding;
	 Depression in the previous month and treatment with antipsychotic drugs
	Use of any MAOI in the last 5 months
	Aiming to recruit 60 participants
nterventions	Experimental: 20 milligram fluoxetine and \$tandard treatment (antiplatelets, anticoagulant and statin)
	Comparator: placebo and β tandard treatment (antiplatelets, anticoagulant and statin)
Outcomes	Primary outcome collected at 1 and 2 months
	Change to side effect of stroke (NIHSS questionnaire)
Starting date	11 October 2017
Contact information	Fariba Farokhi, Arak University of Medical Sciences Iran (Islamic Republic of Iran)
	f.farokhi@arakmu.ac.ir

FOCUS-Poland 2014

Trial name or title	Fluoxetine Or Control Under Supervision - Poland
Methods	Study type: interventional (clinical trial)

FOCUS-Poland 2014 (Continued	y
	Estimated enrolment: 200 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: double (participant, care provider)
	Primary purpose: treatment
Participants	Country: Poland
	Setting: inpatient
	Inclusion criteria:
	 Age ≥ 18 years. Ischaemic or haemorrhagic stroke confirmed by neuroimaging Within 2 to 15 days from the stroke onset Evidence of neurological deficit at randomisation Upper limb functional before stroke
	Exclusion criteria:
	 Subarachnoid haemorrhage (except when secondary to intracerebral bleeding) History of upper limb paresis. A high probability that the patient will not be available during the follow-up examination after 12
	 months Patient or carer or both unable to understand spoken or written Polish language (e.g. aphasia hindering communication)
	 Scoring in NIHSS in subsection 1a > 1 point Presence of life-threatening illness
	 Pregnancy, breastfeeding or reproductive age with no oral contraceptives Epileptic seizures
	Suicide attempt or self-harm
	 Allergic or other contraindications to the use of fluoxetine Taking a monoamine oxidase inhibitor for the last 5 weeks prior to enrolment
	 Faking a monoannie oblasse minister for the last 5 weeks prior to emotiment Current or recent depression (up to 6 months) that requires treatment with selective serotonin reuptake inhibitors (SSRIs)
	• Participation in another clinical trial or other evaluation of a medical product (relative contraindi- cation)
	 For participants with new upper limb paresis and being considered for TMS the following exclusion criteria
	 Presence of devices containing metal components in the immediate vicinity of the coil discharge (e.g. cochlear implants, brain stimulators, infusion pumps, pacemakers) History of craniotomy
	* Use of drugs with central or myorelaxant effect (barbiturates, benzodiazepines, myorelaxants, inhalation and intravenous anaesthetics, antiepileptic drugs, antidepressants, neuroleptic)
	Aiming to recruit 200 participants
Interventions	Fluoxetine 20 mg daily (1 capsule) for 6 months (180 capsules) vs placebo
Outcomes	The primary outcomes
	 mRS at 1, 3, 6 and 12 months after the stroke MEP parameters at 1 and after 3 months (in participants who have received TMS only) Brunnstrom scale Medical Research Council scale

• Medical Research Council scale



FOCUS-Poland 2014 (Continued)

Secondary endpoints

- Stroke Impact Scale
- EuroQol 5D-5L
- MHI-5
- Diagnosis of depression
- Compliance with drug intake
- NIHSS at baseline, 1, 3, 6 and 12 months on BI
- BDNF at baseline, 1 and 3 months.
- Treatment effects and the occurrence of possible adverse reactions are assessed up to 12 months

Starting date	December 2014	
Contact information	jbemenek@o2.pl czlonkow@ipin.edu.pl	
Notes		

regni 2014 Trial name or title	Effects rTMS combined with fluoxetine on motor recovery in stroke patients
That hame of title	
Methods	Study type: interventional (clinical trial)
	Estimated enrolment: 45 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: triple (participant, investigator, outcomes assessor)
	Primary purpose: treatment
Participants	Country: USA
	Setting: inpatient
	Inclusion criteria:
	 Age > 18 years Ischaemic infarction within the past 2 years and resultant impairment Upper extremity weakness defined as a score of > 11 and ≤ 56 on the arm motor FMMS Score of < 3 in the mRSe Able to follow directions and participate in 2 hours of testing with short breaks Consent
	Exclusion criteria:
	 Mental impairment that may interfere with understanding instruction for motor testing Excessive pain in any joint of the paretic extremity Contraindications to single pulse TMS Fluoxetine use in the past 5 weeks SSRI use at the time of enrolment or in the previous month Use of other medication likely to have adverse interaction with SSRIs Score of 24 or higher in the HAM-D



Fregni 2014 (Continued)	 Concurrent medical condition likely to worsen patient's functional status in the next 6 months Pregnancy
Interventions	Experimental 1: active rTMS/active fluoxetine
	10 daily 20-minute sessions over 15 days of active low-frequency rTMS, followed by 8 weekly 20- minute sessions of active low-frequency rTMS + active fluoxetine (20 mg) taken orally consecutively for 90 days
	Comparator 1: sham rTMS/active fluoxetine
	10 daily 20-minute sessions over 15 days of sham low-frequency rTMS, followed by 8 weekly ses- sions of sham low-frequency 20-minute rTMS sessions + active fluoxetine (20 mg) taken orally con- secutively for 90 days
	Comparator 2: sham rTMS/placebo fluoxetine
	10 daily 20-minute sessions over 15 days of sham low-frequency rTMS. This will be followed by 8 weekly sessions of sham low-frequency 20-minute rTMS sessions + placebo fluoxetine (sugar pills) taken orally consecutively for 90 days
Outcomes	Primary outcome over 90-day period
	Changes in Motor Function (JTT, Purdue Pegboard, range of motion)
	Secondary outcome over 90-day period
	Changes in cortical excitability
Starting date	5 August 2014
Contact information	Felipe Fregni, Principal Investigator, Spaulding Rehabilitation Hospital, Charlestown, Massachu- setts, USA
Notes	NCT02208466
Hankey 2011	

Trial name or title	Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial
Methods	Multicentre
	Study type: interventional (clinical trial)
	Estimated enrolment: 1600 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: quadruple (participant, care provider, investigator, outcomes assessor)
	Primary purpose: treatment
Participants	Country: Australia
	Setting: inpatient
	Inclusion criteria
	• Age > 18 years



Hankey 2011 (Continued)

Trusted evidence. Informed decisions. Better health.

lankey 2011 (Continued)	 Clinical diagnosis of stroke 2 to 15 days previously Brain imaging consistent with ischaemic or haemorrhagic stroke (including normal CT brain scan) Persisting measurable focal neurological deficits causing a functional deficit at the time of ran- domisation
	Exclusion criteria:
	 History of epileptic seizures History of bipolar disorder History of drug overdose or attempted suicide Ongoing treatment with any selective serotonin reuptake inhibitor Allergy or contra-indication to fluoxetine Use of medications that may interact seriously with fluoxetine Not available for follow-up over the next 365 days e.g. no fixed home address Life-threatening illness (e.g. advanced cancer) that is likely to reduce 365-day survival Pregnant, breast-feeding or of child-bearing potential and not using contraception Enrolled in another interventional clinical research trial involving an investigational product (medicine) or device
Interventions	Fluoxetine 20 mg once daily or matching placebo capsules for 6 months
Outcomes	Primary outcome
	• Functional outcome as measured by the mRS at 180 days after randomisation
	Secondary outcomes at 180 and 365 days after randomisation
	 Survival Mood (PHQ-9) Cognitive function (TICSm) Communication (SIS) Motor function (SIS) Overall health status (SIS) Health-Related Quality of Life (HRQoL) (EuroQol) Functional recovery (smRSq) at the 365-day assessments New diagnosis of depression requiring treatment with antidepressants Fatigue (vitality domain of the SF-36) Serious adverse events at any time during follow-up including new stroke, acute coronary syndrome, epileptic seizures, fall, new fractures or death
Starting date	July 2012
Contact information	graeme.hankey@health.wa.gov.au
	ACTRN12611000774921

Karimialavijeh 2017

Trial name or title	Comparison of the effects of citalopram versus fluoxetine on motor recovery after stroke: a dou- ble-blind placebo-controlled randomised clinical trial
Methods	Study type: interventional (clinical trial)

Karimialavijeh 2017 (Continued)	
	Estimated enrolment: 90 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: unclear
	Primary purpose: treatment
Participants	Iran (Islamic Republic of Iran)
	Inclusion criteria:
	 Age > 18 years First-time acute (in the past 24 hours) ischaemic stroke hemiparesis or hemiplegia FMMS score < 55
	Exclusion criteria:
	 NIHSS score < 5 Existing impairments including stroke-related aphasia, cognitive or motor disorders, or other neurodegenerative disease Pregnancy or breastfeeding Using antidepressant medication Contraindications of therapy (e.g. renal insufficiency abnormal liver function tests) Signifcant adverse effects (e.g. agitation, hypertension) as a consequence of treatment
Interventions	Experimental: 20 mg of fluoxetine orally, daily for 90 days, as well as physiotherapy sessions 1 hour a day, 5 days a week, for 12 weeks
	Comparator 1: 20 mg of citalopram orally, daily for 90 days, as well as physiotherapy sessions 1 hour a day, 5 days a week, for 12 weeks
	Comparator 2: capsules containing microcrystalline cellulose, orally, daily for 90 days, as well as physiotherapy sessions 1 hour a day, 5 days a week, for 12 weeks
Outcomes	Primary outcome collected at 90 days
	Motor function (FMMS score)
Starting date	3 December 2017
Contact information	Ehsan Karimialavijeh
	Dr Shariati hospital, North Karegar Ave1411713135
	Tehran Iran (Islamic Republic of)
	drkarimi86@gmail.com
Notes	IRCT20141116019971N3

Leibovitch 2018

Trial name or title	FLuoxetine Opens Window to improve motor recovery after stroke (FLOW)
Methods	Study type: interventional (clinical trial)

Leibovitch 2018 (Continued)	
	Estimated enrolment: 176 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Intervention model description
	 Intervention group (trial drug (fluoxetine) and exercise intervention) Placebo group (placebo and exercise intervention)
	Masking: quadruple (participant, care provider, investigator, outcomes assessor)
	Primary purpose: treatment
Participants	Country: Canada
	Setting: inpatient
	Inclusion criteria:
	• Age > 25 years
	Between 60 to 210 days post-stroke at enrolment
	Lower limb FMMS < 30
	Exclusion criteria:
	 Subarachnoid haemorrhage Pre-morbid mRS > 2
	 Fre-mobile mixs > 2 Substantial premorbid disability or pre-existing deficit or language comprehension deficit that could interfere with assessments
	 Diagnosis of major depressive disorder/anxiety disorder requiring antidepressant use within 6 weeks of enrolment
	 Taking neuroleptic drugs, benzodiazepines, MAOIs within 30 days of enrolment Unstable serious medical condition (e.g. terminal cancer, renal or liver failure, congestive heart failure)
	 Resting blood pressure exceeding 180/100 mmHg
	Requires more than a one-person assist for transfer
	 Planned surgery that would affect participation in the trial Daticipating in another oversize programme more than 1 days a weak
	 Participating in another exercise programme more than 1 day a week Pregnant
	Ongoing history of illicit drug use or alcohol abuse or both
	Unwilling or unable to comply with trial requirements
	Unable to understand English
Interventions	Experimental: fluoxetine hydrochloride (Prozac): 10 mg Prozac per day for 3 to 5 weeks and then 20 mg for 12 weeks (the duration of the exercise intervention)
	Comparator: an over-encapsulated placebo (identical 'sugar pill'): 10 mg 'sugar pill' a day for 3 to 5 weeks and then 20 mg for 12 weeks (the duration of the exercise intervention)
Outcomes	Primary outcomes at 12 weeks
	Fugl-Meyer Lower Extremity Score at 12 weeks
	Secondary outcomes at 12 weeks and 6 months
	Ambulatory function measured using 6 Minute Walk Test/10 Metre Walk Test
	Lower limb strength measured using knee strength
	Balance measured using Berg Balance Assessment

Leibovitch 2018 (Continued)	
	Grip Strength
	Waist-to-Hip Ratio
	Body Mass Index
	• SIS
	Fugl-Meyer Lower Extremity Score at 6 months
	Fugl-Meyer Upper Extremity Score
	• PHQ-9
	Simple and Choice Reaction Time Test
	 Trail Making Test - A & B
	Montreal Cognitive Assessment
	Fasting Blood Draws
Starting date	1 November 2018
Contact information	Farrell Leibovitch
	farrell@canadianstroke.ca
Notes	NCT03448159

Levitt 2019

Trial name or title	Depression in haemorrhagic stroke
Methods	Study type: interventional (clinical trial)
	Estimated enrolment: 224 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Intervention model description: double-blinded placebo-controlled randomised trial
	Masking: triple (participant, care provider, investigator)
	Primary purpose: prevention
Participants	Country: USA
	Setting: inpatient
	Inclusion criteria:
	 Age 18 to 85 years Subarachnoid haemorrhage from a ruptured cerebral aneurysm Consent
	Exclusion criteria:
	 Non-English speaking Taking therapy for depression or related mental health diagnoses before admission Medical contraindications to fluoxetine therapy Pregnancy or considering getting pregnant during the trial period at the time of consent. Active psychosis Incarcerated or in police custody



Levitt 2019 (Continued)

Levitt 2019 (Continuea)	 Comorbidity or a score > 26 on the Montreal Cognitive Assessment
Interventions	Experimental: fluoxetine 20 mg/day for a period of 1 year
	Comparator: placebo 20 mg/day for a period of 1 year
Outcomes	Primary outcomes at 1 year
	Depression measured using HAM-D
	Depression measured using PHQ-9
	Secondary outcomes at 1 year:
	Anxiety measured using Hamilton Rating Scale for Anxiety
	Fatigue measured using Fatigue Severity Scale
	Healthcare utilization measured using Self-Report Health Service Utilization and Medication Use
	Social support measured using Multidimensional Scale of Perceived Social Support (MSPSS)
Starting date	1 March 2019
Contact information	Cory M Kelly 206-685-3043 kellycm@neurosurgery.washington.edu
Notes	NCT03826875

Lundström 2014

Trial name or title	Efficacy oF Fluoxetine – a randomisEd Controlled Trial in Stroke (EFFECTS)
Methods	Multicentre RCT
	Study type: interventional (clinical trial)
	Estimated enrolment: 1500 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: quadruple (participant, care provider, investigator, outcomes assessor)
	Primary purpose: treatment
Participants	Sweden
	Inclusion criteria
	 Age ≥ 18 Informed consent can only be obtained from a patient who according to the trial investigator is mentally capable of decision-making and who, after having received information and got answers to their questions, wants to participate in the trial Brain imaging is compatible with intracerebral haemorrhage or ischaemic stroke Randomisation can be performed between 2 and 15 days after stroke onset and by the research group at the person's local/emergency hospital Persisting focal neurological deficit is present at the time of randomisation severe enough to war rant treatment from the physicians and the patient's and relative's perspective
	Exclusion criteria
	Subarachnoidal haemorrhage (except where secondary to a primary intracerebral haemorrhage

Subarachnoidal haemorrhage (except where secondary to a primary intracerebral haemorrhage)



Lundström 2014 (Continued)	 Unlikely to be available for follow-up for the next 12 months e.g. no fixed home address Unable to speak Swedish and no close family member available to help with follow-up forms Other life-threatening illness (e.g. advanced cancer) that will make 12-month survival unlikely History of epileptic seizures History of allergy or contraindications to fluoxetine Pregnant or breastfeeding Previous drug overdose or attempted suicide Already enrolled into a CTIMP Current or recent (within the last month) depression requiring treatment with an SSRI antidepressant Current use of medications which have serious interactions with fluoxetine Use of any MAOI during the last 5 weeks
Interventions	Fluoxetine (20 mg once daily) for 6 months with oral capsules
Outcomes	Outcomes collected at 6 months and 12 months Primary outcome • mRS Secondary outcomes • Death from all causes • HRQoL (EQ5D-5L) • Depression and anxiety (MHI 5) • Level of fatigue (vitality subscale of the Health Questionnaire) • Recovery from stroke (SIS) • New diagnosis of depression since randomisation • Adverse events (including participant-completed diary) • Health and social care utilisation • Adherence to trial medication • Adherence to trial medication • Motor function (NIHSS) • Aphasia (NIHSS), aphasia (Norsk Grunntest for Afasi) • Depression (MADRS + DSM-IV/DSM-V) • Cognitive function (Montreal Cognitive Assessment (MoCA))
Starting date	20 October 2014
Contact information	Associate Professor Erik Lundström, Department of Neuroscience, Neurology, Uppsala University, Akademiska sjukhuset, 751 85 Uppsala, Sweden. Email: erik.lundstrom@neuro.uu.se.
Notes	clinicaltrials.gov/ct2/show/NCT02683213

Pastore-Wapp 2016

Trial name or title	Cortical Ischemic Stroke and Serotonin (CISS)
Methods	Study type: interventional (clinical trial)
	Estimated enrolment: 90 participants
	Allocation: randomised

Pastore-Wapp 2016 (Continued)	Intervention model: parallel assignment
	Masking: quadruple (participant, care provider, investigator, outcomes assessor)
	Primary purpose: supportive care
Participants	Country: Switzerland
	Setting: inpatient
	Inclusion criteria:
	 First-ever stroke Clinically significant contralesional hand plegia or paresis as a main symptom Involvement of the pre-and/or post-central gyri confirmed on DWI and FLAIR scans Written informed consent
	Exclusion criteria:
	 Aphasia or cognitive deficits severe enough to preclude understanding of study purposes Prior cerebrovascular events
	 Significant stenosis (70% to 99% according to NASCET) or occlusion of the carotid and intracrani arteries on MRA
	Purely subcortical stroke
	 Known brain lesion (tumour, old cerebral haemorrhage) Other medical conditions interfering with task performance or SSRI-treatment, specifically: pr longed corrected QT interval (QTc) on electrocardiogram, ongoing drug/alcohol abuse Simultaneous intake of medications which can lead to prolonged QTc syndrome known or su pected hypersensitivity to one of the ingredients of Cipralex[®] or placebo
	Simultaneous administration of antidepressants
	 Conditions interfering with MRI (e.g. patients with a cardiac pacemaker or cochlear implant)
	Pregnant or breastfeedingWomen in childbearing age without sufficient birth control (at least 2 contraceptive methods)
Interventions	Experimental: escitalopram 5 mg/day at the baseline visit (day 14 (±7) post-stroke) for 7 days fol- lowed by a weekly dosage increase of 5 mg/day till target dose of escitalopram 20 mg/day. Partici pants remain on escitalopram 20 mg/day until visit 3 (day 90 (±14) post-stroke) followed by dosag reduction of escitalopram 10 mg/day for 1 week
	Comparator: placebo 5 mg/day at the baseline visit (day 14 (±7) post-stroke) for 7 days followed by a weekly dosage of 5 mg/day until target dose of placebo 20 mg/day. Participants remain on place bo 20 mg/day until visit 3 (day 90 (±14) post-stroke) followed by placebo 10 mg/day for 1 week
Outcomes	Primary outcome
	• Effect of escitalopram on sensorimotor network at month 9 (task-related fMRI (act-fMRI))
	Secondary outcomes:
	 Imaging patterns of rs-fMRI at month 3 and month 9 Imaging patterns of act-fMRI at month 3 and month 9 JTT monthly from baseline to month 9 Mean cortical volume changes at month 3 and month 9 Serum concentration of escitalopram at month 3 Genetic polymorphisms in genes at month 3
	Other outcomes:
	 Glutamate/glutamine concentration at month 3 and month 9 rTMS at month 3 and month 9



Pastore-Wapp 2016 (Continued)

• Number of adverse events due to study medication monthly until month 9

Starting date	August 2016
Contact information	Manuela Pastore-Wapp manuela.pastore-wapp@insel.ch
Notes	NCT02865642

Pirzeh 2012

Trial name or title	A study of sertraline effect on quality of life in stroke inpatients
Methods	Study type: interventional (clinical trial)
	Estimated enrolment: 80 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: unclear
	Primary purpose: prevention
Participants	Iran (Islamic Republic of Iran)
	Inclusion criteria:
	• 55 years old to 75 years old
	first-ever stroke
	Exclusion criteria:
	History of stroke Danal failure
	Renal failureHepatic failure
	Cardiac failure
	Substance related disorders
	Aiming to recruit 80 participants
Interventions	Experimental: 3 weeks after stroke sertraline 50 mg a day for 12 months versus
	Comparator: 3 weeks after stroke a placebo tablet every day
Outcomes	Primary outcomes collected at 3 months, 6 months, 9 months
	Quality of life (NHP)
	Secondary outcomes collected at 3 months, 6 months, 9 months
	Depression (BDI)
Starting date	28 November 2012
Contact information	Reza Pirzeh, Tabriz University of Medical Sciences, Iran (Islamic Republic of)
	pirzehr@tbzmed.ac.ir



Cochrane Database of Systematic Reviews

Pirzeh 2012 (Continued)

Notes

IRCT2012101011062N1

Trial name or title	Effect of fluoxetine on functional recovery of patients with cerebrovascular accident following mid- dle cerebral artery trunk obstruction: a randomised clinical trial
Methods	Study type: interventional (clinical trial)
	Estimated enrolment: 60 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: unclear
	Primary purpose: treatment
Participants	Iran (Islamic Republic of Iran)
	Inclusion criteria
	Age 55 to 85 years
	Informed consent
	Unilateral occlusion of middle cerebral artery trunk
	 Resident in Rasht Admission NIHSS < 20
	No history of alcohol abuse No history of incompia
	No history of insomnia
	No epilepsy"No history of cerebral haemorrhage and heart of cerebral stroke" [sic]
	 No history of systemic diseases of other organs, including liver failure and kidney
	 No cardiac pace maker, severe neuropathy, systemic vascular disease or major affective disorders
	 No concomitant stroke in an area other than the stroke of the middle cerebral artery
	Exclusion criteria
	Dissatisfaction of patient during the study
	 Occurrence of serious adverse drug affects at any time during drug administration
	 Alcohol abuse during the study period
	 Occurrence of post-stroke depression, concomitant use of the MAOIs or serotonergic drugs such as tricyclic antidepressants and SSRI
Interventions	Intervention: fluoxetine, 15 mg oral pill for the first month and 20 mg for the next 2 months
	Comparator: placebo, 15 mg oral pill for the first month and 20 mg for the next 2 months
Outcomes	Primary outcomes collected at discharge, 1 and 3 months
	Disability (mRS)
	Activities of Daily Living (BI)
	Functional recovery (NIHSS)
	Depression (BDI questionnaire)
	Secondary outcomes collected at discharge
	,



Sadaat 2012 (Continued)

• Cerebral blood flow changes of middle cerebral artery (TCD)

Starting date	5 April 2012
Contact information	Dr Babak Bakhshayesh Eghbali
	Poorsina hospital, Guilan University of Medical Sciences
	bakhshayesh@gums.ac.ir
Notes	IRCT201112228490N1
	Contacted 7 February 2019

Sahin 2016

Trial name or title	Fluoxetine for visual recovery after ischemic stroke (FLUORESCE)
Methods	Study type: interventional (clinical trial)
	Estimated enrolment : 40 participants
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: quadruple (participant, care provider, investigator, outcomes assessor)
	Primary purpose: treatment
Participants	USA
	Inclusion criteria
	18 to 85 years
	Inclusion criteria:
	MRI-confirmed acute ischaemic stroke resulting in an isolated homonymous visual field loss
	Exclusion criteria:
	 Known hypersensitivity to fluoxetine or other SSRIs NIHSS score > 5 Premorbid mRS score > 2 Premorbid monocular or binocular visual field deficits Premorbid retinopathy or optic neuropathy Premorbid depression History of cognitive impairment, dementia, or neurodegenerative disorder History of seizure disorder History of mania or hypomania History of angle-closure glaucoma or elevated intraocular pressure Current use of an antidepressant medication Current use of a medication likely to have an adverse interaction with fluoxetine Current use of a medication likely to impair post-stroke recovery Contraindication to MRI



Sahin 2016 (Continued)	 Pregnancy or lactation Haemorrhagic transformation of the index stroke, resulting in mass effect Enrolment in another clinical trial at the time of the index stroke Aiming to recruit 40 participants
Interventions	Experimental: 20 mg fluoxetine capsule by mouth once daily for 90 days
	Comparator: matching placebo
Outcomes	Outcomes collected at 6 months
	Primary outcome
	Improvement in size of visual field deficit at 6 months
	Secondary outcomes
	 Improvement in size of visual field deficit at 6 months Functional field score at 6 months Visual Function Questionnaire-25 score at 6 months
	PHQ-9 score at 6 months
	mRS score at 90 days
	 Post-stroke changes in cortical visual representation as measured by functional magnetic reso- nance imaging at 6 months
	Post-stroke changes in retinal nerve fibre layer thickness at 6 months
Starting date	May 2016
Contact information	Bogachan Sahin
	bogachan_sahin@rocheter.edu
Notes	NCT02737930

BDI: Beck Depression Inventory; BDNF: brain-derived neurotrophic factor; BI: Barthel Index; CT: computerised tomography; CTIMP: Clinical Trial of an Investigational Medicinal Product;

DWI: diffusion-weighted imaging; FAI: Frenchay Activities Index; FLAIR: fluid-attenuated inversion recovery; FMMS: Fugl Meyr Motor Score; fMRI: functional magnetic resonance imaging; HAM-D: Hamilton Depression Rating Scale; HRQoL: Health-Related Quality of Life; JTT: Jebsen Taylor Test; MADRS: Montgomery-Åsberg Depression Rating Scale; MAOI: mono-amino-oxidase inhibitor; MCA: middle cerebral artery; MEP: motor evoked potential; MHI 5: Mental Health Inventory; MHRA: Medicines and Healthcare products Regulatory Agency MRA: magnetic resonance angiography; MRI: magnetic resonance imaging; mRS: modified Rankin score; NHP: Nottingham Health Profile; NIHSS: National Institute of Health Stroke Scale

NPI: Neuropsychiatric Inventory Scale; PHQ-9: Patient Health Questionnaire; rTMS: repetitive transcranial magnetic stimulation; SF-36: Short Form-36; SIS: Stroke Impact Scale; smRSq: simplified modified Rankin Scale questionnaire; SSRI: selective serotonin reuptake inhibitor; TCD: transcranial Doppler; TIA: transient ischaemic attack; TICSm: telephone interview for cognitive status - modified; TMS: transcranial magnetic stimulation

DATA AND ANALYSES

Comparison 1. SSRI versus control at end of treatment, by SSRI

Outcome or subgroup ti- tle	ubgroup ti- No. of studies No. of parti pants		Statistical method	Effect size		
1 Disability (primary analy- sis)	2	2829	Std. Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.09, 0.06]		
1.1 Fluoxetine	2	2829	Std. Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.09, 0.06]		
2 Independent on modi- fied Rankin score (mRS 0 to 2) (primary analysis)	3	3249	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.91, 1.09]		
3 Neurological deficit score	2	142	Std. Mean Difference (IV, Fixed, 95% CI)	-0.30 [-0.63, 0.04]		
3.1 Fluoxetine	2	142	Std. Mean Difference (IV, Fixed, 95% CI)	-0.30 [-0.63, 0.04]		
4 Depression (continuous data)	2	2861	Std. Mean Difference (IV, Fixed, 95% CI)	-0.11 [-0.19, -0.04]		
4.1 Fluoxetine	2	2861	Std. Mean Difference (IV, Fixed, 95% CI)	-0.11 [-0.19, -0.04]		
5 Depression (dichoto- mous data)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected		
5.1 Fluoxetine	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]		
6 Death	3	3254	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.79, 1.25]		
6.1 Fluoxetine	3	3254	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.79, 1.25]		
7 Seizures	3	3275	Risk Ratio (M-H, Fixed, 95% CI)	1.47 [0.99, 2.18]		
7.1 Fluoxetine	3	3275	Risk Ratio (M-H, Fixed, 95% CI)	1.47 [0.99, 2.18]		
8 Gastrointestinal side ef- fects	2	148	Risk Ratio (M-H, Fixed, 95% CI)	2.19 [1.00, 4.76]		
8.1 Fluoxetine	2	148	Risk Ratio (M-H, Fixed, 95% CI)	2.19 [1.00, 4.76]		
9 Bleeding	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected		
9.1 Fluoxetine	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]		
10 Leaving the trial before the end of scheduled fol- low-up	3	3277	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.48, 2.10]		
10.1 Fluoxetine	3	3277	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.48, 2.10]		
11 Motor deficits	3	2936	Std. Mean Difference (IV, Fixed, 95% CI)	0.02 [-0.05, 0.09]		

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright @ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Outcome or subgroup ti- tle	No. of studies	No. of partici- pants	Statistical method	Effect size		
11.1 Fluoxetine	3	2936	Std. Mean Difference (IV, Fixed, 95% CI)	0.02 [-0.05, 0.09]		
12 Disability (sensitivity analyses all studies re- gardless of RoB)	26	5334	Std. Mean Difference (IV, Fixed, 95% CI)	0.23 [0.18, 0.29]		
12.1 Fluoxetine	15	3919	Std. Mean Difference (IV, Fixed, 95% CI)	0.14 [0.08, 0.20]		
12.2 Sertraline	1	130	Std. Mean Difference (IV, Fixed, 95% CI)	1.38 [0.99, 1.76]		
12.3 Paroxetine	5	293	Std. Mean Difference (IV, Fixed, 95% CI)	1.29 [1.03, 1.55]		
12.4 Citalopram	5	992	Std. Mean Difference (IV, Fixed, 95% CI)	0.24 [0.11, 0.37]		
13 Independent on modi- fied Rankin score (mRS 0 to 2) (sensitivity analysis)	5	4002	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.91, 1.03]		
13.1 Fluoxetine	3	3249	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.91, 1.09]		
13.2 Sertraline	1	111	Risk Ratio (M-H, Fixed, 95% CI)	1.0 [0.97, 1.04]		
13.3 Citalopram	1	642	Risk Ratio (M-H, Fixed, 95% CI)	0.90 [0.82, 0.98]		

Analysis 1.1. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 1 Disability (primary analysis).

Study or subgroup		SSRI	c	Control		Std. Mean Difference	Weight	Std. Mean Difference
	N	Mean(SD)	Ν	Mean(SD)		Fixed, 95% CI		Fixed, 95% CI
1.1.1 Fluoxetine								
FOCUS Trial Collaboration 2018	1402	59.7 (31.2)	1397	60.2 (31.5)		+	98.96%	-0.02[-0.09,0.06]
Marquez Romero 2013	14	65 (21.4)	16	45 (73.2)			1.04%	0.35[-0.37,1.07]
Subtotal ***	1416		1413			•	100%	-0.01[-0.09,0.06]
Heterogeneity: Tau ² =0; Chi ² =0.97,	df=1(P=0.3	2); I ² =0%						
Test for overall effect: Z=0.31(P=0.7	75)							
Total ***	1416		1413			•	100%	-0.01[-0.09,0.06]
Heterogeneity: Tau ² =0; Chi ² =0.97,	df=1(P=0.3	2); I ² =0%						
Test for overall effect: Z=0.31(P=0.7	75)							
			Fa	vours control	-1	-0.5 0 0.5	1 Favours SS	RI

Analysis 1.2. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 2 Independent on modified Rankin score (mRS 0 to 2) (primary analysis).

Study or subgroup	SSRI	Control			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		М-	H, Fixed, 95%	6 CI			M-H, Fixed, 95% Cl
Chollet 2011	15/57	5/56			—	•		0.85%	2.95[1.15,7.56]
FOCUS Trial Collaboration 2018	572/1553	588/1553			+			98.68%	0.97[0.89,1.07]
Marquez Romero 2013	8/14	3/16				•	-	0.47%	3.05[1,9.31]
Total (95% CI)	1624	1625			•			100%	1[0.91,1.09]
Total events: 595 (SSRI), 596 (Control)								
Heterogeneity: Tau ² =0; Chi ² =9.23, df=	2(P=0.01); I ² =78.32%	5							
Test for overall effect: Z=0.02(P=0.99)									
		Favours control	0.05	0.2	1	5	20	Favours SSRI	

Analysis 1.3. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 3 Neurological deficit score.

Study or subgroup		SSRI	c	ontrol	Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
1.3.1 Fluoxetine							
Chollet 2011	57	5.8 (3.7)	55	6.9 (4.4)		79.15%	-0.27[-0.64,0.1]
Marquez Romero 2013	14	8.5 (3.3)	16	12 (11.4)		20.85%	-0.39[-1.12,0.33]
Subtotal ***	71		71		•	100%	-0.3[-0.63,0.04]
Heterogeneity: Tau ² =0; Chi ² =0.	09, df=1(P=0.7	6); I ² =0%					
Test for overall effect: Z=1.75(P	=0.08)						
Total ***	71		71		•	100%	-0.3[-0.63,0.04]
Heterogeneity: Tau ² =0; Chi ² =0.	09, df=1(P=0.7	6); I ² =0%					
Test for overall effect: Z=1.75(P	=0.08)						
				Favours SSRI	-2 -1 0 1 2	Favours co	ontrol

Analysis 1.4. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 4 Depression (continuous data).

Study or subgroup		SSRI	c	Control		Std. Mean Differend	e Weight	Std. Mean Difference
	N	Mean(SD)	Ν	Mean(SD)		Fixed, 95% CI		Fixed, 95% CI
1.4.1 Fluoxetine								
Chollet 2011	56	5.4 (4.9)	54	8.4 (7.9)			3.75%	-0.46[-0.83,-0.08]
FOCUS Trial Collaboration 2018	1372	12 (5.2)	1379	12.5 (5.5)		-+-	96.25%	-0.1[-0.18,-0.03]
Subtotal ***	1428		1433			•	100%	-0.11[-0.19,-0.04]
Heterogeneity: Tau ² =0; Chi ² =3.23,	df=1(P=0.0	7); I ² =69.08%						
Test for overall effect: Z=3.05(P=0)								
Total ***	1428		1433			•	100%	-0.11[-0.19,-0.04]
Heterogeneity: Tau ² =0; Chi ² =3.23,	df=1(P=0.0	7); I ² =69.08%						
Test for overall effect: Z=3.05(P=0)								
				Favours SSRI	-1	-0.5 0 0.5	1 Favours c	ontrol



Analysis 1.5. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 5 Depression (dichotomous data).

Study or subgroup	SSRI	Control	Risk Ratio					Risk Ratio
	n/N	n/N		M-H	, Fixed, 95	% CI		M-H, Fixed, 95% Cl
1.5.1 Fluoxetine								
FOCUS Trial Collaboration 2018	210/1564	269/1563			+			0.78[0.66,0.92]
		Favours SSRI	0.01	0.1	1	10	100	Favours control

Analysis 1.6. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 6 Death.

Study or subgroup	SSRI	Control			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		M-H	, Fixed, 95% C	I			M-H, Fixed, 95% CI
1.6.1 Fluoxetine									
Chollet 2011	1/59	1/59						0.76%	1[0.06,15.61]
FOCUS Trial Collaboration 2018	129/1553	130/1553			+			99.24%	0.99[0.79,1.25]
Marquez Romero 2013	0/14	0/16							Not estimable
Subtotal (95% CI)	1626	1628			•			100%	0.99[0.79,1.25]
Total events: 130 (SSRI), 131 (Control))								
Heterogeneity: Tau ² =0; Chi ² =0, df=1(F	P=1); I ² =0%								
Test for overall effect: Z=0.06(P=0.95)									
Total (95% CI)	1626	1628			•			100%	0.99[0.79,1.25]
Total events: 130 (SSRI), 131 (Control)								
Heterogeneity: Tau ² =0; Chi ² =0, df=1(F	P=1); I ² =0%								
Test for overall effect: Z=0.06(P=0.95)									
		Favours SSRI	0.01	0.1	1	10	100	Favours control	

Analysis 1.7. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 7 Seizures.

Study or subgroup	SSRI	Control			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		M-H	, Fixed, 95%	CI			M-H, Fixed, 95% CI
1.7.1 Fluoxetine									
Chollet 2011	1/59	0/59						1.23%	3[0.12,72.18]
FOCUS Trial Collaboration 2018	58/1564	40/1563						98.77%	1.45[0.97,2.15]
Marquez Romero 2013	0/14	0/16							Not estimable
Subtotal (95% CI)	1637	1638			•			100%	1.47[0.99,2.18]
Total events: 59 (SSRI), 40 (Control)									
Heterogeneity: Tau ² =0; Chi ² =0.2, df=1	(P=0.66); l ² =0%								
Test for overall effect: Z=1.91(P=0.06)									
Total (95% CI)	1637	1638			•			100%	1.47[0.99,2.18]
Total events: 59 (SSRI), 40 (Control)									
Heterogeneity: Tau ² =0; Chi ² =0.2, df=1	(P=0.66); l ² =0%								
Test for overall effect: Z=1.91(P=0.06)									
		Favours SSRI	0.01	0.1	1	10	100	Favours control	

Analysis 1.8. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 8 Gastrointestinal side effects.

Study or subgroup	SSRI	Control			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H	, Fixed, 95% CI			M-H, Fixed, 95% CI
1.8.1 Fluoxetine								
Chollet 2011	14/59	6/59					76.27%	2.33[0.96,5.66]
Marquez Romero 2013	3/14	2/16					23.73%	1.71[0.33,8.83]
Subtotal (95% CI)	73	75			-		100%	2.19[1,4.76]
Total events: 17 (SSRI), 8 (Control)								
Heterogeneity: Tau ² =0; Chi ² =0.11, df=1	(P=0.75); I ² =0%							
Test for overall effect: Z=1.97(P=0.05)								
Total (95% CI)	73	75			•		100%	2.19[1,4.76]
Total events: 17 (SSRI), 8 (Control)								
Heterogeneity: Tau ² =0; Chi ² =0.11, df=1	(P=0.75); I ² =0%							
Test for overall effect: Z=1.97(P=0.05)						1		
		Favours SSRI	0.01	0.1	1 10	100	Favours control	

Analysis 1.9. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 9 Bleeding.

Study or subgroup	SSRI	Control	Risk Rat	io	Risk Ratio
	n/N	n/N	M-H, Fixed, 9	95% CI	M-H, Fixed, 95% CI
1.9.1 Fluoxetine					
FOCUS Trial Collaboration 2018	25/1564	26/1563		1	0.96[0.56,1.66]
		Favours SSRI 0.01	0.1 1	10	¹⁰⁰ Favours control

Analysis 1.10. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 10 Leaving the trial before the end of scheduled follow-up.

Study or subgroup	SSRI	Control			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		M-H	, Fixed, 95%	CI			M-H, Fixed, 95% Cl
1.10.1 Fluoxetine									
Chollet 2011	2/59	3/59						21.52%	0.67[0.12,3.85]
FOCUS Trial Collaboration 2018	11/1564	10/1563						71.76%	1.1[0.47,2.58]
Marquez Romero 2013	1/15	1/17			+			6.72%	1.13[0.08,16.59]
Subtotal (95% CI)	1638	1639			•			100%	1.01[0.48,2.1]
Total events: 14 (SSRI), 14 (Control)									
Heterogeneity: Tau ² =0; Chi ² =0.26, df=	2(P=0.88); I ² =0%								
Test for overall effect: Z=0.02(P=0.98)									
Total (95% CI)	1638	1639			•			100%	1.01[0.48,2.1]
Total events: 14 (SSRI), 14 (Control)									
Heterogeneity: Tau ² =0; Chi ² =0.26, df=	2(P=0.88); I ² =0%								
Test for overall effect: Z=0.02(P=0.98)				1					
		Favours SSRI	0.01	0.1	1	10	100	Favours control	

Analysis 1.11. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 11 Motor deficits.

Study or subgroup	SSRI Control		ontrol	:	Std. Mean Difference	Weight	Std. Mean Difference	
	N	Mean(SD)	Ν	Mean(SD)		Fixed, 95% Cl		Fixed, 95% CI
1.11.1 Fluoxetine								
Chollet 2011	57	53.7 (27.8)	56	35.1 (22)			3.61%	0.74[0.35,1.12]
FOCUS Trial Collaboration 2018	1398	57.1 (29.6)	1395	57.4 (29.5)		+	95.42%	-0.01[-0.09,0.06]
Marquez Romero 2013	14	75.5 (33)	16	48.5 (56.9)			0.98%	0.56[-0.18,1.29]
Subtotal ***	1469		1467			•	100%	0.02[-0.05,0.09]
Heterogeneity: Tau ² =0; Chi ² =16.3, o	df=2(P=0);	l ² =87.73%						
Test for overall effect: Z=0.56(P=0.5	58)							
Total ***	1469		1467			•	100%	0.02[-0.05,0.09]
Heterogeneity: Tau ² =0; Chi ² =16.3, o	df=2(P=0);	l ² =87.73%						
Test for overall effect: Z=0.56(P=0.5	58)							
				Favours SSRI -	2 -1	0 1	² Favours co	ontrol

Analysis 1.12. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 12 Disability (sensitivity analyses all studies regardless of RoB).

Study or subgroup	c	ontrol	SSRI		Std. Mean Difference	Weight	Std. Mean Difference
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% Cl		Fixed, 95% CI
1.12.1 Fluoxetine							
Chen 2001	19	79.3 (8.9)	18	71.6 (9.4)		0.66%	0.83[0.15,1.5]
Cheng 2003	25	-26.4 (14.2)	32	-29.1 (17.4)	_ 	1.09%	0.17[-0.35,0.69]
Dam 1996	16	61.9 (13)	16	54.1 (21.1)	++	0.61%	0.43[-0.27,1.14]
FOCUS Trial Collaboration 2018	1402	59.7 (31.2)	1397	60.2 (31.5)		54.76%	-0.02[-0.09,0.06]
He 2016	177	88.8 (14.7)	170	84.7 (18.9)	-+-	6.74%	0.24[0.03,0.45]
Kong 2007	37	60.4 (12.5)	36	52.3 (13.5)	+	1.36%	0.62[0.15,1.09]
Li 2008	58	40.8 (3.7)	28	38.4 (5.8)	+	1.43%	0.53[0.07,0.99]
Marquez Romero 2013	14	65 (21.4)	16	45 (73.2)	++	0.57%	0.35[-0.37,1.07]
Razazian 2014	75	15.7 (2.6)	75	14.3 (1.8)	-+-	2.79%	0.63[0.3,0.96]
Robinson 2000a	14	59.2 (11.6)	13	56.2 (7.7)		0.52%	0.29[-0.47,1.05]
Robinson 2000b	13	60.5 (10.8)	15	63.1 (8.2)	+	0.54%	-0.27[-1.01,0.48]
Wang 2003	51	75 (4.2)	47	61 (6.9)		1.07%	2.46[1.93,2.98]
Wiart 2000	16	87.4 (22.8)	15	88.7 (25.3)		0.61%	-0.05[-0.76,0.65]
Xu 2001	26	73 (4.4)	27	67 (4.1)	-	0.82%	1.39[0.79,2]
Zhao 2011	37	-27.6 (7.1)	34	-34.6 (5.2)		1.19%	1.11[0.6,1.61]
Subtotal ***	1980		1939		•	74.77%	0.14[0.08,0.2]
Heterogeneity: Tau ² =0; Chi ² =143.86	6, df=14(P<	<0.0001); I ² =90.2	7%				
Test for overall effect: Z=4.3(P<0.00	001)						
1.12.2 Sertraline							
Xie 2005	65	88.7 (7.9)	65	79.8 (4.5)	_+_	2.04%	1.38[0.99,1.76]
Subtotal ***	65		65		•	2.04%	1.38[0.99,1.76]
Heterogeneity: Not applicable							
Test for overall effect: Z=7.03(P<0.0	001)						
1.12.3 Paroxetine							
Chen 2005b	40	65.8 (5.9)	38	51.8 (7.3)		0.97%	2.09[1.53,2.64]
Chen 2002	40 24	61 (12.2)	30 20	51.8 (7.3)		0.97%	0.82[0.2,1.44]
He 2005	24 27	61 (12.2) 84.3 (8.4)	20 27	78.3 (10.3)		1.02%	0.82[0.2,1.44]
пе 2003 	21	04.3 (0.4)					
			Fa	wours control	-2 -1 0 1 2	Favours SS	īRI

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright @ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Study or subgroup	с	ontrol		SSRI	Std. Mean Difference	Weight	Std. Mean Difference
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
Xu 2006	28	-27.6 (4.8)	29	-32.8 (4.1)		0.95%	1.14[0.58,1.7]
Ye 2004	30	78.8 (14.2)	30	50.3 (13.4)		0.75%	2.04[1.41,2.67]
Subtotal ***	149		144		•	4.48%	1.29[1.03,1.55]
Heterogeneity: Tau ² =0; Chi ² =24.34	, df=4(P<0.	0001); I ² =83.56%					
Test for overall effect: Z=9.76(P<0.	0001)						
1.12.4 Citalopram							
Acler 2009	10	82 (28)	10	75 (25)		0.39%	0.25[-0.63,1.13]
Andersen 2013	319	1.5 (1.5)	323	1.3 (1.2)	+	12.53%	0.15[-0.01,0.3]
Gao 2016	85	71.5 (16.2)	86	72.3 (15.9)	_ 	3.34%	-0.05[-0.35,0.25]
Li 2006	50	64.4 (8.2)	49	59.2 (9)	- + -	1.85%	0.6[0.19,1]
Liu 2006	30	64.4 (12.1)	30	35.4 (9.1)		0.6%	2.67[1.97,3.38]
Subtotal ***	494		498		◆	18.71%	0.24[0.11,0.37]
Heterogeneity: Tau ² =0; Chi ² =53.39	, df=4(P<0.	0001); I ² =92.51%					
Test for overall effect: Z=3.71(P=0)							
Total ***	2688		2646		•	100%	0.23[0.18,0.29]
Heterogeneity: Tau ² =0; Chi ² =328.1	, df=25(P<0	.0001); I ² =92.389	%				
Test for overall effect: Z=8.39(P<0.	0001)						
Test for subgroup differences: Chi	²=106.51, df	=1 (P<0.0001), I ²	=97.18%				
			Fa	vours control	-2 -1 0 1 2	– Favours SS	SRI

Analysis 1.13. Comparison 1 SSRI versus control at end of treatment, by SSRI, Outcome 13 Independent on modified Rankin score (mRS 0 to 2) (sensitivity analysis).

Study or subgroup	SSRI	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
1.13.1 Fluoxetine					
Chollet 2011	15/57	5/56	· · · · · · · · · · · · · · · · · · ·	0.55%	2.95[1.15,7.56]
FOCUS Trial Collaboration 2018	572/1553	588/1553	•	64.53%	0.97[0.89,1.07]
Marquez Romero 2013	8/14	3/16	+	0.31%	3.05[1,9.31]
Subtotal (95% CI)	1624	1625	•	65.39%	1[0.91,1.09]
Total events: 595 (SSRI), 596 (Control)					
Heterogeneity: Tau ² =0; Chi ² =9.23, df=2(P=0.01); I ² =78.32%				
Test for overall effect: Z=0.02(P=0.99)					
1.13.2 Sertraline					
Almeida 2006	55/55	56/56	+	6.15%	1[0.97,1.04]
Subtotal (95% CI)	55	56	•	6.15%	1[0.97,1.04]
Total events: 55 (SSRI), 56 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
1.13.3 Citalopram					
Andersen 2013	231/319	261/323	-	28.46%	0.9[0.82,0.98]
Subtotal (95% CI)	319	323	•	28.46%	0.9[0.82,0.98]
Total events: 231 (SSRI), 261 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=2.5(P=0.01)					
		Favours SSRI (0.1 0.2 0.5 1 2 5 10	Favours control	

Cochrane Database of Systematic Reviews

Study or subgroup	SSRI n/N	Control n/N	_			sk Ra ixed,	tio 95% CI			Weight	Risk Ratio M-H, Fixed, 95% Cl
Total (95% CI)	1998	2004				•				100%	0.97[0.91,1.03]
Total events: 881 (SSRI), 913 (Cont	rol)										
Heterogeneity: Tau ² =0; Chi ² =15.57	, df=4(P=0); l ² =74.32%										
Test for overall effect: Z=0.93(P=0.3	35)										
Test for subgroup differences: Chi ²	² =5.44, df=1 (P=0.07), I ² =	=63.26%									
		Favours SSRI	0.1	0.2	0.5	1	2	5	10	Favours control	

APPENDICES

Appendix 1. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy

#1. MeSH descriptor Cerebrovascular Disorders explode all trees

#2. (stroke in Title, Abstract or Keywords or poststroke in Title, Abstract or Keywords or post-stroke in Title, Abstract or Keywords or cerebrovasc* in Title, Abstract or Keywords or (brain in Title, Abstract or Keywords and vasc* in Title, Abstract or Keywords) or (cerebral in Title, Abstract or Keywords and vasc* in Title, Abstract or Keywords) or cva* in Title, Abstract or Keywords or apoplex* in Title, Abstract or Keywords or Keywords or Keywords) or cva* in Title, Abstract or Keywords or Abstract or Keywords or Keywords) or cva* in Title, Abstract or Keywords or Abstract or Keywords or Keywords) or cva* in Title, Abstract or Keywords or Abstract or Keywords or Keywords) or cva* in Title, Abstract or Keywords or Abstract or Keywords) or cva* in Title, Abstract or Keywords or Abstract or Keywords) or cva* in Title, Abstract or Keywords or Abstract or Keywords) or cva* in Title, Abstract or Keywords or Abstract or Keywords) or cva* in Title, Abstract or Keywords or Abstract or Keywords) or cva* in Title, Abstract or Keywords or Abstract or Keywords) or cva* in Title, Abstract or Keywords or Abstract or Keywords) or cva* in Title, Abstract or Keywords or Abstract or Keywords)

#3. ((brain* in Title, Abstract or Keywords or cerebr* in Title, Abstract or Keywords or cerebell* in Title, Abstract or Keywords or intracran* in Title, Abstract or Keywords or intracerebral in Title, Abstract or Keywords) and (ischemi* in Title, Abstract or Keywords or ischaemi* in Title, Abstract or Keywords or infarct* in Title, Abstract or Keywords or thrombo* in Title, Abstract or Keywords or emboli* in Title, Abstract or Keywords or Keywords or cerebell* in Title, Abstract or Keywords or infarct* in Title, Abstract or Keywords or thrombo* in Title, Abstract or Keywords or emboli* in Title, Abstract or Keywords or Keywords or cerebell* in Title, Abstract or Keywords or Keywords or occlus* in Title, Abstract or Keywords))

#4. ((brain* in Title, Abstract or Keywords or cerebr* in Title, Abstract or Keywords or cerebell* in Title, Abstract or Keywords or intracerebral in Title, Abstract or Keywords or intracerebral in Title, Abstract or Keywords or intracerebral in Title, Abstract or Keywords or subarachnoid in Title, Abstract or Keywords) and (haemorrhage* in Title, Abstract or Keywords or hemorrhage* in

#5. MeSH descriptor hemiplegia this term only

#6. MeSH descriptor paresis explode all trees

#7. MeSH descriptor Gait Disorders, Neurologic explode all trees

#8. (hemipleg* in Title, Abstract or Keywords or hemipar* in Title, Abstract or Keywords or paresis in Title, Abstract or Keywords or paretic in Title, Abstract or Keywords)

#9. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)

#10. MeSH descriptor Serotonin Uptake Inhibitors explode all trees

#11. (serotonin in Title, Abstract or Keywords or 5-HT in Title, Abstract or Keywords or "5 HT" in Title, Abstract or Keywords or 5hydroxytryptamine in Title, Abstract or Keywords or "5 hydroxytryptamine" in Title, Abstract or Keywords)

#12. (uptake in Title, Abstract or Keywords or reuptake in Title, Abstract or Keywords or re-uptake in Title, Abstract or Keywords)

#13. inhib* in Title, Abstract or Keywords

#14. (#11 and #12 and #13)

#15. SSRI* in Title, Abstract or Keywords

#16. (alaproclat* in Title, Abstract or Keywords or cericlamin* in Title, Abstract or Keywords or citalopram in Title, Abstract or Keywords or dapoxetin* in Title, Abstract or Keywords or escitalopram in Title, Abstract or Keywords or fluoxetin* in Title, Abstract or Keywords or sertralin* in Title, Abstract or Keywords or trazodone in Title, Abstract or Keywords or vilazodone in Title, Abstract or Keywords or zimelidine in Title, Abstract or Keywords)

#17. (Celexa in Title, Abstract or Keywords or Cipramil in Title, Abstract or Keywords or Cipram in Title, Abstract or Keywords or Seroparm in Title, Abstract or Keywords or Cibram in Title, Abstract or Keywords or Seroparm in Title, Abstract or Keywords or Cibra in Title, Abstract or Keywords or Seroparm in Title, Abstract or Keywords or Cibra in Title, Abstract or Keywords or Seroparm in Title, Abstract or Keywords or Cipralex in Title, Abstract or Keywords or Seroplex in Title, Abstract or Keywords or Esertia in Title, Abstract or Keywords or Prozac in Title, Abstract or Keywords or Fontex in Title, Abstract or Keywords or Seromex in Title, Abstract or Keywords or Fluctin in Title, Abstract or Keywords or fluox in Title, Abstract or Keywords or Lovan in Title, Abstract or Keywords or Lovan in Title, Abstract or Keywords or Seromex or Novox in Title, Abstract or Keywords or Paxil in Title, Abstract or Keywords or Seromex or Seromex in Title, Abstract or Keywords or Seromex or Seromex in Title, Abstract or Keywords or Seromex or Seromex in Title, Abstract or Keywords or Seromex or Seromex in Title, Abstract or Keywords or Faverin in Title, Abstract or Keywords or Seromex in Title, Abstract or Keywords or Faverin in Title, Abstract or Keywords or Seromex in Title, Abstr



Paroxat in Title, Abstract or Keywords or Loxamine in Title, Abstract or Keywords or Zoloft in Title, Abstract or Keywords or Lustral in Title, Abstract or Keywords or Serlain in Title, Abstract or Keywords or Asentra in Title, Abstract or Keywords) #18. (#10 or #14 or #15 or #16 or #17)

#19. (#9 and #18)

Appendix 2. MEDLINE (Ovid) search strategy

1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp intracranial arterial diseases/ or exp "intracranial embolism and thrombosis"/ or exp intracranial hemorrhages/ or stroke/ or exp brain infarction/ or vertebral artery dissection/

2. (stroke or poststroke or cerebrovasc\$ or brain vasc\$ or cerebral vasc\$ or cva\$ or apoplex\$ or SAH).tw.

- 3. ((brain\$ or cerebr\$ or cerebell\$ or intracran\$ or intracerebral) adj5 (isch?emi\$ or infarct\$ or thrombo\$ or emboli\$ or occlus\$)).tw.
- 4. ((brain\$ or cerebr\$ or cerebell\$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage\$ or hemorrhage\$ or haematoma \$ or hematoma\$ or bleed\$)).tw.
- 5. hemiplegia/ or exp paresis/

6. (hemipleg\$ or hemipar\$ or paresis or paretic).tw.

- 7. exp Gait Disorders, Neurologic/
- 8. or/1-7

9. exp Serotonin Uptake Inhibitors/

10. ((serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine) adj5 (uptake or reuptake or re-uptake) adj5 inhib\$).tw. 11. SSRI\$1.tw.

12. (alaproclat\$ or cericlamin\$ or citalopram or dapoxetin\$ or escitalopram or femoxetin\$ or fluoxetin\$ or fluoxamin\$ or paroxetin\$ or sertralin\$ or trazodone or vilazodone or zimelidine).tw,nm.

13. (Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or Citox or Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or Seronil or Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin or Favoxil or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or Xetanor or Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra).tw,nm.

14. 9 or 10 or 11 or 12 or 13

15.8 and 14

16. exp animals/ not humans.sh.

17. 15 not 16

18. Randomized Controlled Trials as Topic/

19. random allocation/

20. Controlled Clinical Trials as Topic/

21. control groups/

22. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical trials,

- trials, phase iv as topic/
- 23. Clinical Trials Data Monitoring Committees/
- 24. double-blind method/
- 25. single-blind method/
- 26. Placebos/
- 27. placebo effect/
- 28. cross-over studies/
- 29. Multicenter Studies as Topic/
- 30. Therapies, Investigational/
- 31. Drug Evaluation/
- 32. Research Design/
- 33. Program Evaluation/
- 34. evaluation studies as topic/
- 35. randomized controlled trial.pt.
- 36. controlled clinical trial.pt.
- 37. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
- 38. multicenter study.pt.
- 39. (evaluation studies or comparative study).pt.
- 40. meta analysis.pt.
- 41. meta-analysis as topic/
- 42. random\$.tw.
- 43. (controlled adj5 (trial\$ or stud\$)).tw.
- 44. (clinical\$ adj5 trial\$).tw.
- 45. ((control or treatment or experiment\$ or intervention) adj5 (group\$ or subject\$ or patient\$)).tw.
- 46. (quasi-random\$ or quasi random\$ or pseudo-random\$ or pseudo random\$).tw.
- 47. ((multicenter or multicentre or therapeutic) adj5 (trial\$ or stud\$)).tw.



- 48. ((control or experiment\$ or conservative) adj5 (treatment or therapy or procedure or manage\$)).tw.
- 49. ((singl\$ or doubl\$ or tripl\$ or trebl\$) adj5 (blind\$ or mask\$)).tw.
- 50. (coin adj5 (flip or flipped or toss\$)).tw.
- 51. latin square.tw.
- 52. versus.tw.
- 53. (cross-over or cross over or crossover).tw.
- 54. placebo\$.tw.
- 55. sham.tw.
- 56. (assign\$ or alternate or allocat\$ or counterbalance\$ or multiple baseline).tw.
- 57. controls.tw.
- 58. (treatment\$ adj6 order).tw.
- 59. (meta-analy\$ or metaanaly\$ or meta analy\$ or systematic review or systematic overview).tw.
- 60. or/18-59
- 61. 17 and 60

Appendix 3. EMBASE (Ovid) search strategy

1. cerebrovascular disease/ or basal ganglion hemorrhage/ or exp brain hematoma/ or exp brain hemorrhage/ or exp brain infarction/ or exp brain ischemia/ or exp carotid artery disease/ or cerebral artery disease/ or cerebrovascular accident/ or exp intracranial aneurysm/ or exp occlusive cerebrovascular disease/ or stroke/

2. stroke unit/ or stroke patient/

3. (stroke or poststroke or post-stroke or cerebrovasc\$ or brain vasc\$ or cerebral vasc\$ or cva\$ or apoplex\$ or SAH).tw.

- 4. ((brain\$ or cerebr\$ or cerebell\$ or intracran\$ or intracerebral) adj5 (isch?emi\$ or infarct\$ or thrombo\$ or emboli\$ or occlus\$)).tw.
- 5. ((brain\$ or cerebr\$ or cerebell\$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage\$ or hemorrhage\$ or haematoma
- \$ or hematoma\$ or bleed\$)).tw.
- 6. hemiparesis/ or hemiplegia/ or paresis/
- 7. (hemipleg\$ or hemipar\$ or paresis or paretic).tw.
- 8. or/1-7
- 9. exp serotonin uptake inhibitor/

10. ((serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine) adj5 (uptake or reuptake or re-uptake) adj5 inhib\$).tw. 11. SSRI\$1.tw.

12. (alaproclat\$ or cericlamin\$ or citalopram or dapoxetin\$ or escitalopram or femoxetin\$ or fluoxetin\$ or fluoxamin\$ or paroxetin\$ or sertralin\$ or trazodone or vilazodone or zimelidine).tw.

13. (Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or Citox or Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or Seronil or Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin or Favoxil or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or Xetanor or Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra).tw,tn.

14. 9 or 10 or 11 or 12 or 13 $\,$

- 15.8 and 14
- 16. limit 15 to human
- 17. Randomized Controlled Trial/
- 18. Randomization/
- 19. Controlled Study/
- 20. control group/
- 21. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ or controlled clinical trial/
- 22. Double Blind Procedure/
- 23. Single Blind Procedure/ or triple blind procedure/
- 24. placebo/
- 25. "types of study"/
- 26. research subject/
- 27. random\$.tw.
- 28. (controlled adj5 (trial\$ or stud\$)).tw.
- 29. (clinical\$ adj5 trial\$).tw.
- 30. ((control or treatment or experiment\$ or intervention) adj5 (group\$ or subject\$ or patient\$)).tw.
- 31. (quasi-random\$ or quasi random\$ or pseudo-random\$ or pseudo random\$).tw.
- 32. ((singl\$ or doubl\$ or tripl\$ or trebl\$) adj5 (blind\$ or mask\$)).tw.
- 33. (coin adj5 (flip or flipped or toss\$)).tw.
- 34. versus.tw.
- 35. placebo\$.tw.
- 36. controls.tw.
- 37. or/17-36
- 38.16 and 37

Appendix 4. CINAHL (Ebsco) search strategy

S23. S12 and S22

S22. S13 or S17 or S18 or S19 or S20 or S21

S21. AB Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or Citox or Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or Seronil or Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin or Favoxil or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or Xetanor or Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra

S20. TI Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or Citox or Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or Seronil or Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin or Favoxil or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or Xetanor or Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra

S19. TI (alaproclat* or cericlamin* or citalopram or dapoxetin* or escitalopram or femoxetin* or fluoxetin* or fluoxamin* or paroxetin* or sertralin* or trazodone or vilazodone or zimelidine) OR AB (alaproclat* or cericlamin* or citalopram or dapoxetin* or escitalopram or femoxetin* or fluoxetin* or fluoxamin* or paroxetin* or sertralin* or trazodone or vilazodone or zimelidine)

S18. TI SSRI* OR AB SSRI*

S17. S14 and S15 and S16

S16. TI inhib* OR AB inhib*

S15. TI (uptake or reuptake or re-uptake) OR AB (uptake or reuptake or re-uptake)

S14. TI (serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine) OR AB (serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine)

S13. (MH "Serotonin Uptake Inhibitors+")

S12. S1 or S2 or S3 or S6 or S9 or S10 or S11

S11. TI (hemipleg* or hemipar* or paresis or paretic) or AB (hemipleg* or hemipar* or paresis or paretic)

S10. (MH "Hemiplegia")

S9. S7 and S8

S8. TI (haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed*) or AB (haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed*)

S7. TI (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) or AB (brain* or cerebr* or cerebell* or intracerebral or intracerebral or subarachnoid)

S6. S4 and S5

S5. TI (ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus*) or AB (ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus*)

S4. TI (brain* or cerebr* or cerebell* or intracran* or intracerebral) or AB (brain* or cerebr* or cerebell* or intracran* or intracerebral)

S3. TI (stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH) or AB (stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH)

S2. (MH "Stroke Patients") OR (MH "Stroke Units")

S1. (MH "Cerebrovascular Disorders") OR (MH "Basal Ganglia Cerebrovascular Disease+") OR (MH "Carotid Artery Diseases+") OR (MH "Cerebral Ischemia+") OR (MH "Cerebral Vasospasm") OR (MH "Intracranial Arterial Diseases+") OR (MH "Intracranial Embolism and Thrombosis") OR (MH "Intracranial Hemorrhage+") OR (MH "Stroke") OR (MH "Vertebral Artery Dissections")

Appendix 5. AMED (Ovid) search strategy

1. cerebrovascular disorders/ or cerebral hemorrhage/ or cerebral infarction/ or cerebral ischemia/ or cerebrovascular accident/ or stroke/ 2. (stroke or poststroke or post-stroke or cerebrovasc\$ or brain vasc\$ or cerebral vasc\$ or cva\$ or apoplex\$ or SAH).tw.

3. ((brain\$ or cerebr\$ or cerebell\$ or intracran\$ or intracerebral) adj5 (isch?emi\$ or infarct\$ or thrombo\$ or emboli\$ or occlus\$)).tw.

4. ((brains or cerebes) or cerebells or intracerebral or intracerebral or subarachnoid) adj5 (haemorrhages or hemorrhages or haematoma

\$ or hematoma\$ or bleed\$)).tw.

5. hemiplegia/

6. (hemipleg\$ or hemipar\$ or paresis or paretic).tw.

7. or/1-6

8. antidepressive agents/

9. ((serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine) adj5 (uptake or re-uptake or re-uptake) adj5 inhib\$).tw. 10. SSRI\$1.tw.

11. (alaproclat\$ or cericlamin\$ or citalopram or dapoxetin\$ or escitalopram or femoxetin\$ or fluoxetin\$ or fluoxamin\$ or paroxetin\$ or sertralin\$ or trazodone or vilazodone or zimelidine).tw.

12. (Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or Citox or Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or Seronil or Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin or Favoxil or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or Xetanor or Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra).tw.

13. 8 or 9 or 10 or 11 or 12

14.7 and 13

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review) Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Appendix 6. PsycINFO (Ovid) search strategy

1. cerebrovascular disorders/ or cerebral hemorrhage/ or exp cerebral ischemia/ or cerebral small vessel disease/ or cerebrovascular accidents/ or subarachnoid hemorrhage/

- 2. (stroke or poststroke or post-stroke or cerebrovasc\$ or brain vasc\$ or cerebral vasc\$ or cva\$ or apoplex\$ or SAH).tw.
- 3. ((brain\$ or cerebr\$ or cerebell\$ or intracran\$ or intracerebral) adj5 (isch?emi\$ or infarct\$ or thrombo\$ or emboli\$ or occlus\$)).tw.
- 4. ((brain\$ or cerebr\$ or cerebell\$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage\$ or hemorrhage\$ or haematoma
- \$ or hematoma\$ or bleed\$)).tw.
- 5. (hemipleg\$ or hemipar\$ or paresis or paretic).tw.
- 6. hemiparesis/ or hemiplegia/
- 7. or/1-6
- 8. exp serotonin reuptake inhibitors/

9. ((serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine) adj5 (uptake or reuptake or re-uptake) adj5 inhib\$).tw. 10. SSRI\$1.tw.

11. (alaproclat\$ or cericlamin\$ or citalopram or dapoxetin\$ or escitalopram or femoxetin\$ or fluoxetin\$ or fluoxamin\$ or paroxetin\$ or sertralin\$ or trazodone or vilazodone or zimelidine).tw.

12. (Celexa or Cipramil or Cipram or Recital or Emocal or Dalsan or Sepram or Seropram or Citox or Priligy or Lexapro or Cipralex or Seroplex or Esertia or Prozac or Fontex or Seromex or Seronil or Sarafem or Ladose or Motivest or Fluctin or fluox or Lovan or Luvox or Fevarin or Faverin or Favoxil or Movox or Paxil or Seroxat or Sereupin or Aropax or Deroxat or Divarius or Rexetin or Xetanor or Paroxat or Loxamine or Zoloft or Lustral or Serlain or Asentra).tw.

13. 8 or 9 or 10 or 11 or 12

14.7 and 13

Appendix 7. Search strategy for the trial registers

Patient: stroke

Intervention: alaproclate OR cericlamineOR citalopram OR clomipramine OR dapoxetine OR etoperidone OR femoxetine OR fenfluramine OR fluoxetine OR fluoxetine OR fluoxetine OR fluoxetine OR norfenfluramine OR paroxetine OR sertraline OR trazodone OR vilazodone OR zimelidine

Comparison: placebo

Trial status: ongoing OR Recruiting OR Not yet recruiting OR Active

Age: adult OR older adult

Methods: Randomised Controlled Study

WHAT'S NEW

Date	Event	Description
14 March 2019	New citation required and conclusions have changed	We include 2 new high-quality trials. Meta-analysis of all the high-quality trials shows no effect on either of the co-primary outcomes of independence and disability. Meta-analysis of all trials irrespective of trial quality showed that SSRIs reduced dis- ability at the end of treatment.
14 March 2019	New search has been performed	We have clarified that there are 2 primary outcomes: indepen- dence and disability.
		For modified Rankin Score (mRS) in advance of starting this up- date, we decided to report the proportion of independent partic- ipants compared with the proportion dead or dependent which is the usual convention in stroke trials. In the previous version we had reported the proportion dependent and had excluded the dead participants from the analysis.
		We checked the total number of participants included in the 2012 review. We had stated that the trials included 4060 partici- pants; there were errors in the arithmetic (due to counting num- ber allocated rather than those recruited, and omitting to count data from 2 small trials). When we recalculated the figures, there

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)

Copyright $\ensuremath{\mathbb S}$ 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Date	Event	Description
		were 4109 recruited. We excluded 7 of these trials (439 partici- pants) which had combined an SSRI with another active inter- vention and compared it to the active treatment alone or where there was a non-random component to sequence generation process (see list of excluded studies in text).
		We added 14 new completed trials, recruiting 5498 participants.
		There are now a total of 63 trials recruiting a total of 9168 partici- pants.
		We decided to restrict our primary analyses only to those trials at low risk of bias. We did this because we wished to provide a clear answer about the risks and benefits of SSRIs, which was not in- fluenced by trial quality and because it would have been imprac- tical, given the resources for this update, to perform analyses in- cluding all the low-quality trials. We made this decision before we knew the results of the largest trial in this review (FOCUS). We have, however, performed a sensitivity analysis for depen- dence and disability (our primary outcomes) using data from all trials; as in the first version of the review, this sensitivity analysis showed that when low-quality trials are included, results tend to be in favour of SSRIs.
		We adhered to the MECIR standards for conduct and reporting.
		We shortened our list of excluded studies in line with the Cochrane Handbook, by not listing those studies that obvious- ly did not fulfil inclusion criteria, including those studies which clearly had an ineligible comparator, intervention or study de- sign.

HISTORY

Protocol first published: Issue 11, 2011 Review first published: Issue 11, 2012

Date	Event	Description
26 August 2013	Amended	The review authors identified minor errors following publica- tion of the previous version. These errors have now been correct- ed and have resulted in very minor changes in SMD for disabili- ty and some I ² values. The changes have not materially changed the results or conclusions of the review.
		Changes made:
		(1) the total number of participants has been changed from 4059 to 4060;
		(2) Almeida 2006 recruited people without depression; this has been corrected in the 'Characteristics of included studies' table, and data have been moved to 'did not have to have depression' in the relevant subgroup analyses;
		(3) disability data for Acler 2009 had been entered incorrectly; this has now been corrected.

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery (Review)



CONTRIBUTIONS OF AUTHORS

Gillian Mead conceived the study, screened references, extracted data, assessed risk of bias, performed the analyses and wrote the first draft.

Lynn Legg searched for studies selected studies for inclusion, collected data, assessed risk of bias, managed studies through the review process, contributed to the final version.

Russel Tilney screened citations, retrieved potentially relevant papers and screened their eligibility, assisted with data extraction, performed 'Risk of bias' assessments and drafted an initial version of a manuscript for the fluoxetine trials.

Cheng Fang Hsieh screened citations, retrieved potentially relevant papers and screened their eligibility, assisted with data extraction, performed 'Risk of bias' assessments and approved the final version.

Simiao Wu screened citations, retrieved potentially relevant papers and screened their eligibility, assisted with data extraction, performed 'Risk of bias' assessments and approved the final version.

Erik Lundström screened citations, retrieved potentially relevant papers and screened their eligibility, assisted with data extraction performed 'Risk of bias' assessments and approved the final version.

Ann-Sofie Rudberg screened citations, retrieved potentially relevant papers and screened their eligibility, assisted with data extraction, performed 'Risk of bias' assessments and approved the final version.

Mansur Kutlubaev screened citations, retrieved potentially relevant papers and screened their eligibility, assisted with data extraction, performed 'Risk of bias' assessments and approved the final version.

Babak Soleimani screened citations, retrieved potentially relevant papers and screened their eligibility, assisted with data extraction, performed 'Risk of bias' assessments and approved the final version.

Amanda Barugh screened citations, retrieved potentially relevant papers and screened their eligibility, assisted with data extraction, drafted the manuscript for submission, performed 'Risk of bias' assessments and approved the final version.

Maree Hackett screened citations, retrieved potentially relevant papers and screened their eligibility, assisted with data extraction, performed 'Risk of bias' assessments and approved the final version.

Graeme Hankey conceived the review, provided expertise in relation to analysis methods, checked the list of excluded studies and approved the final version of the review.

Martin Dennis provided topic expertise, advised on methods of analysis and approved the final version.

DECLARATIONS OF INTEREST

Lynn A Legg: none known.

Russel Tilney: none known.

Cheng-Fang Hsieh: none known.

Simiao Wu: none known.

Erik Lundström: none known.

Ann-Sofie Rudberg: none known.

Mansur A Kutlubaev: none known.

Martin Dennis: none known.

Babak Soleimani: none known.

Amanda Barugh: none known.

Maree L Hackett: during the completion of this work Maree Hackett was supported by a National Health and Medical Research Council of Australia Career Development Fellowship, Population Health (Level 2), APP1141328 (1/1/18-31/12/21)



Graeme J Hankey: in the past three years, GJH has a project grant from the National Health and Medical Research Council of Australia to lead a trial of fluoxetine for stroke recovery (AFFINITY trial). He has also received honoraria from the American Heart Assocaition for serving as an associated editor of the journal Circulation, and from AC Immune for chairing the data safety monitoring committee of two clinical trials of vaccines for Alzheimer's disease.

Gillian E Mead: has developed a course on exercise after stroke which was licensed to Later Life Training, who pay royalties for the course. These royalties are used to support further research in this area. She has received expenses for speaking at conferences on exercise and fatigue after stroke.

Gillian Mead, Martin Dennis, Maree Hackett, Erik Lundstrom and Graeme Hankey are investigators on the FOCUS trial (Fluoxetine or control under supervision) in the UK, the AFFINITY (Assessment of fluoxetine in stroke recovery) trial in Australia (Hankey 2011), and the EFFECTs trial in Sweden designed to assess the impact of fluoxetine on disability and dependency after stroke (Lundström 2014). None of these review authors extracted data from FOCUS Trial Collaboration 2018.

SOURCES OF SUPPORT

Internal sources

• None, Other.

External sources

• Stroke Research Network, UK.

Stroke Research Network in England provided some financial support to the Cochrane Stroke Group for assistance with the searches Scotland, Other.

Scottish Stroke Research Network provided some funding to the Cochrane Stroke group for assistance with the searches

Incentive grant from National Institute of Health Research, UK.

£5000 incentive grant to support an honorarium to Lynn Legg

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Changes to 'Criteria for considering studies for this review'

We edited the Types of studies section: we excluded trials which combined an SSRI with another active intervention and compared it to the active treatment alone. We restricted the criteria for considering studies for this review to randomised controlled trials and excluded studies where investigators described a non-random component in the sequence generation process.

Changes to 'Data collection and analysis'

We edited the Methods section of the review to reflect current MECIR standards, adding information for Assessment of risk of bias in included studies; Measures of treatment effect; Unit of analysis issues; Dealing with missing data; Assessment of heterogeneity; Assessment of reporting biases; and Subgroup analysis and investigation of heterogeneity. We also restricted the meta-analyses to studies at low risk of bias.

Changes to Results

We excluded three studies that were previously included but were no longer eligible for this review, as there was a non-random component in the sequence generation process (Li 2002; Liang 2003; Zhou 2003). We excluded four studies that combined an SSRI with another active intervention and compared it to the active treatment alone (Finkenzeller 2009; Ji 2000; Liu 2004; Xu 2007). We excluded two studies (Graffagnino 2002; Sitzer 2002), listed as 'Awaiting classification' in the previous version of this review (Mead 2012). We could find no published results and when we sought further information from the authors, we received no responses.

We renamed previously included studies to match current Cochrane standards: EMOTION 2011 is now Kim 2011; FOCUS 2011 is now FOCUS Trial Collaboration 2018; AFFINITY is now Hankey 2011; EFFECTS is now Lundström 2014.

INDEX TERMS

Medical Subject Headings (MeSH)

Anxiety [*drug therapy]; Citalopram [therapeutic use]; Cognition [drug effects]; Depression [*drug therapy]; Fluoxetine [therapeutic use]; Nervous System Diseases [drug therapy]; Paroxetine [therapeutic use]; Randomized Controlled Trials as Topic; Serotonin Uptake Inhibitors [adverse effects] [*therapeutic use]; Sertraline [therapeutic use]; Stroke [*drug therapy] [psychology]; Stroke Rehabilitation



MeSH check words

Adult; Humans